<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults - Sutherland, A - 2018 | Cochrane Library</title> <meta content="Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults - Sutherland, A - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012555.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults - Sutherland, A - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012555.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012555.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults" name="citation_title"/> <meta content="Anna Sutherland" name="citation_author"/> <meta content="annasutherland@doctors.org.uk" name="citation_author_email"/> <meta content="Katrien Naessens" name="citation_author"/> <meta content="Oxford Radcliffe Trust/Health Education Thames Valley" name="citation_author_institution"/> <meta content="Emma Plugge" name="citation_author"/> <meta content="Cochrane UK" name="citation_author_institution"/> <meta content="Lynda Ware" name="citation_author"/> <meta content="Cochrane UK" name="citation_author_institution"/> <meta content="Karen Head" name="citation_author"/> <meta content="Nuffield Department of Surgical Sciences, University of Oxford" name="citation_author_institution"/> <meta content="Martin J Burton" name="citation_author"/> <meta content="Cochrane UK" name="citation_author_institution"/> <meta content="Bee Wee" name="citation_author"/> <meta content="Churchill Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD012555.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/09/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012555.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012555.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012555.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antiemetics [adverse effects, *therapeutic use]; Antineoplastic Agents [adverse effects]; Benzodiazepines [adverse effects, *therapeutic use]; Chemoradiotherapy [adverse effects]; Dexamethasone [therapeutic use]; Disorders of Excessive Somnolence [chemically induced]; Fatigue; Metoclopramide [therapeutic use]; Nausea [*drug therapy, etiology, prevention &amp; control]; Neoplasms [*complications]; Olanzapine; Quality of Life; Randomized Controlled Trials as Topic; Vomiting [*drug therapy, etiology, prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012555.pub2&amp;doi=10.1002/14651858.CD012555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="cdmLYOAV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012555\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012555\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012555\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012555\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","ja","fr","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012555.pub2",title:"Olanzapine for the prevention and treatment of cancer\\u2010related nausea and vomiting in adults",firstPublishedDate:"Sep 21, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012555.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012555.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012555.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012555.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012555.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012555.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012555.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012555.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012555.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012555.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10109 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012555.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/full#CD012555-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/full#CD012555-sec-0201"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/full#CD012555-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/full#CD012555-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/full#CD012555-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/full#CD012555-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/full#CD012555-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/full#CD012555-sec-0174"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/appendices#CD012555-sec-0214"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/table_n/CD012555StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/table_n/CD012555StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/information#CD012555-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Anna Sutherland</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/information#CD012555-cr-0003">Katrien Naessens</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/information#CD012555-cr-0004">Emma Plugge</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/information#CD012555-cr-0005">Lynda Ware</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/information#CD012555-cr-0006">Karen Head</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/information#CD012555-cr-0007">Martin J Burton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012555.pub2/information#CD012555-cr-0008">Bee Wee</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/information/en#CD012555-sec-0221">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 September 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012555.pub2">https://doi.org/10.1002/14651858.CD012555.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012555-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012555-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012555-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012555-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012555-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012555-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012555-abs-0001" lang="en"> <section id="CD012555-sec-0001"> <h3 class="title" id="CD012555-sec-0001">Background</h3> <p>Olanzapine as an antiemetic represents a new use of an antipsychotic drug. People with cancer may experience nausea and vomiting whilst receiving chemotherapy or radiotherapy, or whilst in the palliative phase of illness. </p> </section> <section id="CD012555-sec-0002"> <h3 class="title" id="CD012555-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of olanzapine when used as an antiemetic in the prevention and treatment of nausea and vomiting related to cancer in adults. </p> </section> <section id="CD012555-sec-0003"> <h3 class="title" id="CD012555-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE and Embase for published data on 20th September 2017, as well as ClinicalTrials.gov and World Health Organization International Clinical Trials Registry Platform for unpublished trials. We checked reference lists, and contacted experts in the field and study authors. </p> </section> <section id="CD012555-sec-0004"> <h3 class="title" id="CD012555-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of olanzapine versus any comparator with or without adjunct therapies for the prevention or treatment, or both, of nausea or vomiting in people with cancer aged 18 years or older, in any setting, of any duration, with at least 10 participants per treatment arm. </p> </section> <section id="CD012555-sec-0005"> <h3 class="title" id="CD012555-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodology. We used GRADE to assess quality of evidence for each main outcome<i>.</i> We extracted data for absence of nausea or vomiting and frequency of serious adverse events as primary outcomes. We extracted data for patient perception of treatment, other adverse events, somnolence and fatigue, attrition, nausea or vomiting severity, breakthrough nausea and vomiting, rescue antiemetic use, and nausea and vomiting as secondary outcomes at specified time points. </p> </section> <section id="CD012555-sec-0006"> <h3 class="title" id="CD012555-sec-0006">Main results</h3> <p>We included 14 RCTs (1917 participants) from high‐, middle‐ and low‐income countries, representing over 24 different cancers. Thirteen studies were in chemotherapy‐induced nausea and vomiting. Oral olanzapine was administered during highly emetogenic (HEC) or moderately emetogenic (MEC) chemotherapy (12 studies); chemoradiotherapy (one study); or palliation (one study). Eight studies await classification and 13 are ongoing. </p> <p>The main comparison was olanzapine versus placebo/no treatment. Other comparisons were olanzapine versus NK1 antagonist, prokinetic, 5‐HT3 antagonist or dexamethasone. </p> <p>We assessed all but one study as having one or more domains that were at high risk of bias. Eight RCTs with fewer than 50 participants per treatment arm, and 10 RCTs with issues related to blinding, were at high risk of bias. We downgraded GRADE assessments due to imprecision, inconsistency and study limitations. </p> <p><b>Olanzapine versus placebo/no treatment</b> </p> <p><i>Primary outcomes</i> </p> <p>Olanzapine probably doubles the likelihood of no nausea or vomiting during chemotherapy from 25% to 50% (risk ratio (RR) 1.98, 95% confidence interval (CI) 1.59 to 2.47; 561 participants; 3 studies; solid tumours; HEC or MEC therapy; moderate‐quality evidence) when added to standard therapy. Number needed to treat for additional beneficial outcome (NNTB) was 5 (95% CI 3.3 ‐ 6.6). </p> <p>It is uncertain if olanzapine increases the risk of serious adverse events (absolute risk difference 0.7% more, 95% CI 0.2 to 5.2) (RR 2.46, 95% CI 0.48 to 12.55; 7 studies, 889 participants, low‐quality evidence). </p> <p><i>Secondary outcomes</i> </p> <p>Four studies reported patient perception of treatment. One study (48 participants) reported no difference in patient preference. Four reported quality of life but data were insufficient for meta‐analysis. </p> <p>Olanzapine may increase other adverse events (RR 1.71, 95% CI 0.99 to 2.96; 332 participants; 4 studies; low‐quality evidence) and probably increases somnolence and fatigue compared to no treatment or placebo (RR 2.33, 95% CI 1.30 to 4.18; anticipated absolute risk 8.2% more, 95% CI 1.9 to 18.8; 464 participants; 5 studies; moderate‐quality evidence). Olanzapine probably does not affect all‐cause attrition (RR 0.99, 95% CI 0.57 to 1.73; 943 participants; 8 studies; I² = 0%). We are uncertain if olanzapine increases attrition due to adverse events (RR 3.00, 95% CI 0.13 to 70.16; 422 participants; 6 studies). No participants withdrew due to lack of efficacy. </p> <p>We are uncertain if olanzapine reduces breakthrough nausea and vomiting (RR 0.38, 95% CI 0.10 to 1.47; 501 participants; 2 studies; I² = 54%) compared to placebo or no treatment. No studies reported 50% reduction in severity of nausea or vomiting, use of rescue antiemetics, or attrition. </p> <p>We are uncertain of olanzapine's efficacy in reducing acute nausea or vomiting. Olanzapine probably reduces delayed nausea (RR 1.71, 95% CI 1.40 to 2.09; 585 participants; 3 studies) and vomiting (RR 1.28, 95% CI 1.14 to 1.42; 702 participants; 5 studies). </p> <p><i>Subgroup analysis: 5 mg versus 10 mg</i> </p> <p>Planned subgroup analyses found that it is unclear if 5 mg is as effective an antiemetic as 10 mg. There is insufficient evidence to exclude the possibility that 5 mg may confer a lower risk of somnolence and fatigue than 10 mg. </p> <p><b>Other comparisons</b> </p> <p>One study (20 participants) compared olanzapine versus NK1 antagonists. We observed no difference in any reported outcomes. </p> <p>One study (112 participants) compared olanzapine versus a prokinetic (metoclopramide), reporting that olanzapine may increase freedom from overall nausea (RR 2.95, 95% CI 1.73 to 5.02) and overall vomiting (RR 3.03, 95% CI 1.78 to 5.14). </p> <p>One study (62 participants) examined olanzapine versus 5‐HT3 antagonists, reporting olanzapine may increase the likelihood of 50% or greater reduction in nausea or vomiting at 48 hours (RR 1.82, 95% CI 1.11 to 2.97) and 24 hours (RR 1.36, 95% CI 0.80 to 2.34). </p> <p>One study (229 participants) compared olanzapine versus dexamethasone, reporting that olanzapine may reduce overall nausea (RR 1.73, 95% CI 1.37 to 2.18), overall vomiting (RR 1.27, 95% CI 1.10 to 1.48), delayed nausea (RR 1.66, 95% CI 1.33 to 2.08) and delayed vomiting (RR 1.25, 95% CI 1.07 to 1.45). </p> </section> <section id="CD012555-sec-0007"> <h3 class="title" id="CD012555-sec-0007">Authors' conclusions</h3> <p>There is moderate‐quality evidence that oral olanzapine probably increases the likelihood of not being nauseous or vomiting during chemotherapy from 25% to 50% in adults with solid tumours, in addition to standard therapy, compared to placebo or no treatment. There is uncertainty whether it increases serious adverse events. It may increase the likelihood of other adverse events, probably increasing somnolence and fatigue. There is uncertainty about relative benefits and harms of 5 mg versus 10 mg. </p> <p>We identified only RCTs describing oral administration. The findings of this review cannot be extrapolated to provide evidence about the efficacy and safety of any injectable form (intravenous, intramuscular or subcutaneous) of olanzapine. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012555-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012555-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012555-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012555-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012555-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012555-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012555-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012555-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012555-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012555-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012555-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012555-abs-0005" lang="en"> <h3>Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults </h3> <p><b>Background</b> </p> <p>Olanzapine has been studied to see if it might work as an antisickness (antiemetic) medication and if it is safe. People with cancer may commonly experience distressing nausea and vomiting, despite the current medications available, before, during, and after chemotherapy or radiotherapy, and during a palliative phase of illness (when the aim of treatment is symptom relief rather than cure). Some people still experience problematic nausea and vomiting with chemotherapy even when they are given standard antisickness medication. </p> <p>Recently research studies have focused on preventing and treating chemotherapy‐induced nausea and vomiting. </p> <p><b>Review question</b> </p> <p>We investigated the benefits and harms of using olanzapine for preventing and treating nausea and vomiting in adults with cancer. </p> <p><b>Search date</b> </p> <p>We searched for studies in September 2017.</p> <p><b>Study characteristics</b> </p> <p>We included 14 randomised controlled trials (RCTs) because they provide the most reliable evidence, with 1917 participants in total, from all around the world that investigated the use of oral olanzapine in treating or preventing nausea and vomiting. </p> <p>All the included studies used olanzapine in combination with other medications, usually antiemetics (antisickness medications). Nine studies compared olanzapine to placebo (a substance with no therapeutic effect) or no treatment. Other studies compared olanzapine to other antiemetics. </p> <p><b>Were participants receiving anticancer treatments?</b> </p> <p>Thirteen RCTs included participants receiving chemotherapy. Chemotherapy is graded according to how likely it is to provoke nausea and vomiting (i.e. how emetogenic it is). In six RCTs participants received highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). In six RCTs participants only received HEC. One RCT did not state whether participants received HEC or MEC. </p> <p>No RCTs included participants receiving radiotherapy alone. One trial included participants who were receiving both chemotherapy and radiotherapy treatment for their cancer. One trial included participants who were not receiving either chemotherapy or radiotherapy. </p> <p><b>Study funding sources</b> </p> <p>No included RCTs reported receiving funds from pharmaceutical companies. Five studies stated that they had received funding from cancer foundations, endowments, or universities. Nine studies made no declaration regarding funding. </p> <p><b>Key results</b> </p> <p>Fifty percent of people who received olanzapine as well as standard treatment probably would not be nauseous or vomit during chemotherapy compared to just 25% of those who received standard treatment. Olanzapine probably makes unwanted sleepiness more likely. We are uncertain if using 5 mg olanzapine a day instead of 10 mg olanzapine a day reduces the likelihood of being sleepy without reducing the antisickness benefit. We are not certain about the risk of experiencing other side effects or serious side effects, so it is important to be aware that these might happen. There was some suggestion that people who take olanzapine with standard treatment might have an improved quality of life compared to those who used standard treatment alone, but we were very uncertain of this because we were unable to analyse the data. There was not enough evidence to say whether people prefer to use olanzapine compared to not taking it. </p> <p>There is not enough evidence to say whether olanzapine is as good as, worse or better than other antisickness medications currently in use. </p> <p><b>Quality of the evidence</b> </p> <p>We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high. 'Very low‐quality evidence' means that we are very uncertain about the results. 'High‐quality evidence' means that we are very confident in the results. We found moderate‐quality evidence that olanzapine reduces overall nausea and vomiting but that it also increases unwanted sleepiness when compared to placebo or no treatment. There was moderate‐quality evidence for patient preference and low‐quality evidence for adverse events. The remaining evidence was of low‐ or very‐low quality. </p> <p><b>Implications of the review</b> </p> <p>Olanzapine is probably an effective antisickness medication. We are unsure which dose is best to use, 5 mg or 10 mg, or if 2.5 mg might work just as well. However, this review only found information about giving olanzapine by mouth and did not find any about injecting it. More research is needed to inform practice. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012555-sec-0201" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012555-sec-0201">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012555-sec-0290">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012555-sec-0201"></div> <h3 class="title" id="CD012555-sec-0202">Implications for practice</h3> <section id="CD012555-sec-0202"> <section id="CD012555-sec-0203"> <h5 class="title">For adults with cancer‐related nausea and vomiting</h5> <p>Olanzapine probably reduces the number of people with cancer who experience chemotherapy‐induced nausea and vomiting (CINV), when given by mouth in addition to a standard antisickness treatment, compared to the standard antisickness treatment alone. Olanzapine probably almost doubles the likelihood that there will be no nausea or vomiting during a course of chemotherapy. The evidence we reviewed found that with standard antisickness treatment about 75% of participants experienced some nausea and may have vomited during chemotherapy. When olanzapine was added to standard antisickness treatment this fell to 50%. </p> <p>Unfortunately, olanzapine probably increases somnolence. This may be more likely with 10 mg a day than 5 mg. The risk of other adverse events may be increased by olanzapine when used with other antisickness treatment compared to using the antisickness treatment alone. </p> <p>Olanzapine is unlicensed for this indication.</p> </section> <section id="CD012555-sec-0204"> <h5 class="title">For clinicians</h5> <p>Oral olanzapine is probably an effective antiemetic when used with a standard antiemetic regimen compared to the standard antiemetic regiment alone in the treatment of people experiencing CINV with solid tumours. Whilst 5 mg may have a similar antiemetic effect to 10 mg, we did not include studies directly comparing doses in this review. There is a lack of randomised controlled trial (RCT), evidence to support the use of 2.5 mg olanzapine as an antiemetic or to support the use of olanzapine administration by any route other than oral. There may be an increase in adverse events with olanzapine, and somnolence is probably more likely and may limit its clinical use, although 5 mg may cause less somnolence than 10 mg. We are less certain about the risk of serious adverse events, particularly hyperglycaemia, agranulocytosis, QTc prolongation and extra‐pyramidal adverse events. </p> <p>There is limited information regarding the efficacy and safety of olanzapine compared to other antiemetics. </p> <p>Safety concerns have been raised in the literature that intravenous olanzapine may lead to serious respiratory depression. Cardiovascular and respiratory depression have also been noted when it is administered intramuscularly. The results of this review therefore cannot be extrapolated to support the use of olanzapine via the intravenous, intramuscular or subcutaneous route. </p> <p>Olanzapine is currently listed as an antipsychotic, however, it is not licensed for the prevention or treatment of nausea and vomiting in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), or in the USA by the Food and Drug Administration (FDA). Its use as an antiemetic is therefore currently an off‐licence use in the UK and USA. </p> </section> <section id="CD012555-sec-0205"> <h5 class="title">For policy makers</h5> <p>Oral olanzapine is probably an effective antiemetic when added to standard treatment regimens for adults with CINV. Olanzapine is a low‐cost, once‐daily antiemetic that is available as an oral dispersible wafer, with infrequent adverse events. Olanzapine is currently listed as an antipsychotic, however, it is not licensed for the prevention or treatment of nausea and vomiting in the UK by the MHRA, or in the USA by the FDA. Its use as an antiemetic is therefore currently an off‐licence use in the UK and USA. </p> <p>Additionally, there remains limited evidence for use of olanzapine instead of other antiemetics. In particular there is insufficient evidence to support its use in preference to NK1 antagonists for the treatment of chemotherapy related nausea and vomiting. </p> </section> <section id="CD012555-sec-0206"> <h5 class="title">For funders</h5> <p>There is moderate‐quality evidence that oral olanzapine is an effective antiemetic in CINV. Further research is urgently needed to assess the optimal dose regimen. Additionally, further research is needed to assess the relative efficacies of olanzapine and NK1 antagonists, as olanzapine may be a more cost‐effective option. Studies are also needed to look at which settings it is most effective in, particularly in patients receiving radiotherapy or no active anticancer treatment, to address the current paucity of evidence in these groups. </p> <p>Future trials should be adequately powered to detect a difference and should have an explicit method for reporting adverse effects, including serious adverse events and somnolence. </p> </section> </section> <h3 class="title" id="CD012555-sec-0207">Implications for research</h3> <section id="CD012555-sec-0207"> <section id="CD012555-sec-0208"> <h5 class="title">General implications</h5> <p>Large, high‐quality RCTs, with patient‐centred outcomes are needed in order to establish the optimal effective dose regimen of olanzapine that achieves the greatest antiemetic effect with the least incidence of adverse events, particularly somnolence. We await the outcomes of the 13 ongoing studies, and the 8 studies awaiting classification, with interest. </p> <p>One published abstract (<a href="./references#CD012555-bbs2-0021" title="HashimotoH , YanaiT , NagashimaK , TsudaN , HorinouchiH , TakiguchiT , et al. A double‐blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin. Journal of Clinical Oncology2016;34:(no pagination). ">Hashimoto 2016</a>), one unpublished study (<a href="./references#CD012555-bbs2-0034" title="YanaiT , YamamotoN . A double‐blind randomized phase II study of olanzapine 10mg versus 5mg for highly emetogenic chemotherapy‐induced nausea and vomiting. rctportal.niph.go.jp/en/detail?trial_id=UMIN0000142142015. ">Yanai 2015</a>), and two ongoing studies (<a href="./references#CD012555-bbs2-0047" title="MukhopadhyayS , DuttaP , BhattacharyaB , BanerjeeS , BiswasS , Mukhopadhyay‐SamantaB . Low dose vs. standard dose adjuvant olanzapine in chemotherapy induced nausea and vomiting: a prospective, randomized, double blinded, controlled study. Clinical Therapeutics2017;39(8 Supplement 1):e17. MukhopadhyayS , DuttaP , BhattacharyaB , BanerjeeS , BiswasS , SamantaB . Comparison of efficacy, safety and sedation with two doses of add on olanzapine in chemotherapy induced nausea and vomiting: a randomized controlled pilot study. Supportive Care in Cancer2016;24(1 Supplement 1):S248‐9. MukhopadhyayS , DuttaP , BhattacharyaB , DasD , BiswasS . Low dose olanzapine in chemotherapy induced nausea and vomiting: a balance game between sedation and nausea?. Supportive Care in Cancer: International MASCC/ISOO Symposium2017;25(2 Supplement 1):S69. ">Mukhopadhyay 2017a</a>; <a href="./references#CD012555-bbs2-0048" title="NagashimaK , IwasaS , YanaiT , HashimotoH , SuzukiK , OhyanagiF , et al. A double‐blind randomized phase II study of olanzapine 10 mg versus 5 mg for emesis induced by highly emetogenic chemotherapy. Japanese Journal of Clinical Oncology2015;45(2):229‐31. ">Nagashima et al 2015</a>), address 10 mg olanzapine compared to 5 mg. The review authors are not aware of any studies exploring the efficacy of 2.5 mg olanzapine as an antiemetic. </p> </section> <section id="CD012555-sec-0209"> <h5 class="title">Design</h5> <p>In future RCTs, investigators should ensure that the dosing regimen of the standard therapy is the same in both arms so that any observed effect is attributable to the intervention of interest, olanzapine, rather than its combined effect with the variation in the standard therapy administered. In particular, the dose of dexamethasone, which is known to be an effect modifier, should be the same in the intervention and comparator arms. However, it is also important that the regimen of NK1 antagonist or 5‐HT3 antagonist are identical in each comparison arm. </p> <p>RCTs with a longer intervention and follow‐up period are needed to establish olanzapine's efficacy and safety when used for more than five days. </p> <p>The parenteral administration of olanzapine is yet to be studied in an RCT. This is of clinical importance as inherent in vomiting is the risk of failure to ingest and absorb it when the oral route is used, although counterbalanced by the known serious respiratory and cardiovascular adverse events associated with the intravenous and intramuscular routes. </p> <p>Further research is needed to establish its non‐inferiority or otherwise when compared to other antiemetics currently used, including NK1 antagonists, 5‐HT3 antagonists, prokinetics, steroids, and when compared directly to current standard care. We await the full published results of <a href="./references#CD012555-bbs2-0041" title="NguyenN , PhamV , NguyenT , TranT . Olanzapine and omeprazole combination is simple, safe and effective for delayed nausea and vomiting control in adjuvant chemotherapy for early stage breast cancer. Supportive Care in Cancer2017;25(2 Supplement 1):S72. ">Nguyen 2017</a>, an RCT comparing olanzapine and omeprazole directly to standard care and omeprazole without any other standard therapy. The published abstract states that olanzapine 10 mg oral and omeprazole 20 mg, once daily for three days is "simple, cheap cost, safe, and effective in preventing vomiting, reducing nausea, and preserving QoL [quality of life)" when compared to dexamethasone 4 mg twice daily, omeprazole 20 mg twice daily and metoclopramide 20 mg three times daily, all for five days. </p> </section> <section id="CD012555-sec-0210"> <h5 class="title">Measurement</h5> <p>We encourage investigators to use the 'hard' outcome of 'no nausea, no vomiting' rather than the surrogate outcome 'no vomiting, no breakthrough medication' when reporting primary outcomes. When reporting serious adverse events it is important that the nature of these are fully defined. Additionally, if consensus were reached in the future to enable one quality‐of‐life measure to be universally adopted this would allow comparison of data across studies more easily, and therefore aid the applicability of this data in the clinical setting. </p> </section> <section id="CD012555-sec-0211"> <h5 class="title">Other</h5> <p>Studies are urgently needed to explore impact of the different anticancer treatment on the efficacy and safety of olanzapine during different phases of illness, particularly in radiotherapy, chemoradiotherapy or no active cancer treatment. We are aware of two ongoing studies (<a href="./references#CD012555-bbs2-0046" title="JPRN‐UMIN000010317 . Efficacy of olanzapine for relief of nausea with incomplete bowel obstruction in advanced cancer patient: pragmatic randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000010317 (first received 26 March 2013). ">JPRN‐UMIN000010317</a> and <a href="./references#CD012555-bbs2-0055" title="NCT03137121 . Olanzapine for the treatment of chronic nausea and/or vomiting in advanced cancer patients [Olanzapine for the treatment of chronic nausea and/or vomiting, unrelated to chemotherapy or radiation, in advanced cancer patient ‐ a pilot, dose‐finding trial]. clinicaltrials.gov/ct2/show/NCT03137121 (first received 2 May 2017). ">NCT03137121</a>), addressing the use of olanzapine in participants with advanced cancer who are not receiving any active anticancer therapy. In <a href="./references#CD012555-bbs2-0046" title="JPRN‐UMIN000010317 . Efficacy of olanzapine for relief of nausea with incomplete bowel obstruction in advanced cancer patient: pragmatic randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000010317 (first received 26 March 2013). ">JPRN‐UMIN000010317</a> participants have malignant bowel obstruction. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012555-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012555-sec-0029"></div> <div class="table" id="CD012555-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Olanzapine compared to placebo/no treatment for the prevention and treatment of cancer‐related nausea and vomiting in adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Olanzapine compared to placebo/no treatment for the prevention and treatment of cancer‐related nausea and vomiting in adults</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> adults with cancer </p> <p><b>Setting:</b> hospital or medical institutions; either inpatient or not stated if inpatient or outpatient<br/> <b>Intervention:</b> olanzapine<br/> <b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Results</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Without olanzapine</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>With olanzapine</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Difference</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No nausea or vomiting over trial period</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.98 (1.59 to 2.47)</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population: 561 participants (3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Olanzapine probably improves freedom from nausea or vomiting over the trial period when compared to placebo or no intervention if used in conjunction with standard therapy </p> <p>(OR 5.48 (95% CI 1.35 to 22.20) I² = 85%).</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.7%<br/> (39.9 to 62.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.6% more<br/> (14.8 more to 36.9 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 2.46<br/> (0.48 to 12.55) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population: 889 participants (7 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain if olanzapine increases the risk of serious adverse events when compared to placebo or no intervention if used in conjunction with standard therapy. Six RCTs reported no serious adverse events in either arm </p> <p>(OR 2.50, 95% CI 0.48 to 13.04; I² = 0%).</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1%<br/> (0.2 to 5.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7% more<br/> (0.2 fewer to 5.2 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Participant preference ‐ wish to use drug in next treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.43<br/> (0.97 to 2.09) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population: 48 participants (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Moderate<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain if participants preferred olanzapine when compared to placebo or no intervention if used in conjunction with standard therapy </p> <p>(OR 3.57, 95% CI 0.93 to 13.72).</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.4%<br/> (56.6 to 100.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.1% more<br/> (1.8 fewer to 63.6 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Study population: 258 participants (4 RCTs)</p> <p><a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>: "[olanzapine] group experienced a better QOL than the control group, as reported on the Functional Living Index‐Emesis questionnaire (P &lt; 0.0004)". </p> <p><a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a>: global health status improved in the olanzapine group using the EORTC QLQ C30. Control group's global health status deteriorated from 10.08 ± 0.43 before treatment to 8.70 ± 0.44 P &lt; 0.0001 after chemotherapy. This decline was not seen in the olanzapine group (before 9.48 ± 0.48 and after treatment 9.60 ± 0.47; P = 0.537). </p> <p><a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a> 23/39 participants in the megestrol plus olanzapine arm had an improved QOL at 4 and 8 weeks compared to 5/37 who received megestrol alone on the "Functional Assessment of Cancer Therapy‐General (version 3)". </p> <p><a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016:</a> "no significant difference was observed between the case and control groups about the patients QOL in ... total QOL score (P &gt; 0.05)" using the WHO‑QOL‑BREF </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is unclear whether participants who used olanzapine had an improved quality of life compared to placebo or no intervention, if used with standard therapy due to inter‐study heterogeneity in scales used. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Patient Global Impression of Change</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome was not measured or not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Other adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.71<br/> (0.99 to 2.96) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population: 332 participants (4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Olanzapine may lead to more adverse events when compared to placebo or no treatment if used in conjunction with standard therapy </p> <p>(OR 2.05, 95% CI 0.99 to 4.22; I² = 0%).</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.4%<br/> (8.3 to 25.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0% more<br/> (0.1 fewer to 16.5 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Somnolence/fatigue</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 2.33<br/> (1.30 to 4.18) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population: 464 participants (5 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Olanzapine probably leads to increased risk of somnolence or fatigue when compared to placebo or no intervention if used in conjunction with standard therapy </p> <p>(OR 2.84, 95% CI 1.39 to 5.78; I² = 0%).</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.4%<br/> (7.0 to 24.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2% more<br/> (1.9 more to 18.8 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>EORTC QLQ‐C30:</b> European Organisation for Research and Treatment of Cancer quality of life questionnaire; <b>QOL:</b> quality of life; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio; <b>WHO‐QOL‐BREF:</b> World Health Organization Quality of Life‐BREF </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded to moderate quality due to inconsistency (‐1). The risk of nausea and vomiting in the control group varied from 19% to 40%. This variation was probably due to the characteristics of the trials being different (such as type of cancer, chemotherapy treatment given, dose of olanzapine etc). We observed statistical heterogeneity when using odds ratios (I² = 85%). <br/> <sup>2</sup>Downgraded to low quality due to imprecision (‐1) and inconsistency (‐1). There was only a small number of events (5 in olanzapine, 2 in control arm) in one trial only. No events in either arm of six other trials, leading to wide confidence intervals.<br/> <sup>3</sup>Downgraded to moderate quality due to imprecision (‐1). There was a very small sample size, 24 participants per arm, resulting in very large confidence intervals.<br/> <sup>4</sup>Downgraded to low quality due to imprecision (‐1) and inconsistency (‐1). There were wide confidence intervals. There was large variation in risks of adverse events between studies with one study reporting an event rate of 23% in the placebo arm and 35% in the olanzapine arm.<br/> <sup>5</sup>Downgraded to moderate quality due to inconsistency (‐1). There was unexplained heterogeneity in the risk of somnolence between studies making it difficult to be confident that the true effect lies close to the estimate of the effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012555-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Olanzapine compared to NK1 antagonist for the prevention and treatment of cancer‐related nausea and vomiting in adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Olanzapine compared to NK1 antagonist for the prevention and treatment of cancer‐related nausea and vomiting in adults</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with cancer </p> <p><b>Setting:</b> military medical centre; not stated if inpatient or outpatient<br/> <b>Intervention:</b> olanzapine<br/> <b>Comparison:</b> NK1 antagonist </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Results</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With NK1 antagonist</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>With olanzapine</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Difference</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No nausea or vomiting over trial period</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome was not measured.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.02 to 7.32) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population: 20 participants (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are uncertain if there is a difference in the incidence of serious adverse events with olanzapine compared with NK1 antagonists. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome was not measured or not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome was not measured or not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient Global Impression of Change</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome was not measured or not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome was not measured or not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Somnolence/fatigue</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.33<br/> (0.40 to 4.49) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population: 20 participants (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are uncertain whether there is a difference in incidence of somnolence or fatigue with olanzapine compared with NK1 antagonists (OR 1.56, 95% CI 0.24 to 9.91). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.0%<br/> (12.0 to 100.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10% more<br/> (18 fewer to 104.7 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded to very low quality due to imprecision (‐1) and very serious study limitations (‐2). There was only one study with a small sample size (n = 20) and very few events (1 event in NK1 arm) leading to very imprecise results. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012555-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012555-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012555-sec-0231">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012555-sec-0030"></div> <p>This protocol is based on templates from both Cochrane Pain, Palliative and Supportive Care (PaPaS) and Cochrane Ear, Nose and Throat Disorders. </p> <section id="CD012555-sec-0031"> <h3 class="title" id="CD012555-sec-0031">Description of the condition</h3> <p>People with cancer may experience nausea and vomiting at different stages of their illness: before, during, and after chemotherapy or radiotherapy; and during a palliative phase of illness. </p> <p><a href="./references#CD012555-bbs2-0069" title="GlareP , MillerJ , NikolovaT , TickooR . Treating nausea and vomiting in palliative care: a review. Clinical Interventions in Aging2011;6:243–59. ">Glare 2011</a> defined nausea as, "...an entirely subjective experience... that immediately precede vomiting" [sic). Vomiting is a highly specific physical event and is defined as "the rapid, forceful evacuation of gastric contents in retrograde fashion from the stomach up to and out of the mouth". </p> <p><a href="./references#CD012555-bbs2-0079" title="KrisM . Impact of CINV. Clinical Advances in Hematology and Oncology2011;9(1):9‐13. ">Kris 2011</a> observed that, "one of the largest misconceptions in the field of oncology today is that the problem of Chemotherapy‐Induced Nausea and Vomiting (CINV), has been solved" whilst noting that "CINV is the most significant side effect of chemotherapy from the patient’s perspective". The prevalence of CINV has been reported to be: 36% for acute CINV (within 24 hours of administration of chemotherapy); 59% for delayed CINV (two to five days after administration of chemotherapy); and 47% for both (<a href="./references#CD012555-bbs2-0063" title="CohenL , deMoorC , EisenbergP , MingE , HuH . Chemotherapy‐induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Supportive Care in Cancer2007;15(5):497‐503. ">Cohen 2007</a>). The cost per return hospital visit for CINV to the USA healthcare system, likely to occur if CINV remains uncontrolled, has been stated to be USD 5299 (<a href="./references#CD012555-bbs2-0058" title="BurkeT , WisniewskiT , ErnstF . Resource utilization and costs associated with chemotherapy‐induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Supportive Care in Cancer2011;19(1):131‐40. ">Burke 2011</a>). Nausea and vomiting, particularly CINV, are also known to have a negative impact on quality of life (<a href="./references#CD012555-bbs2-0093" title="SommarivaS , PongiglioneB , TarriconeR . Impact of chemotherapy‐induced nausea and vomiting on health‐related quality of life and resource utilization: a systematic review. Critical Reviews in Oncology/Hematology2016;99:13‐36. ">Sommariva 2016</a>), even when only moderately emetogenic chemotherapy (MEC), is administered. While the treatment of CINV has greatly improved over time, some people experience nausea and vomiting despite optimal treatment. </p> <p>The prevalence of nausea in the palliative population has been estimated to range from 6% to 68% (<a href="./references#CD012555-bbs2-0092" title="SolanoJ , GomesB , HigginsonI . A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. Journal of Pain and Symptom Management2006;31(1):58–69. ">Solano 2006</a>). A systematic review of symptom prevalence in people with terminal cancer reported a pooled prevalence of 31% (95% CI 27 to 35), for nausea and 20% (95% CI 17 to 22), for vomiting (<a href="./references#CD012555-bbs2-0094" title="TeunissenS , WeskerW , KruitwagenC , DeHaesH , VoestE , DeGraeffA . Symptom prevalence in patients with incurable cancer: a systematic review. Journal of Pain and Symptom Management2007;31(1):94‐104. ">Teunissen 2007</a>). Persistent nausea and vomiting in people with palliative conditions can lead to unplanned hospital visits. In one study, gastrointestinal symptoms, including nausea and vomiting, were the most common reason for a participant receiving palliative care to attend the emergency department (48% of participants), despite one third preferring not to be cared for in hospital (<a href="./references#CD012555-bbs2-0075" title="HjermstadM , KolflaathJ , LøkkenA , HanssenS , NormannA , AassN . Are emergency admissions in palliative cancer care always necessary? Results from a descriptive study. BMJ Open2013;3(5):e002515. ">Hjermstad 2013</a>). </p> <p>This review will address the use of olanzapine in adults with cancer‐related nausea and vomiting at each stage of the illness: before, during, and after chemotherapy or radiotherapy; and during the palliative phase of illness. </p> </section> <section id="CD012555-sec-0032"> <h3 class="title" id="CD012555-sec-0032">Description of the intervention</h3> <p>The use of olanzapine for the prevention and treatment of nausea and vomiting has been reported in the literature in the form of case reports and case series since 2000 (<a href="./references#CD012555-bbs2-0077" title="JacksonW , TavernierL . Olanzapine for intractable nausea in palliative care patients. Journal of Palliative Medicine2003;6(2):251‐5. ">Jackson 2003</a>; <a href="./references#CD012555-bbs2-0087" title="PirlW F , RothA J . Remission of chemotherapy‐induced emesis with concurrent olanzapine treatment: a case report. Psycho‐oncology2000;9(1):84‐7. ">Pirl 2000</a>). These articles described its use for CINV and for palliation. <a href="./references#CD012555-bbs2-0088" title="PrommerE . Olanzapine: palliative medicine update. American Journal of Hospice &amp; Palliative Medicine2012;30(1):75‐82. ">Prommer 2012</a> went on to identify olanzapine as a drug of multi‐palliation, "... being useful for the management of several symptoms commonly encountered in palliative care, such as delirium, nausea, vomiting, and pain". </p> <p>There has been a growing interest in establishing the safety and efficacy of olanzapine as an antiemetic, particularly in the prevention and treatment of CINV, through randomised controlled trials (RCTs). The use of olanzapine as an antiemetic represents a new use of an old second generation atypical antipsychotic drug. Phase I, II, and III trials have been undertaken to assess its efficacy and tolerability in the prevention and treatment of CINV. </p> <p>Olanzapine is available in many countries, in both branded and generic forms. It is most often administered orally, either as a tablet (2.5 mg to 20 mg), velotab, as an oral solution, or orally‐disintegrating 'wafer', but it may also be given by intramuscular injection. Olanzapine has also been used in the treatment of cancer‐related cachexia, as it is known to promote weight gain, and in the treatment of delirium (<a href="./references#CD012555-bbs2-0078" title="KishiT , HirotaT , MatsunagaS , IwataN . Antipsychotic medications for the treatment of delirium: a systematic review and meta‐analysis of randomised controlled trials. Journal of Neurology, Neurosurgery, and Psychiatry2016;87(7):767‐74. ">Kishi 2015</a>; Navari 2010). </p> <p>In this review we have only identified RCTs describing oral administration. Furthermore, the literature has raised serious safety concerns relating to respiratory distress following intravenous administration (<a href="./references#CD012555-bbs2-0081" title="MartelM , KleinL , RivardR , ColevJ . A large retrospective cohort of patients receiving intravenous olanzapine in the emergency department. Society for Academic Emergency Medicine2016;23:29‐33. ">Martel 2016</a>). These include hypoxia and the need for airway and ventilatory support. Therefore, the findings of this review cannot be extrapolated to justify use of the injectable form for intravenous, intramuscular or subcutaneous administration for the treatment or prevention of nausea and vomiting at the present time. </p> </section> <section id="CD012555-sec-0033"> <h3 class="title" id="CD012555-sec-0033">How the intervention might work</h3> <p>Olanzapine is a second generation, atypical thienobenzodiazepine antipsychotic with a broad spectrum of neurotransmitter blockade including serotonin 5‐HT2a, 5‐HT2c, 5‐HT3, 5‐HT6 receptors, dopamine D1, D2, D3, D4 brain receptors, ∝1 adrenergic receptors, acetylcholine (ACh), muscarinic receptors, and H1 histamine receptors. This broad spectrum of action, particularly on the dopamine and serotonin receptors, has led to increasing interest in its use as an antiemetic, as it is likely to act at the vomiting centre and chemoreceptor trigger zone (<a href="./references#CD012555-bbs2-0086" title="NavariR . Management of chemotherapy‐induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs2013;73(3):249‐62. ">Navari 2013a</a>). </p> <p>Olanzapine's broad spectrum of action in the prevention and treatment of nausea and vomiting may be similar to that of levomepromazine. </p> <p>Olanzapine is known to cause adverse effects. The most relevant of these include weight gain, sedation, loss of control of diabetes mellitus, and blood dyscrasias. Extra‐pyramidal side effects and dyskinesias, as well as prolongation of the corrected QT interval, have also been noted within this class of medications (<a href="./references#CD012555-bbs2-0057" title="British National Formulary. www.evidence.nhs.uk/formulary/bnf/current/4‐central‐nervous‐system/42‐drugs‐used‐in‐psychoses‐and‐related‐disorders/421‐antipsychotic‐drugs/second‐generation‐antipsychotic‐drugs/olanzapine (accessed 28 September 2017). ">BNF</a>). The QT interval, measured on an Electrodariogram (ECG) as the time between the Q and T waves, is a measure of the time taken for the heart to repolarise and is corrected to take account of the heart rate. Prolongation of the QT interval is a risk factor for sudden death due to the increased potential of malignant ventricular tachyarrhythmias. </p> </section> <section id="CD012555-sec-0034"> <h3 class="title" id="CD012555-sec-0034">Why it is important to do this review</h3> <p>Given the emerging use of olanzapine as an antiemetic in both CINV and palliative care, it is important to establish the evidence base for its use in the prevention and treatment of nausea and vomiting. Nausea and vomiting during a patient's cancer journey is a common symptom. The antiemetics currently available are not effective for all people, particularly for the prevention or treatment of nausea. Providing another treatment option may provide relief to more people whose nausea is currently not relieved, and in situations where other antiemetics are unavailable. </p> <p>Olanzapine is currently listed as an antipsychotic, however, it is not licensed for the prevention or treatment of nausea and vomiting in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), or in the USA by the Food and Drug Administration (FDA). Its use as an antiemetic is therefore currently an off‐licence use in the UK and USA. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012555-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012555-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012555-sec-0236">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012555-sec-0035"></div> <p>To assess the efficacy and safety of olanzapine when used as an antiemetic in the prevention and treatment of nausea and vomiting related to cancer in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012555-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012555-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012555-sec-0237">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012555-sec-0036"></div> <section id="CD012555-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012555-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs; described as ‘randomised’ anywhere in the manuscript), of olanzapine for the prevention or treatment of nausea or vomiting, or both, in any setting. We considered open‐label studies. We only used the first phase of cross‐over studies. We excluded quasi‐randomised trials. Included studies required a minimum of 10 participants per treatment arm. </p> <p>We excluded non‐randomised studies, case series and case reports, and clinical observations. Studies were required to be fully published or available as extended abstracts (for example from clinical trials websites); we did not include short (usually conference), abstracts unless we had received satisfactory additional information the author through personal correspondence. </p> </section> <section id="CD012555-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included studies of inpatients or outpatients with cancer (of any type or stage), who had nausea and vomiting treated with olanzapine, or where olanzapine was used to prevent nausea and vomiting. Adult participants were male or female, and aged 18 years and older. </p> <p>We excluded studies in which olanzapine was used for the treatment or prevention of nausea and vomiting in non‐cancer patients. </p> </section> <section id="CD012555-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included studies that gave olanzapine for the prevention or treatment of nausea and vomiting and compared it with placebo or any active comparator, by any route, in any dose, frequency, or duration of treatment. For the purpose of this review, we defined prevention as the use of an antiemetic prior to the first cycle of chemotherapy. </p> <p>The main comparators were placebo, usual care, prokinetics (metoclopramide or domperidone), serotonin (5‐HT3), receptor antagonists, and neurokinin 1 (NK1), receptor antagonists. </p> <p>The main comparison pairs were:</p> <p> <ul id="CD012555-list-0001"> <li> <p>olanzapine versus placebo;</p> </li> <li> <p>olanzapine versus usual care.</p> </li> </ul> </p> <p>Other possible comparison pairs, if data were available, were:</p> <p> <ul id="CD012555-list-0002"> <li> <p>olanzapine versus prokinetics;</p> </li> <li> <p>olanzapine versus 5‐HT3 antagonists;</p> </li> <li> <p>olanzapine versus NK1 antagonists;</p> </li> <li> <p>olanzapine plus dexamethasone versus any possible comparators noted above plus dexamethasone.</p> </li> </ul> </p> </section> <section id="CD012555-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD012555-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012555-list-0003"> <li> <p>Absence of nausea or vomiting as measured by the proportion of participants with no nausea or vomiting over the time period studied </p> </li> <li> <p>Serious adverse events, specifically, extra pyramidal adverse events, prolonged QTc interval, neutropenia and agranulocytosis, as measured by the proportion of participants experiencing at least one of these events </p> </li> </ul> </p> </section> <section id="CD012555-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012555-list-0004"> <li> <p>Patient perception of treatment including: patient satisfaction as measured by any scale including Likert; patient preference (as a dichotomous yes/no outcome); validated quality‐of‐life measures; number of participants with Patient Global Impression of Change (PGIC), of much improved or very much improved (or equivalent wording) </p> </li> <li> <p>Other adverse events, as measured by the proportion of participants experiencing at least one of these </p> </li> <li> <p>Somnolence and fatigue, as measured by the proportion of participants experiencing at least one of these (<a href="#CD012555-sec-0225">Differences between protocol and review</a>) </p> </li> <li> <p>Attrition: withdrawals due to all causes (including lack of efficacy, adverse events, and death) </p> </li> <li> <p>Number of participants with at least a 50% reduction in the severity of nausea or vomiting from baseline, as measured by a validated scale </p> </li> <li> <p>Number of participants with breakthrough nausea and vomiting, and number of participants requiring rescue antiemetics </p> </li> <li> <p>Number of participants with no overall nausea and no overall vomiting, no anticipatory (prior to chemotherapy), nausea or vomiting, no acute (within 24 hours of administration of chemotherapy), nausea or vomiting, and no delayed (two to five days after administration of chemotherapy, nausea or vomiting </p> </li> </ul> </p> <p>We did not exclude studies solely on the basis that the data were not available relating to any of these outcomes. </p> </section> </section> </section> <section id="CD012555-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>The Cochrane Pain, Palliative and Supportive Care Information Specialist conducted the search. There were no language, publication year, or publication status restrictions. We arranged translations of papers where necessary. </p> <section id="CD012555-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases without language restrictions for published data:</p> <p> <ul id="CD012555-list-0005"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, issue 9), via the CRSO; </p> </li> <li> <p>MEDLINE and MEDLINE in Process (Ovid), 1946 to 19 September 2017;</p> </li> <li> <p>Embase (Ovid), 1974 to 2017 week 38.</p> </li> </ul> </p> <p>See <a href="./appendices#CD012555-sec-0215">Appendix 1</a> , <a href="./appendices#CD012555-sec-0216">Appendix 2</a> and <a href="./appendices#CD012555-sec-0217">Appendix 3</a> for the search strategies. </p> </section> <section id="CD012555-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We searched the following unpublished databases without language restrictions:</p> <p> <ul id="CD012555-list-0006"> <li> <p><a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>; </p> </li> <li> <p><a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>. </p> </li> </ul> </p> <p>In addition, we checked reference lists of reviews identified in the search and retrieved full‐text articles for additional studies on key articles. We contacted experts in the field for unpublished and ongoing trials. We contacted study authors where necessary for additional information. </p> </section> </section> <section id="CD012555-sec-0047"> <h3 class="title" id="CD012555-sec-0047">Data collection and analysis</h3> <section id="CD012555-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Using <a href="./references#CD012555-bbs2-0064" title="Veritas Health Innovation. Covidence. Version 30 September 2017. Melboune, Australia: Veritas Health Innovation, 2017. ">Covidence</a>, at least two review authors (AS, KH and KN), screened the titles and abstracts of all identified studies, and excluded those that clearly did not meet the inclusion criteria. For the remaining studies, we read the full manuscript to assess if it should be included. A minimum of two review authors (AS, KH and KN), independently screened all titles, abstracts and full‐text manuscripts. We resolved discrepancies between review authors by discussion and consensus; where necessary, we consulted a third review author (BW). We did not anonymise studies before selection. </p> <p>We have presented a PRISMA flow chart in <a href="#CD012555-fig-0001">Figure 1</a> (<a href="./references#CD012555-bbs2-0084" title="MoherD , LiberatiA , TetzlaffJ , AltmanD . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. ">Moher 2009</a>). This shows the status of identified studies, as recommended in Part 2, Section 11.2.1 of the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD012555-bbs2-0090" title="SchünemannH J , OxmanA D , HigginsJ P , VistG E , GlasziouP , GuyattG H . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins J P T, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Schünemann 2011</a>). We included studies in the review regardless of whether the measured outcome data were reported in a ‘usable’ way. </p> <div class="figure" id="CD012555-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD012555-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD012555-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Four review authors (AS, LW, KH and EP), extracted data from the included studies using a standardised data collection form. All included articles were data extracted independently by a minimum of two review authors. Where there were differences in the data extracted by different review authors, we resolved this by reference to the original publications and through discussion and consensus, involving a third review author as necessary before entering them into Review Manager 5 (RevMan 5), (<a href="./references#CD012555-bbs2-0089" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). Where a study had more than one publication, we retrieved all publications to ensure complete extraction of data. Where data were missing or unclear, we contacted the original study authors for clarification. We assessed the data using intention‐to‐treat as the basis for our data analysis. Where data were reported in divided groups following post hoc analysis without stipulating that stratified randomisation had been undertaken, we recombined the groups when extracting the data to mitigate the potential for breaking randomisation (<a href="./references#CD012555-bbs2-0013" title="ZhangD . Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting (AOPDPCINV). clinicaltrials.gov/ct2/show/NCT02484911 (accessed 28 September 2017). ">Zhang 2017</a>). </p> <p>We included key information from each of the included studies in sufficient detail to populate a table of <a href="./references#CD012555-sec-0227" title="">Characteristics of included studies</a>, including: study design (placebo or active control, and cross‐over), and methods, sample size, baseline demographic details, type of chemotherapy or radiotherapy received, if any, type of cancer, drug and dosing regimen (including when olanzapine is used in combination with another). </p> <p>In addition to the pre‐specified information about study characteristics and aspects of methodology relevant to risk of bias (see below), we extracted the following summary statistics for each trial and each outcome. </p> <p> <ul id="CD012555-list-0007"> <li> <p>For continuous data: the mean values, standard deviations, and number of participants for each treatment group. Where endpoint data were not available, we extracted the values for change from baseline. </p> </li> <li> <p>For dichotomous data: the numbers of participants experiencing an event and the number of patients randomised. </p> </li> <li> <p>For ordinal scale data: if the data appeared to be approximately normally distributed, or if the analysis that the investigators performed suggested parametric tests were appropriate, then we would have treated the outcome measures as continuous data. Alternatively, if data were available, we planned to convert them into dichotomous data. </p> </li> </ul> </p> </section> <section id="CD012555-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Four review authors (AS, KH, LW and EP), independently assessed the risk of bias for each included study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions,</i> and we used the Cochrane 'Risk of bias' table in RevMan 5, with any disagreements resolved by discussion (<a href="./references#CD012555-bbs2-0074" title="HigginsJ P , AltmanD G , SterneJ A C (editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins J P T, Churchill R, Chandler J, Cumpston M S (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>; <a href="./references#CD012555-bbs2-0089" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> <p>We assessed risk of bias as low, high, or unclear for each of the following six domains for each study. </p> <p> <ul id="CD012555-list-0008"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non‐random process (e.g. odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); unclear risk of bias (method not clearly stated). We included studies that did not conceal allocation (e.g. open list), but considered them to have high risk of bias. </p> </li> <li> <p>Blinding of participants and personnel (checking for possible performance bias). We assessed the methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed methods as: low risk of bias (study states that it was blinded and describes the method used to achieve blinding, such as identical tablets matched in appearance or smell, or a double‐dummy technique); unclear risk of bias (study states that it was blinded but does not provide an adequate description of how it was achieved). We considered studies that were not double‐blind to have high risk of bias. </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants (for participant‐reported outcomes), and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study had a clear statement that outcome assessors were unaware of treatment allocation, and ideally described how they achieved this); unclear risk of bias (study stated that outcome assessors were blinded to treatment allocation but lacked a clear statement on how they achieved this). Studies where outcome assessment was not blinded we considered as having a high risk of bias. </p> </li> <li> <p>Selective reporting (checking for reporting bias). We assessed whether primary and secondary outcome measures were prespecified and whether these were consistent with those reported. We assessed the methods as: low risk of bias (where prespecified outcome measures were available and reflected the published results); unclear risk of bias (where no protocol was available); and high risk (where published results did not reflect prespecified outcome measures). </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (&lt; 10% of participants did not complete the study and/or used ‘baseline observation carried forward’ analysis); unclear risk of bias (used 'last observation carried forward' analysis); high risk of bias (used 'completer' analysis). </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (≥ 200 participants per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); and high risk of bias (&lt; 50 participants per treatment arm). </p> </li> </ul> </p> <p>We defined studies at high risk of bias overall as those that had a high risk of bias within the random sequence generation or allocation concealment domains, or both, and a high risk of attrition bias (overall loss to follow‐up greater than 20%, differential follow‐up observed, or both). If further information was not available, this was reflected in a designation of unclear risk of bias overall (<a href="./references#CD012555-bbs2-0074" title="HigginsJ P , AltmanD G , SterneJ A C (editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins J P T, Churchill R, Chandler J, Cumpston M S (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). </p> </section> <section id="CD012555-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We summarised the effects of dichotomous outcomes by using risk ratios (RR), with 95% confidence intervals (CI), but noted that this appeared to underestimate the heterogeneity in the data set largely due to the differences in the event rates between studies. We therefore decided to also present the data using the odds ratio (OR), in the results and 'Summary of findings' table as this provided a truer reflection of heterogeneity in the I² value, although we recognise that this is not as easily interpreted as the RR in clinical practice. </p> <p>For continuous outcomes, we expressed treatment effects as a mean difference (MD), with standard deviation (SD), or as standardised mean difference (SMD), if studies used different scales to measure the same outcome. We provided a clinical interpretation of the SMD values. </p> <p>For the key outcomes presented in the 'Summary of findings' table, we also expressed the results as absolute numbers, based on the pooled results and compared to the assumed risk. We calculated the number needed to treat for an additional beneficial outcome (NNTB), using the pooled results. The assumed baseline risk was either (a), the median of the risks of the control groups in the included studies (this being used to represent a medium risk population), or alternatively, (b), the average risk of the control groups in the included studies, this being the study population (<a href="./references#CD012555-bbs2-0066" title="DeeksJ J , HigginsJ P , Altman D G (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins J P T, Churchill R, Chandler J, Cumpston M S (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> <p>If a large number of studies had been available, and if it were appropriate, we would have also presented additional data based on the assumed baseline risk in (c), a low‐risk population, and (d), a high‐risk population. </p> <p>For unwanted effects, we calculated the number needed to treat for an additional harmful outcome (NNTH), in the same manner. </p> <p>We used the following terms to describe adverse outcomes in terms of harm or prevention of harm. </p> <p> <ul id="CD012555-list-0009"> <li> <p>When significantly more participants experienced adverse outcomes with olanzapine compared with control (placebo or active), we used the term, number needed to harm or cause one event. </p> </li> <li> <p>If significantly fewer participants had experienced adverse outcomes with olanzapine than with control (placebo or active), we would have used the term number needed to treat to prevent one event (NNTp). </p> </li> </ul> </p> <p>We did not plan to use continuous data for the primary outcome because it was inappropriate where there is an underlying skewed distribution, as is likely to be the case with nausea and vomiting response reporting. </p> </section> <section id="CD012555-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of randomisation was the individual participant. We excluded trials comparing differing doses of olanzapine in this review. However, in future updates we intend to include these. In these studies comparing differing doses of olanzapine, if data were not combined for analysis, we planned to split the control treatment arm between active treatment arms. Where only combined data for different periods (such as anticipatory, acute or delayed), were reported, we would treat the study as if it were a parallel study, drawing attention to the potential bias that this confers, and interpreting the results accordingly. </p> </section> <section id="CD012555-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We used an intention‐to‐treat (ITT), analysis, that is, participants who were randomised, took the study medication, and gave a minimum of one post‐baseline assessment. Where there were missing participants or information, we assigned them to a zero improvement category, where possible, for the efficacy outcomes (e.g. assigned them to having nausea or vomiting). We also looked for information about how data from withdrawals and dropouts were handled. In original studies, participants might have been analysed using last observation carried forward (LOCF, that is, their level of nausea or vomiting when stopping the medication), or returned to their baseline observation (BOCF, baseline observation carried forward). </p> <p>Where there were substantial numbers (more than 10%), of participants missing from analyses, we commented on this. </p> <p>Where data relating to an outcome of interest were not reported, but the methods of the study suggested that the outcome had been measured, we attempted to contact study authors by email to obtain this information. We also did this if some of the data required for meta‐analysis were unreported, unless the missing data were SDs. </p> <p>If SD data were not available, we approximated these using the standard estimation methods from P values, standard errors, or 95% CIs, if these were reported, as detailed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012555-bbs2-0066" title="DeeksJ J , HigginsJ P , Altman D G (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins J P T, Churchill R, Chandler J, Cumpston M S (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). If it was impossible to estimate these, we contacted the study authors. </p> <p>We did not make any imputations apart from those for missing standard deviations. We extracted and analysed all data using the ITT method. </p> </section> <section id="CD012555-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed both clinical and statistical heterogeneity. Clinical heterogeneity might be present even in the absence of statistical heterogeneity. We anticipated that there might be an effect of differences between participants, environment (inpatient versus outpatient), and outcome measures. We examined the included trials for evidence of differences in the types of participants recruited, setting, dose, and route of interventions, controls, or outcomes measured. </p> <p>We assessed statistical heterogeneity by visually inspecting the forest plots and by considering the I² statistic (<a href="./references#CD012555-bbs2-0073" title="HigginsJ P , ThompsonS G , DeeksJ J , AltmanD G . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). This calculates the percentage of variability that is not due to chance. I² statistic values over 50% suggest substantial heterogeneity (<a href="./references#CD012555-bbs2-0066" title="DeeksJ J , HigginsJ P , Altman D G (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins J P T, Churchill R, Chandler J, Cumpston M S (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> <p>If heterogeneity (I²), was high, we investigated this. We explored this with subgroup and sensitivity analyses where there were sufficient data. </p> </section> <section id="CD012555-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed two aspects of reporting bias: between‐study publication bias and within‐study outcome reporting bias. </p> <section id="CD012555-sec-0056"> <h5 class="title">Publication bias (between‐study reporting bias)</h5> <p>If we had suspected publication bias, we would have conducted a more formal investigation using the methods proposed by <a href="./references#CD012555-bbs2-0067" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>. </p> </section> <section id="CD012555-sec-0057"> <h5 class="title">Outcome reporting bias (within‐study reporting bias)</h5> <p>We assessed within‐study reporting bias by comparing the outcomes reported in the published report with those listed in the study protocol whenever possible, or, if the protocol was not available, with those listed in the methods section. If results were mentioned in the protocol or methods section, but were not reported in a way that allowed analysis, we sought further information from the study authors in order to try and reduce bias in the meta‐analysis. </p> </section> </section> <section id="CD012555-sec-0058"> <h4 class="title">Data synthesis</h4> <p>We used RevMan 5 to carry out meta‐analyses (<a href="./references#CD012555-bbs2-0089" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). Where possible, we analysed data to give a summary measure of effect. If no or minimal heterogeneity was seen, we used a fixed‐effect model for meta‐analysis to measure the effect. Where considerable heterogeneity was observed, we used a random‐effects model. </p> <p>For dichotomous data, we analysed treatment differences as a risk ratio (RR), calculated using the Mantel‐Haenszel methods. If we had found any time‐to event data we would have analysed them using the generic inverse variance method. </p> <p>For continuous outcomes, if all the data were from the same scale, we pooled mean values obtained at follow‐up (endpoint data), with change outcomes, and reported this as a MD. If the SMD had to be used as an effect measure, we did not pool endpoint and change data. </p> <p>When statistical heterogeneity was low, the differences in treatment effects seen when using methods based on a random‐effects versus a fixed‐effect model were trivial. When statistical heterogeneity was high, we used the random‐effects method, as this provides a more conservative estimate of the difference. </p> <section id="CD012555-sec-0059"> <h5 class="title">GRADE and 'Summary of findings' table</h5> <p>We used the GRADE approach to rate the overall quality of evidence (<a href="./references#CD012555-bbs2-0072" title="GuyattG H , OxmanA D , SchunemannH J , TugwellP , KnottnerusA . GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2011;64:380‐2. ">Guyatt 2011</a>). We used the GRADEpro GDT tool listed in the <a href="#CD012555-sec-0040">Types of interventions</a> section (<a href="./references#CD012555-bbs2-0070" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a>, accessed 30th October 2017). The quality of evidence reflects the extent to which we are confident that an estimate of effect is correct, and we applied this in the interpretation of results. There are four possible ratings: high, moderate, low, and very low. A rating of high‐quality evidence implies that we are very confident that the true effect lies close to that of the estimate of the effect. A rating of very low‐quality implies that we have very little confidence in the effect estimate and the true effect is likely to be substantially different from the estimate of effect. </p> <p>The GRADE approach rates evidence from RCTs that do not have any serious limitations as high quality. However, several factors can lead to the downgrading of the evidence to moderate, low, or very low. The degree of downgrading was determined by the seriousness of these factors: </p> <p> <ul id="CD012555-list-0010"> <li> <p>study limitations (risk of bias);</p> </li> <li> <p>inconsistency;</p> </li> <li> <p>indirectness of evidence;</p> </li> <li> <p>imprecision;</p> </li> <li> <p>publication bias.</p> </li> </ul> </p> <p>We decreased the grade rating by one (‐ 1) or two (‐ 2) (up to a maximum of ‐ 3 to 'very low') if we identified: </p> <p> <ul id="CD012555-list-0011"> <li> <p>serious (‐ 1) or very serious (‐ 2) limitation to study quality;</p> </li> <li> <p>important inconsistency (‐ 1);</p> </li> <li> <p>some (‐ 1) or major (‐ 2) uncertainty about directness;</p> </li> <li> <p>imprecise or sparse data (‐ 1);</p> </li> <li> <p>high probability of reporting bias (‐ 1).</p> </li> </ul> </p> <p>We have included two 'Summary of findings' tables to present the main findings in a transparent and simple tabular format according to the recommendations described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012555-bbs2-0091" title="SchünemannH J , OxmanA D , HigginsJ P , VistG E , GlasziouP , AklE , et al. on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins J P T, Churchill R, Chandler J, Cumpston M S (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017</a>). In particular, we have included key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the number of participants in which the effect was observed from the available data on the following outcomes: </p> <p> <ul id="CD012555-list-0012"> <li> <p>absence of nausea or vomiting, as measured by the proportion of participants with no nausea or vomiting over the time period studied; </p> </li> <li> <p>serious adverse events (specifically extra‐pyramidal adverse events, prolonged QTc, neutropenia, and agranulocytosis), as measured by the proportion of participants experiencing at least one of these events; </p> </li> <li> <p>participant satisfaction or preference;</p> </li> <li> <p>quality‐of‐life measures;</p> </li> <li> <p>number of participants with Patient Global Impression of Change (PGIC), of much improved or very much improved (or equivalent wording); </p> </li> <li> <p>other adverse events (e.g. somnolence), as measured by the proportion of participants experiencing at least one of these. </p> </li> </ul> </p> </section> </section> <section id="CD012555-sec-0060"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We conducted some subgroup analyses even if we did not observe statistical heterogeneity. We planned these analyses as the factors indicated are suspected to be potential effect modifiers. This was particularly the case when comparing participants with a cancer diagnosis who were receiving active treatment to those in a palliative phase of their illness. </p> <p>We have presented the main analyses of this review without dividing by subgroup. Where subgrouping was possible, we have presented all of the results of the subgroup analyses in the <a href="#CD012555-sec-0090">Effects of interventions</a> section of the review, and as forest plots. We have discussed the clinical importance of the analyses in the discussion section. </p> <p>Where there were sufficient data, we used subgroup analysis to establish:</p> <p> <ul id="CD012555-list-0013"> <li> <p>the effect of dose (2.5 mg versus 5 mg versus 10 mg twice daily), on efficacy and adverse events. This was in order to establish the dose response effect of olanzapine in the context of nausea and vomiting, in order to identify the lowest effective dose; </p> </li> <li> <p>the efficacy of olanzapine in different clinical settings, such as patients undergoing chemotherapy, patients undergoing radiotherapy, or no active oncology treatment. This was because the mechanisms of nausea and vomiting are thought to differ in each of these settings, and therefore, may affect the efficacy of olanzapine as an antiemetic; </p> </li> <li> <p>the efficacy of olanzapine in moderately versus highly emetogenic chemotherapy. The proportion of participants expected to suffer from nausea and vomiting are different in MEC versus HEC, and therefore, the degree of emetogenicity of the chemotherapy may affect the efficacy of olanzapine as an antiemetic. </p> </li> </ul> </p> </section> <section id="CD012555-sec-0061"> <h4 class="title">Sensitivity analysis</h4> <p>Where necessary we carried out sensitivity analyses to determine whether the findings were robust, based on the decisions made in undertaking the review. We planned analyses for the following factors: </p> <p> <ul id="CD012555-list-0014"> <li> <p>model chosen: fixed‐effect versus random‐effects;</p> </li> <li> <p>risk of bias of included studies (excluding studies with high risk of bias);</p> </li> <li> <p>methods of outcome measurement (evaluating the impact of including data where the validity of the measurement was unclear). </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012555-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012555-sec-0062"></div> <section id="CD012555-sec-0063"> <h3 class="title">Description of studies</h3> <section id="CD012555-sec-0064"> <h4 class="title">Results of the search</h4> <p>The planned searches of published databases identified 947 potentially relevant records and 92 additional records were identified through other sources. Of these, 41 were unpublished records found in clinical trials registries. We screened titles and abstracts, screening the full texts where necessary. We excluded 722 records during the screening process. </p> <p>We assessed full texts of 81 potentially relevant records. We included 13 published studies (30 records), and one unpublished study. We excluded 20 studies (27 records), with reasons, including four RCTs in paediatric populations. We identified 13 ongoing studies (15 records), and eight studies that are awaiting classification. </p> <p>A flow chart of study retrieval and selection is provided in <a href="#CD012555-fig-0001">Figure 1</a>. </p> </section> <section id="CD012555-sec-0065"> <h4 class="title">Included studies</h4> <p>We included 14 RCTs, with a total of 1917 participants (<a href="./references#CD012555-bbs2-0001" title="ClemonsM , BouganimN , SmithS , MazzarelloS , VandermeerL , SegalR , et al. Risk model‐guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early‐stage breast cancer: a randomized clinical trial. JAMA Oncology2016;2(2):225‐31. DranitsarisG , MazzarelloS , SmithS , VandermeerL , BouganimN , ClemonsM . Measuring the impact of guideline‐based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Supportive Care in Cancer2016;24(4):1563‐9. ">Clemons 2016</a>; <a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a>; <a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a>; <a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>; <a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a>; <a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a>; <a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>; <a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a>; <a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>; <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>; <a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a>; <a href="./references#CD012555-bbs2-0012" title="WangX , WangL , WangH , ZhangH . Effectiveness of olanzapine combined with ondansetron in the prevention of chemotherapy‐induced nausea and vomiting of non‐small cell lung cancer. Cell Biochemistry and Biophysics2015;72:471‐3. ">Wang 2015</a>; <a href="./references#CD012555-bbs2-0013" title="ZhangD . Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting (AOPDPCINV). clinicaltrials.gov/ct2/show/NCT02484911 (accessed 28 September 2017). ">Zhang 2017</a>; <a href="./references#CD012555-bbs2-0014" title="ZhaoJ , LiX , JinghuaG , LiY , LiJ , ShiY , et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy ‐ induced nausea and vomiting. Modern Oncology. Modern Oncology, 2014; Vol. 22, issue 8:1941‐3. ">Zhao 2014</a>). Thirteen of these reported at least one of our prespecified outcome measures and contributed data to the meta‐analysis. One RCT was included in our qualitative synthesis but did not contribute data to the quantitative analysis (<a href="./references#CD012555-bbs2-0001" title="ClemonsM , BouganimN , SmithS , MazzarelloS , VandermeerL , SegalR , et al. Risk model‐guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early‐stage breast cancer: a randomized clinical trial. JAMA Oncology2016;2(2):225‐31. DranitsarisG , MazzarelloS , SmithS , VandermeerL , BouganimN , ClemonsM . Measuring the impact of guideline‐based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Supportive Care in Cancer2016;24(4):1563‐9. ">Clemons 2016</a>). See <a href="./references#CD012555-sec-0227" title="">Characteristics of included studies</a>. </p> <section id="CD012555-sec-0066"> <h5 class="title">Trial design</h5> <p>All of the studies were RCTs ranging in size from 20 to 401 participants, were blinded or unblinded, parallel‐arm design. Most trials had two comparator arms, whilst one had three arms (<a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a>). We were able to obtain data for all included RCTs except for one study, which did not contribute data to our meta‐analysis as it compared a risk stratification model of care to physician choice, rather than directly assessing the olanzapine versus a comparator (<a href="./references#CD012555-bbs2-0001" title="ClemonsM , BouganimN , SmithS , MazzarelloS , VandermeerL , SegalR , et al. Risk model‐guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early‐stage breast cancer: a randomized clinical trial. JAMA Oncology2016;2(2):225‐31. DranitsarisG , MazzarelloS , SmithS , VandermeerL , BouganimN , ClemonsM . Measuring the impact of guideline‐based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Supportive Care in Cancer2016;24(4):1563‐9. ">Clemons 2016</a>). </p> </section> <section id="CD012555-sec-0067"> <h5 class="title">Comparison pairs</h5> <p>The comparisons in the included studies varied. Nine studies compared olanzapine to placebo or no treatment. Four studies compared olanzapine to other antiemetics: NK1 antagonists (one study <a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a>); 5‐HT3 antagonists (one study <a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a>); prokinetics (one study <a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a>); and one study compared olanzapine to steroids (<a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a>). All participants in all of the trials had treatment in conjunction with various other medications, chiefly antiemetics. </p> </section> <section id="CD012555-sec-0068"> <h5 class="title">Population</h5> <p>The participants were both male and female with ages ranging from 18 to 81 years. Participants had a range of histologically diagnosed cancer types. Solid and haematological malignancies were represented within the included trials. These included bladder, breast, cervical, colorectal, gingival, glioblastoma, head and neck cancer, laryngeal, lung, leukaemia, lymphoma (including Hodgkins lymphoma), malignant melanoma, oesophageal, oropharyngeal, osteosarcoma, ovarian, pancreatic, pharynx, sarcoma, stomach, teratoma and thymus. </p> <p>We did not identify any RCTs that included participants who were receiving radiotherapy without concurrent chemotherapy. One RCT included participants who were receiving both chemotherapy and radiotherapy treatment for their cancer (<a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a>). Participants in <a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a> were undergoing hematopoietic stem cell transplantation. They received, "conditioning regimens [that) included high‐dose melphalan (200 mg/m2) and BEAM for autologous HSCT and Cy/TBI and fludarabine/melphalan (melphalan 120 mg/m2) for allogeneic protocols" and some also received total body irradiation. </p> <p>One RCT included participants who were not receiving either chemotherapy or radiotherapy for their cancer (<a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>), and instead received olanzapine with megestrol or megestrol alone. </p> </section> <section id="CD012555-sec-0069"> <h5 class="title">Setting</h5> <p>The countries of origin represent both high‐, middle‐ and low‐income countries, including: Australia (<a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a>); Canada (<a href="./references#CD012555-bbs2-0001" title="ClemonsM , BouganimN , SmithS , MazzarelloS , VandermeerL , SegalR , et al. Risk model‐guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early‐stage breast cancer: a randomized clinical trial. JAMA Oncology2016;2(2):225‐31. DranitsarisG , MazzarelloS , SmithS , VandermeerL , BouganimN , ClemonsM . Measuring the impact of guideline‐based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Supportive Care in Cancer2016;24(4):1563‐9. ">Clemons 2016</a>); China (<a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a>; <a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a>; <a href="./references#CD012555-bbs2-0012" title="WangX , WangL , WangH , ZhangH . Effectiveness of olanzapine combined with ondansetron in the prevention of chemotherapy‐induced nausea and vomiting of non‐small cell lung cancer. Cell Biochemistry and Biophysics2015;72:471‐3. ">Wang 2015</a>; <a href="./references#CD012555-bbs2-0013" title="ZhangD . Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting (AOPDPCINV). clinicaltrials.gov/ct2/show/NCT02484911 (accessed 28 September 2017). ">Zhang 2017</a>; <a href="./references#CD012555-bbs2-0014" title="ZhaoJ , LiX , JinghuaG , LiY , LiJ , ShiY , et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy ‐ induced nausea and vomiting. Modern Oncology. Modern Oncology, 2014; Vol. 22, issue 8:1941‐3. ">Zhao 2014</a>); Iran (<a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>); India (<a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a>); Japan (<a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>); and the USA (<a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>; <a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a>; <a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>; <a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a>). The included articles were published in English and Chinese. Non‐English language papers were translated and data extracted when necessary. </p> <p>The trials were conducted in hospital settings including university hospitals, a military medical centre, oncology centres and a bone marrow transplant centre. Trials recruited both outpatients and inpatients. The number of centres where the trials were conducted ranged from single centres to multicentre recruitment models, with the largest trial recruiting participants from 46 different centres around the USA (<a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>). </p> </section> <section id="CD012555-sec-0070"> <h5 class="title">Primary outcomes</h5> <p>Only two (<a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a>; <a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a>), out of 13 studies contributing to the meta‐analyses reported the primary outcome of the number of participants who were free from both nausea and vomiting over the whole time period. Instead, most studies reported the number of participants with no vomiting and no use of breakthrough antiemetic medication, which they defined as "complete response". Additionally, two studies did not report serious adverse events (<a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a>; <a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a>). </p> <p>Most studies reported adverse effects of treatment using defined standards. When reviewing the studies we noted that somnolence or fatigue were the most frequently reported adverse events. We felt that these have a large impact on patients and so we decided, as a change from protocol, to investigate this adverse event separately from other adverse events (see <a href="#CD012555-sec-0225">Differences between protocol and review</a>). </p> </section> <section id="CD012555-sec-0071"> <h5 class="title">Funding</h5> <p>None of the included RCTs declared having received funding from pharmaceutical companies. Of the studies that reported having received funding support, two were supported by universities (<a href="./references#CD012555-bbs2-0013" title="ZhangD . Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting (AOPDPCINV). clinicaltrials.gov/ct2/show/NCT02484911 (accessed 28 September 2017). ">Zhang 2017</a>; <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>), one by a hospital foundation <a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a>, one by an endowed fund (<a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a>), one by a cancer foundation (<a href="./references#CD012555-bbs2-0001" title="ClemonsM , BouganimN , SmithS , MazzarelloS , VandermeerL , SegalR , et al. Risk model‐guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early‐stage breast cancer: a randomized clinical trial. JAMA Oncology2016;2(2):225‐31. DranitsarisG , MazzarelloS , SmithS , VandermeerL , BouganimN , ClemonsM . Measuring the impact of guideline‐based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Supportive Care in Cancer2016;24(4):1563‐9. ">Clemons 2016</a>), and one study received funding from both an endowed fund and a cancer foundation (<a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>). Seven RCTs did not provide information as to how the studies were funded (<a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a>; <a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a>; <a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>; <a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>; <a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a>; <a href="./references#CD012555-bbs2-0012" title="WangX , WangL , WangH , ZhangH . Effectiveness of olanzapine combined with ondansetron in the prevention of chemotherapy‐induced nausea and vomiting of non‐small cell lung cancer. Cell Biochemistry and Biophysics2015;72:471‐3. ">Wang 2015</a>; <a href="./references#CD012555-bbs2-0014" title="ZhaoJ , LiX , JinghuaG , LiY , LiJ , ShiY , et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy ‐ induced nausea and vomiting. Modern Oncology. Modern Oncology, 2014; Vol. 22, issue 8:1941‐3. ">Zhao 2014</a>), and one study reported that “the authors have no financial disclosure, and the study was not a sponsored study” (<a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a>). </p> </section> <section id="CD012555-sec-0072"> <h5 class="title">Interventions</h5> <p>All included studies administered olanzapine via the oral route only.</p> <p>The most frequently reported dose was 10 mg daily (as a single dose or divided doses of 5 mg twice daily), reported in eight RCTs. four RCTs reported a 5 mg daily dose (as a single dose or divided doses of 2.5 mg twice daily). One trial reported a range of doses according to participant tolerance from 2.5 mg daily up to 10 mg daily (<a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>), although the data are not presented in a way to make analysis of the efficacy of the 2.5 mg dose possible. One trial used 2.5 mg of olanzapine daily but could not be included in the meta‐analysis (<a href="./references#CD012555-bbs2-0001" title="ClemonsM , BouganimN , SmithS , MazzarelloS , VandermeerL , SegalR , et al. Risk model‐guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early‐stage breast cancer: a randomized clinical trial. JAMA Oncology2016;2(2):225‐31. DranitsarisG , MazzarelloS , SmithS , VandermeerL , BouganimN , ClemonsM . Measuring the impact of guideline‐based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Supportive Care in Cancer2016;24(4):1563‐9. ">Clemons 2016</a>). </p> <p>Olanzapine can be administered orally, either as a tablet, an oral solution, or as an orally‐disintegrating 'wafer' or 'velotab'. 10 RCTs did not state which oral preparation they used, one study used the tablet (<a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>), two studies used the oral wafer (<a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>; <a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a>), and one study had "black gel capsule prepared by the central oncology pharmacy" so that they were indistinguishable from the black gel capsules used as a placebo (<a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a>). </p> <section id="CD012555-sec-0073"> <h6 class="title">Standard adjuvant antiemetic regimens</h6> <p>All included studies used olanzapine in conjunction with 'treatment as usual' (chiefly, antiemetics, although one study used megestrol), versus 'treatment as usual' plus placebo or no additional treatment. </p> <p>Reported standard regimens used in the context of chemotherapy‐ or chemoradiotherapy‐induced nausea and vomiting included: </p> <p> <ul id="CD012555-list-0015"> <li> <p>a 5‐HT3 antagonist (<a href="./references#CD012555-bbs2-0012" title="WangX , WangL , WangH , ZhangH . Effectiveness of olanzapine combined with ondansetron in the prevention of chemotherapy‐induced nausea and vomiting of non‐small cell lung cancer. Cell Biochemistry and Biophysics2015;72:471‐3. ">Wang 2015</a>); </p> </li> <li> <p>a 5‐HT3 antagonist and an NK1 antagonist (<a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a>); </p> </li> <li> <p>dexamethasone and a 5‐HT3 antagonist (<a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a>; <a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a>; <a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a>); </p> </li> <li> <p>dexamethasone, an NK1 antagonist and a 5‐HT3 antagonist (<a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>; <a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a>; <a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>; <a href="./references#CD012555-bbs2-0013" title="ZhangD . Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting (AOPDPCINV). clinicaltrials.gov/ct2/show/NCT02484911 (accessed 28 September 2017). ">Zhang 2017</a>) </p> </li> <li> <p>dexamethasone, an antihistamine and a 5‐HT3 antagonist (<a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a>; <a href="./references#CD012555-bbs2-0014" title="ZhaoJ , LiX , JinghuaG , LiY , LiJ , ShiY , et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy ‐ induced nausea and vomiting. Modern Oncology. Modern Oncology, 2014; Vol. 22, issue 8:1941‐3. ">Zhao 2014</a>). </p> </li> <li> <p>standard regimen not stated (<a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>) </p> </li> </ul> </p> <p>These standard treatment regimens were used in both arms of the studies, therefore the presence or absence of olanzapine was the only difference between each intervention and control arm, enabling us to undertake meta‐analysis. However, <a href="./references#CD012555-bbs2-0001" title="ClemonsM , BouganimN , SmithS , MazzarelloS , VandermeerL , SegalR , et al. Risk model‐guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early‐stage breast cancer: a randomized clinical trial. JAMA Oncology2016;2(2):225‐31. DranitsarisG , MazzarelloS , SmithS , VandermeerL , BouganimN , ClemonsM . Measuring the impact of guideline‐based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Supportive Care in Cancer2016;24(4):1563‐9. ">Clemons 2016</a> compared a "risk model–guided (RMG) antiemetic prophylaxis with physician’s choice (PC)" resulting in the standard adjuvant anti‐emetic regimens varying between participants within each arm of the trial. This meant that the data from <a href="./references#CD012555-bbs2-0001" title="ClemonsM , BouganimN , SmithS , MazzarelloS , VandermeerL , SegalR , et al. Risk model‐guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early‐stage breast cancer: a randomized clinical trial. JAMA Oncology2016;2(2):225‐31. DranitsarisG , MazzarelloS , SmithS , VandermeerL , BouganimN , ClemonsM . Measuring the impact of guideline‐based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Supportive Care in Cancer2016;24(4):1563‐9. ">Clemons 2016</a> did not contribute to our quantitative analysis. </p> <p>The study that contributed to the meta‐analysis in adults with cancer not receiving chemotherapy or radiotherapy used olanzapine and megestrol versus megestrol alone to investigate the effect of olanzapine on cachexia and anorexia, in addition to its effect on nausea and vomiting (<a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>). </p> <section id="CD012555-sec-0074"> <p><b>Possible confounding factors</b></p> <p>There were several issues with the interventions used in some of the included studies, either as standard treatment regimens or as comparators, that inhibited the certainty with which the observed effects could be attributed solely to olanzapine. </p> <p><a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a> used differing doses of dexamethasone for participants receiving MEC to those receiving HEC, however, this approach was consistent between the two comparator arms. </p> <p>In <a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a> participants in both arms received a 5‐HT3 antagonist. However a range of medications, doses and regimens were used from across the class of 5‐HT3 antagonists including: day one to three granisetron, day one to two ondansetron, day one to three ramosetron, or day one palonosetron. It is not known if participants receiving each of these were matched pairs across the arms or if a consistent number of participants were randomised to each of the four different 5‐HT3 antagonists. </p> <p><a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a> failed to state the nature of the standard regimen. </p> <p><a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a> used high doses of ondansetron (ondansetron 32 mg intravenous over 24 hours in one study arm and ondansetron eight mg intravenous three times day as standard therapy in the other arms), beyond the doses recommended by the manufacturer (<a href="./references#CD012555-bbs2-0083" title="EMC . Zofran Tablets 4 mg and 8 mg. www.medicines.org.uk/emc/medicine/17650/spc (accessed 1 November 2017). ">Medicines.org a</a>). </p> <p><a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a> and <a href="./references#CD012555-bbs2-0014" title="ZhaoJ , LiX , JinghuaG , LiY , LiJ , ShiY , et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy ‐ induced nausea and vomiting. Modern Oncology. Modern Oncology, 2014; Vol. 22, issue 8:1941‐3. ">Zhao 2014</a> used diphenhydramine (Benadryl), in both comparator arms, which has a potent sedative effect when used alone. In addition to its anticholinergic and antimuscarinic effects, it is known to "potentiate the sedative effects of alcohol and other central nervous system (CNS), depressants (e.g. tranquillizers, hypnotics and anxiolytics)" (<a href="./references#CD012555-bbs2-0082" title="EMC . Nytol One‐A‐Night. www.medicines.org.uk/emc/medicine/19778 (accessed 1 November 2017). ">Medicines.org</a>). It is plausible that diphenhydramine may exacerbate the somnolence effects of olanzapine when used in combination. </p> </section> </section> </section> <section id="CD012555-sec-0075"> <h5 class="title">Studies awaiting classification</h5> <p>We identified eight RCTs that are awaiting classification. We are awaiting further information from the authors for four RCTs that were only published as abstracts (<a href="./references#CD012555-bbs2-0035" title="ChasickA , DeFreitasE , EdwardsM . Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic antineoplastic chemotherapy. Journal of the American Pharmacists Association2012;52(5):681. ">Chasick 2012</a>; <a href="./references#CD012555-bbs2-0037" title="JeonS , HanH , BaeW , ParkM , LeeS , GoS , et al. A randomized, double‐blind, placebo‐controlled study of the safety and efficacy of olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Journal of Clinical Oncology2017;35(15 Supplement 1):(no pagination). ">Jeon 2017</a>; <a href="./references#CD012555-bbs2-0040" title="MukeshS , SathyaM , AkshayJ . Olanzapine versus aprepitant in the prevention of chemotherapy induced nausea and vomiting (CINV) in breast cancer patients. Journal of Clinical Oncology2017;35(15 Supplement 1):‐. ">Mukesh 2017</a>; <a href="./references#CD012555-bbs2-0041" title="NguyenN , PhamV , NguyenT , TranT . Olanzapine and omeprazole combination is simple, safe and effective for delayed nausea and vomiting control in adjuvant chemotherapy for early stage breast cancer. Supportive Care in Cancer2017;25(2 Supplement 1):S72. ">Nguyen 2017</a>). </p> <p>Additionally, we are awaiting information from authors regarding three RCTs that meet our inclusion criteria: </p> <p> <ul id="CD012555-list-0016"> <li> <p><a href="./references#CD012555-bbs2-0036" title="ChiCTR‐TTRCC‐14004093 . Olanzapine versus aprepitant for the prevention of high dose cisplatin‐induced nausea and vomiting: a randomized phase III trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR‐TTRCC‐14004093 (accessed 28 September 2017). ">CTRCC‐14004093</a> a completed RCT with no published or unpublished results available; </p> </li> <li> <p><a href="./references#CD012555-bbs2-0038" title="MaoW‐K , PengL . Clinical observation of olanzepine combined with granisterom and hexadecadrol prevent nausea vomit induced by chemoradiotherapy. Chinese Journal of Medicinal Guide2011;13(3):452‐4. ">Mao 2011</a> is a cross‐over study where only the combined phase one and two data have been published; and </p> </li> <li> <p><a href="./references#CD012555-bbs2-0039" title="MengQ , ChenG , GuoP . Olanzapine combined with normal antiemetic drugs in patients on solid tumor chemotherapy: antiemetic effect and impact on quality of life. World Chinese Journal of Digestology2016;24(7):1117‐23. ">Meng 2016</a> a study where the age range of participants has not been published. </p> </li> </ul> </p> <p>One study was unobtainable despite multiple searches (<a href="./references#CD012555-bbs2-0012" title="WangX , WangL , WangH , ZhangH . Effectiveness of olanzapine combined with ondansetron in the prevention of chemotherapy‐induced nausea and vomiting of non‐small cell lung cancer. Cell Biochemistry and Biophysics2015;72:471‐3. ">Wang 2015</a>). See <a href="./references#CD012555-sec-0229" title="">Characteristics of studies awaiting classification</a>. </p> </section> <section id="CD012555-sec-0076"> <h5 class="title">Ongoing studies</h5> <p>We identified a further 13 ongoing studies (<a href="./references#CD012555-bbs2-0043" title="AbeM , YanaiT , NakashimaK , HirashimaY , MurakamiH , HamauchiS , et al. A randomized, double‐blind, placebo‐controlled phase iii study evaluating olanzapine 5mg combined with standard antiemetic therapy for the prevention of CINV in patients receiving cisplatin‐based chemotherapy. Supportive Care in Cancer. Conference: 2017 International MASCC/ISOO Symposium2017;25((2 Supplement 1)):S632017. ">Abe 2017</a>; <a href="./references#CD012555-bbs2-0044" title="ChiCTR‐TTRCC‐14004093 . Olanzapine versus aprepitant for the prevention of high‐dose cisplatin‐induced nausea and vomiting: a randomised phase III trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR‐TTRCC‐14004093 (accessed 28 September 2017) (first received 08 January 2014). ">ChiCTR‐TTRCC‐14004093</a>; <a href="./references#CD012555-bbs2-0045" title="HashimotoH , AbeM . A randomized, double‐blind, placebo‐controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving cisplatin‐based highly emetogenic chemotherapy: J‐SUPPORT 1604. rctportal.niph.go.jp/en/detail?trial_id=UMIN0000246762017;‐:‐. HashimotoH , IwasaS , AbeM , YanaiT , ZendaS , YamaguchiT , et al. 1607TiP ‐ J‐FORCE study: a randomized, double‐blind, placebo‐controlled phase III study evaluating olanzapine (5 mg) combined with standard antiemetic therapy. Annals of Oncology2017;28(suppl_5):v543‐67. ">Hashimoto 2017</a>; <a href="./references#CD012555-bbs2-0046" title="JPRN‐UMIN000010317 . Efficacy of olanzapine for relief of nausea with incomplete bowel obstruction in advanced cancer patient: pragmatic randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000010317 (first received 26 March 2013). ">JPRN‐UMIN000010317</a>; <a href="./references#CD012555-bbs2-0047" title="MukhopadhyayS , DuttaP , BhattacharyaB , BanerjeeS , BiswasS , Mukhopadhyay‐SamantaB . Low dose vs. standard dose adjuvant olanzapine in chemotherapy induced nausea and vomiting: a prospective, randomized, double blinded, controlled study. Clinical Therapeutics2017;39(8 Supplement 1):e17. MukhopadhyayS , DuttaP , BhattacharyaB , BanerjeeS , BiswasS , SamantaB . Comparison of efficacy, safety and sedation with two doses of add on olanzapine in chemotherapy induced nausea and vomiting: a randomized controlled pilot study. Supportive Care in Cancer2016;24(1 Supplement 1):S248‐9. MukhopadhyayS , DuttaP , BhattacharyaB , DasD , BiswasS . Low dose olanzapine in chemotherapy induced nausea and vomiting: a balance game between sedation and nausea?. Supportive Care in Cancer: International MASCC/ISOO Symposium2017;25(2 Supplement 1):S69. ">Mukhopadhyay 2017a</a>; <a href="./references#CD012555-bbs2-0048" title="NagashimaK , IwasaS , YanaiT , HashimotoH , SuzukiK , OhyanagiF , et al. A double‐blind randomized phase II study of olanzapine 10 mg versus 5 mg for emesis induced by highly emetogenic chemotherapy. Japanese Journal of Clinical Oncology2015;45(2):229‐31. ">Nagashima et al 2015</a>; <a href="./references#CD012555-bbs2-0049" title="NCT02290470 . Olanzapine against delayed nausea and vomiting in women receiving carboplatin plus paclitaxel. clinicaltrials.gov/ct2/show/NCT02290470 (first received 14 November 2014). ">NCT02290470</a>; <a href="./references#CD012555-bbs2-0050" title="NCT02400866 . A randomized study of olanzapine for the prevention of CINV in patients receiving moderately emetogenic chemotherapy. clinicaltrials.gov/ct2/show/NCT02400866 (first received 27 March 2015). ">NCT02400866</a>; <a href="./references#CD012555-bbs2-0051" title="NCT02635984 . Study of FOND versus FOND+O for the prevention of CIV in hematology patients receiving highly emetogenic chemotherapy regimens [Randomized, placebo controlled study of FOND (fosaprepitant, ondansetron, dexamethasone) versus FOND+O (FOND plus olanzapine) for the prevention of chemotherapy induced nausea and vomiting in hematology patients receiving highly emetogenic chemotherapy regimens]. clinicaltrials.gov/ct2/show/NCT02635984 (first received 21 December 2015). ">NCT02635984</a>; <a href="./references#CD012555-bbs2-0052" title="NCT02939287 . Aprepitant versus olanzapine with high dose melphalan [Aprepitant versus olanzapine for prevention of acute and delayed nausea and vomiting associated with high dose melphalan and BEAM in autologous stem dell transplant patients]. clinicaltrials.gov/ct2/show/NCT02939287 (first received 20 October 2016). ">NCT02939287</a>; <a href="./references#CD012555-bbs2-0053" title="NCT02970643 . Proof‐of‐concept trial of palonosetron and olanzapine without dexamethasone for the prevention of CIN [Proof‐of‐concept trial of palonosetron and olanzapine without dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting]. clinicaltrials.gov/ct2/show/NCT02970643 (first received 22 November 2016). ">NCT02970643</a>; <a href="./references#CD012555-bbs2-0054" title="NCT03079219 . Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in Chinese breast cancer patients [A randomized study to determine the efficacy and tolerability of olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in Chinese breast cancer patients]. clinicaltrials.gov/ct2/show/NCT03079219 (first received 14 March 2017). ">NCT03079219</a>; <a href="./references#CD012555-bbs2-0055" title="NCT03137121 . Olanzapine for the treatment of chronic nausea and/or vomiting in advanced cancer patients [Olanzapine for the treatment of chronic nausea and/or vomiting, unrelated to chemotherapy or radiation, in advanced cancer patient ‐ a pilot, dose‐finding trial]. clinicaltrials.gov/ct2/show/NCT03137121 (first received 2 May 2017). ">NCT03137121</a>). See <a href="./references#CD012555-sec-0230" title="">Characteristics of ongoing studies</a>. </p> </section> </section> <section id="CD012555-sec-0077"> <h4 class="title">Excluded studies</h4> <p>We excluded 20 studies. The reasons for exclusion were as follows.</p> <p> <ul id="CD012555-list-0017"> <li> <p>Three did not fit our definition of a RCT on full‐text review, such as cohorts, case reports and case series (wrong study design), (<a href="./references#CD012555-bbs2-0016" title="EUCTR2015‐002294‐38‐DK . DANSAC‐pilot: an open label pilot study to investigate the tolerability and efficacy of olanzapine in patients with advanced cancer not receiving chemotherapy or irradiation. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015‐002294‐38‐DK (accessed 28 September 2017). ">EUCTR2015‐002294‐38‐DK</a>; <a href="./references#CD012555-bbs2-0026" title="NakashimaK , MurakamiH . A phase II study of aprepitant, palonosetron, dexamethasone and olanzapine for the prevention of cisplatin‐based hemotherapy‐induced nausea and vomiting for thoracic malignancy. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;recptno=R000020267&amp;type=summary&amp;language=E2015. ">Nakashima 2015</a>; <a href="./references#CD012555-bbs2-0033" title="SlimanoF , NetzerF , BorgetI , LemareF , BesseB . Is the addition of olanzapine effective in restoration of CINV prevention in non‐responders to standard antiemetic therapy? A retrospective controlled study. International Journal of Clinical Pharmacy2016;38(6):491. ">Slimano 2016</a>). </p> </li> <li> <p>Two used the wrong intervention (<a href="./references#CD012555-bbs2-0021" title="HashimotoH , YanaiT , NagashimaK , TsudaN , HorinouchiH , TakiguchiT , et al. A double‐blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin. Journal of Clinical Oncology2016;34:(no pagination). ">Hashimoto 2016</a>; <a href="./references#CD012555-bbs2-0034" title="YanaiT , YamamotoN . A double‐blind randomized phase II study of olanzapine 10mg versus 5mg for highly emetogenic chemotherapy‐induced nausea and vomiting. rctportal.niph.go.jp/en/detail?trial_id=UMIN0000142142015. ">Yanai 2015</a>). </p> </li> <li> <p>Four studied olanzapine in the wrong population (paediatric), (<a href="./references#CD012555-bbs2-0017" title="FlankJ , RobinsonP , HoldsworthM , PortwineC , GibsonP , PhillipsR , et al. Guideline for the prevention of breakthrough and treatment of refractory chemotherapy‐induced nausea and vomiting in pediatric cancer patients. Canadian Journal of Hospital Pharmacy2015;68(1):87‐8. ">Flank 2015a</a>; <a href="./references#CD012555-bbs2-0018" title="FlankJ , ThackrayJ , NielsonD , AugustA , SchechterT , AlexanderS , et al. Olanzapine for treatment and prevention of acute chemotherapy‐induced vomiting (CIV) in children: a retrospective, multi‐centre review. Supportive Care in Cancer2014;22(1 Suppl. 1):S157. FlankJ , ThackrayJ , NielsonD , AugustA , SchechterT , AlexanderS , et al. Olanzapine for treatment and prevention of acute chemotherapy‐induced vomiting in children: a retrospective, multi‐center review. Pediatric Blood and Cancer2015;62(3):496‐501. FlankJ , ThackrayJ , NielsonD , AugustA , SchechterT , AlexanderS , et al. Olanzapine for treatment and prevention of acute chemotherapy‐induced vomiting in children: a retrospective, multi‐centre review. Pediatric Blood and Cancer2014;61:S241. ">Flank 2015b</a>; <a href="./references#CD012555-bbs2-0019" title="FountaineR , TaylorA , MancusoJ , GreenwayF , ByerleyL , SmithS , et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring, Md.)2010;18(8):1646‐51. ">Fountaine 2010</a>; <a href="./references#CD012555-bbs2-0024" title="LongC , KnodererH , MuellerE . A pilot study comparing the addition of olanzapine or aprepitant in an antiemetic regimen for highly emetogenic chemotherapyPediatric Blood and Cancer. American Society of Pediatric Hematology/Oncology, ASPHO2015;62:S104. NCT02097823 . Pilot study of olanzapine and aprepitant to prevent nausea and vomiting in children receiving chemotherapy NCT02097823. www.clinicaltrials.gov (accessed 28 September 2017). ">Long 2017</a>). </p> </li> <li> <p>Four studies terminated early, for example due to low recruitment (<a href="./references#CD012555-bbs2-0032" title="NCT01148264 . Comparison of olanzapine and metoclopramide for treatment of breakthrough emesis (COMFORT). www.clinicaltrials.gov (accessed 28 September 2017). ">NCT01148264</a>; <a href="./references#CD012555-bbs2-0022" title="ISRCTN58624349 . Olanzapine (ZYPREXA) versus haloperidol (Novo‐Peridol) for the relief of nausea and vomiting (N&amp;V) in patients with advanced cancer. www.isrctn.com/ISRCTN58624349?q=&amp;filters=conditionCategory:Signs%20and%20Symptoms,trialStatus:Stopped&amp;sort=relevance&amp;offset=23&amp;totalResults=23&amp;page=3&amp;pageSize=10&amp;searchType=basic‐search (accessed 28 September 2017). ">ISRCTN58624349</a>; <a href="./references#CD012555-bbs2-0020" title="GuntschF , JahnF , SteinA , RusselJ , TimoB , WassM , et al. COMFORT trial‐comparison of olanzapin and metoclopramid for treatment of breakthrough emesis: first experiences of this trial in progress. Onkologie2012;35:76. ">Guntsch 2012</a>; <a href="./references#CD012555-bbs2-0031" title="NCT00124930 . Study comparing olanzapine with haloperidol for the relief of nausea and vomiting in patients with advanced cancer. clinicaltrials.gov/ct2/show/NCT00124930 (first received 29 July 2005). ">NCT00124930</a>). </p> </li> <li> <p>Five studies used the wrong comparison, comparing differing doses of olanzapine (<a href="./references#CD012555-bbs2-0015" title="BabuG , SaldanhaS , KuntegowdanahalliC , JacobL , MallekavuS , DasappaL , et al. The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India. Chemotherapy Research and Practice2016;‐:(no pagination). ">Babu 2016</a>; <a href="./references#CD012555-bbs2-0027" title="NavariR , GrayS . Treatment of chemotherapy‐induced breakthrough nausea and vomiting. Journal of Clinical Oncology2009;1(27(supp)):e20536. ">Navari 2009a</a>; <a href="./references#CD012555-bbs2-0028" title="NavariR , GrayS . Treatment of chemotherapy‐induced breakthrough nausea and vomiting. Psycho‐oncology2010;19(supp):S1‐102. ">Navari 2010a</a>; <a href="./references#CD012555-bbs2-0029" title="NavariR , GrayS , KerrA . Olanzapine versus aprepitant for the prevention of chemotherapy induced nausea and vomiting: a randomized Phase III trial. Psycho‐oncology2012;21:111‐2. NavariR , GrayS , KerrA . Olanzapine versus aprepitant for the prevention of chemotherapy‐induced nausea and vomiting (CINV): a randomized phase III trial. Journal of Clinical Oncology2010;28((15 SUPPL. 1)):‐. NavariR , GrayS , KerrA . Olanzapine versus aprepitant for the prevention of chemotherapy‐induced nausea and vomiting: a randomized phase III trial. The Journal of Supportive Oncology2011; Vol. 9, issue 5:188‐95. NavariR , GrayS , Kerr , A . Olanzapine versus aprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV): a randomized trial. Supportive Care in Cancer2010;18:S81‐2. ">Navari 2011</a>; <a href="./references#CD012555-bbs2-0030" title="NavariR , NagyC . Olanzapine versus fosaprepitant for the prevention of nausea and vomiting in patients receiving concurrent chemoradiation treatment. Journal of Clinical Oncology2015;33(15 suppl. 1):‐. NavariR , NagyC , Le‐RademacherJ , LoprinziC . Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy‐induced nausea and vomiting. The Journal of Community and Supportive Oncology2016;14(4):141‐7. ">Navari 2016b</a>). </p> </li> <li> <p>Two used olanzapine for the wrong indication (<a href="./references#CD012555-bbs2-0023" title="KwatraG , BadyalD K , AliceK , MukhopadhyayP S . Olanzapine for post‐chemotherapy dysgeusia and anorexia: The unidentified saviour?. Supportive Care in Cancer2013;21:S79. ">Kwatra 2013</a>; <a href="./references#CD012555-bbs2-0025" title="MukhopadhyayS , KwatraG , BadyalD K , AliceK . Anorexia in concurrent chemoradiation patients: Can olanzapine calm down the monster?. Indian Journal of Physiology and Pharmacology2012;56(5 SUPPL. 1):219‐20. ">Mukhopadhyay 2012</a>). </p> </li> </ul> </p> <p>Five of these excluded RCTs used a higher dose of dexamethasone in the olanzapine arm than in the comparison arm and we excluded them as they did not assess the effect of olanzapine alone (<a href="./references#CD012555-bbs2-0015" title="BabuG , SaldanhaS , KuntegowdanahalliC , JacobL , MallekavuS , DasappaL , et al. The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India. Chemotherapy Research and Practice2016;‐:(no pagination). ">Babu 2016</a>, <a href="./references#CD012555-bbs2-0029" title="NavariR , GrayS , KerrA . Olanzapine versus aprepitant for the prevention of chemotherapy induced nausea and vomiting: a randomized Phase III trial. Psycho‐oncology2012;21:111‐2. NavariR , GrayS , KerrA . Olanzapine versus aprepitant for the prevention of chemotherapy‐induced nausea and vomiting (CINV): a randomized phase III trial. Journal of Clinical Oncology2010;28((15 SUPPL. 1)):‐. NavariR , GrayS , KerrA . Olanzapine versus aprepitant for the prevention of chemotherapy‐induced nausea and vomiting: a randomized phase III trial. The Journal of Supportive Oncology2011; Vol. 9, issue 5:188‐95. NavariR , GrayS , Kerr , A . Olanzapine versus aprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV): a randomized trial. Supportive Care in Cancer2010;18:S81‐2. ">Navari 2011</a>, <a href="./references#CD012555-bbs2-0030" title="NavariR , NagyC . Olanzapine versus fosaprepitant for the prevention of nausea and vomiting in patients receiving concurrent chemoradiation treatment. Journal of Clinical Oncology2015;33(15 suppl. 1):‐. NavariR , NagyC , Le‐RademacherJ , LoprinziC . Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy‐induced nausea and vomiting. The Journal of Community and Supportive Oncology2016;14(4):141‐7. ">Navari 2016b</a>, <a href="./references#CD012555-bbs2-0027" title="NavariR , GrayS . Treatment of chemotherapy‐induced breakthrough nausea and vomiting. Journal of Clinical Oncology2009;1(27(supp)):e20536. ">Navari 2009a</a>, <a href="./references#CD012555-bbs2-0028" title="NavariR , GrayS . Treatment of chemotherapy‐induced breakthrough nausea and vomiting. Psycho‐oncology2010;19(supp):S1‐102. ">Navari 2010a</a>). Instead they used olanzapine in conjunction with dexamethasone 20 mg, alongside standard therapy, on day one in the intervention group and compared this to standard therapy using 12 mg dexamethasone on day one in the control arm. See <a href="./references#CD012555-sec-0228" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD012555-sec-0078"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD012555-fig-0002">Figure 2</a> and <a href="#CD012555-fig-0003">Figure 3</a> present a summary of our assessment of the risk of bias in the included studies. </p> <div class="figure" id="CD012555-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD012555-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD012555-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD012555-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD012555-sec-0079"> <h4 class="title">Allocation</h4> <section id="CD012555-sec-0080"> <h5 class="title">Random sequence bias</h5> <p>In six RCTs, investigators used a table of random digits, computer‐generated random numbers, or simple randomisation methods such as shuffling opaque envelopes to generate the allocation and we assessed them to be at low risk of bias (<a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a>; <a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a>; <a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a>; <a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a>; <a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>; <a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a>). However, eight studies did not adequately describe their randomisation method and we therefore assessed them to be at unclear risk of bias (<a href="./references#CD012555-bbs2-0001" title="ClemonsM , BouganimN , SmithS , MazzarelloS , VandermeerL , SegalR , et al. Risk model‐guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early‐stage breast cancer: a randomized clinical trial. JAMA Oncology2016;2(2):225‐31. DranitsarisG , MazzarelloS , SmithS , VandermeerL , BouganimN , ClemonsM . Measuring the impact of guideline‐based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Supportive Care in Cancer2016;24(4):1563‐9. ">Clemons 2016</a>; <a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a>; <a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>; <a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>; <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>; <a href="./references#CD012555-bbs2-0012" title="WangX , WangL , WangH , ZhangH . Effectiveness of olanzapine combined with ondansetron in the prevention of chemotherapy‐induced nausea and vomiting of non‐small cell lung cancer. Cell Biochemistry and Biophysics2015;72:471‐3. ">Wang 2015</a>; <a href="./references#CD012555-bbs2-0013" title="ZhangD . Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting (AOPDPCINV). clinicaltrials.gov/ct2/show/NCT02484911 (accessed 28 September 2017). ">Zhang 2017</a>; <a href="./references#CD012555-bbs2-0014" title="ZhaoJ , LiX , JinghuaG , LiY , LiJ , ShiY , et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy ‐ induced nausea and vomiting. Modern Oncology. Modern Oncology, 2014; Vol. 22, issue 8:1941‐3. ">Zhao 2014</a>). We did not judge any studies at high risk of random sequence bias. </p> </section> <section id="CD012555-sec-0081"> <h5 class="title">Allocation concealment</h5> <p>Three RCTs clearly described adequately concealing the allocation assigned to participants (<a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a>; <a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>; <a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a>). However this was one of the least well reported areas of the 'Risk of bias' assessment, with 11 studies giving insufficient accounts or not making reference to it, hence we judged them to be at unclear risk of bias for this domain (<a href="./references#CD012555-bbs2-0001" title="ClemonsM , BouganimN , SmithS , MazzarelloS , VandermeerL , SegalR , et al. Risk model‐guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early‐stage breast cancer: a randomized clinical trial. JAMA Oncology2016;2(2):225‐31. DranitsarisG , MazzarelloS , SmithS , VandermeerL , BouganimN , ClemonsM . Measuring the impact of guideline‐based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Supportive Care in Cancer2016;24(4):1563‐9. ">Clemons 2016</a>; <a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a>; <a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a>; <a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>; <a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a>; <a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>; <a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a>; <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>; <a href="./references#CD012555-bbs2-0012" title="WangX , WangL , WangH , ZhangH . Effectiveness of olanzapine combined with ondansetron in the prevention of chemotherapy‐induced nausea and vomiting of non‐small cell lung cancer. Cell Biochemistry and Biophysics2015;72:471‐3. ">Wang 2015</a>; <a href="./references#CD012555-bbs2-0013" title="ZhangD . Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting (AOPDPCINV). clinicaltrials.gov/ct2/show/NCT02484911 (accessed 28 September 2017). ">Zhang 2017</a>; <a href="./references#CD012555-bbs2-0014" title="ZhaoJ , LiX , JinghuaG , LiY , LiJ , ShiY , et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy ‐ induced nausea and vomiting. Modern Oncology. Modern Oncology, 2014; Vol. 22, issue 8:1941‐3. ">Zhao 2014</a>). </p> </section> </section> <section id="CD012555-sec-0082"> <h4 class="title">Blinding</h4> <section id="CD012555-sec-0083"> <h5 class="title">Performance bias</h5> <p>We assessed whether the personnel running the trials and the participants were blinded as to which intervention arm participants were allocated to. We assessed 10 studies as high risk (<a href="./references#CD012555-bbs2-0001" title="ClemonsM , BouganimN , SmithS , MazzarelloS , VandermeerL , SegalR , et al. Risk model‐guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early‐stage breast cancer: a randomized clinical trial. JAMA Oncology2016;2(2):225‐31. DranitsarisG , MazzarelloS , SmithS , VandermeerL , BouganimN , ClemonsM . Measuring the impact of guideline‐based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Supportive Care in Cancer2016;24(4):1563‐9. ">Clemons 2016</a>; <a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a>; <a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a>; <a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a>; <a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a>; <a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>; <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>; <a href="./references#CD012555-bbs2-0012" title="WangX , WangL , WangH , ZhangH . Effectiveness of olanzapine combined with ondansetron in the prevention of chemotherapy‐induced nausea and vomiting of non‐small cell lung cancer. Cell Biochemistry and Biophysics2015;72:471‐3. ">Wang 2015</a>; <a href="./references#CD012555-bbs2-0013" title="ZhangD . Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting (AOPDPCINV). clinicaltrials.gov/ct2/show/NCT02484911 (accessed 28 September 2017). ">Zhang 2017</a>; <a href="./references#CD012555-bbs2-0014" title="ZhaoJ , LiX , JinghuaG , LiY , LiJ , ShiY , et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy ‐ induced nausea and vomiting. Modern Oncology. Modern Oncology, 2014; Vol. 22, issue 8:1941‐3. ">Zhao 2014</a>), as they were unblinded studies. Only four studies described procedures used to blind participants and healthcare professionals and so we assessed them to be at low risk of performance bias (<a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>; <a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a>; <a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>; <a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a>). </p> </section> <section id="CD012555-sec-0084"> <h5 class="title">Detection bias</h5> <p>We assessed whether the person reporting the outcome was blinded as to which arm the participants were in. </p> <p>Some trials asked the participants to self‐report, typically through use of a daily diary. We assessed this method to be at low risk of bias if the participants were blinded and at high risk if they were not. Other trials used personnel to assess the outcome face to face or over the phone. Again, we assessed this method to be at low risk of bias if the personnel assessing the outcome were blinded and at high risk if they were not. </p> <p>We assessed four studies to be at low risk of detection bias (<a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>; <a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a>; <a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>; <a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a>); six at high risk (<a href="./references#CD012555-bbs2-0001" title="ClemonsM , BouganimN , SmithS , MazzarelloS , VandermeerL , SegalR , et al. Risk model‐guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early‐stage breast cancer: a randomized clinical trial. JAMA Oncology2016;2(2):225‐31. DranitsarisG , MazzarelloS , SmithS , VandermeerL , BouganimN , ClemonsM . Measuring the impact of guideline‐based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Supportive Care in Cancer2016;24(4):1563‐9. ">Clemons 2016</a>; <a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a>; <a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a>; <a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>; <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>; <a href="./references#CD012555-bbs2-0013" title="ZhangD . Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting (AOPDPCINV). clinicaltrials.gov/ct2/show/NCT02484911 (accessed 28 September 2017). ">Zhang 2017</a>); and felt it was unclear in a further four studies (<a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a>; <a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a>; <a href="./references#CD012555-bbs2-0012" title="WangX , WangL , WangH , ZhangH . Effectiveness of olanzapine combined with ondansetron in the prevention of chemotherapy‐induced nausea and vomiting of non‐small cell lung cancer. Cell Biochemistry and Biophysics2015;72:471‐3. ">Wang 2015</a>; <a href="./references#CD012555-bbs2-0014" title="ZhaoJ , LiX , JinghuaG , LiY , LiJ , ShiY , et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy ‐ induced nausea and vomiting. Modern Oncology. Modern Oncology, 2014; Vol. 22, issue 8:1941‐3. ">Zhao 2014</a>). </p> </section> </section> <section id="CD012555-sec-0085"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed attrition of 10% of participants or more due to any reason as causing a study to be at high risk of attrition bias. We assessed all included studies to be at low risk of bias. </p> </section> <section id="CD012555-sec-0086"> <h4 class="title">Selective reporting</h4> <p>We assessed studies that failed to report all outcomes set out in their study protocol (if available), or methods as being at high risk of selective reporting bias and those that reported all planned outcomes at low risk of selective reporting bias. Two trials were at high risk of reporting bias (<a href="./references#CD012555-bbs2-0001" title="ClemonsM , BouganimN , SmithS , MazzarelloS , VandermeerL , SegalR , et al. Risk model‐guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early‐stage breast cancer: a randomized clinical trial. JAMA Oncology2016;2(2):225‐31. DranitsarisG , MazzarelloS , SmithS , VandermeerL , BouganimN , ClemonsM . Measuring the impact of guideline‐based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Supportive Care in Cancer2016;24(4):1563‐9. ">Clemons 2016</a>; <a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>). We assessed <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a> to be at low risk of reporting bias. All other included studies were at unclear risk of selective reporting bias, as pre‐planned outcomes were not available (<a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a>; <a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a>; <a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>; <a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a>; <a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a>; <a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>; <a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a>; <a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a>; <a href="./references#CD012555-bbs2-0012" title="WangX , WangL , WangH , ZhangH . Effectiveness of olanzapine combined with ondansetron in the prevention of chemotherapy‐induced nausea and vomiting of non‐small cell lung cancer. Cell Biochemistry and Biophysics2015;72:471‐3. ">Wang 2015</a>; <a href="./references#CD012555-bbs2-0014" title="ZhaoJ , LiX , JinghuaG , LiY , LiJ , ShiY , et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy ‐ induced nausea and vomiting. Modern Oncology. Modern Oncology, 2014; Vol. 22, issue 8:1941‐3. ">Zhao 2014</a>). </p> <p>We assessed <a href="./references#CD012555-bbs2-0013" title="ZhangD . Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting (AOPDPCINV). clinicaltrials.gov/ct2/show/NCT02484911 (accessed 28 September 2017). ">Zhang 2017</a> to be at unclear risk of bias because it is an unpublished study, where both the clinical study protocol and some of the results were available to us at clinicaltrials.gov (Protocol 02484911). It was clear that the outcomes had changed during the trial process. Some of the original outcomes that they had initially planned to report had not been reported (e.g. quality of life). In addition, the initial plan was not to analyse HEC and MEC populations separately, and this change appeared to be made after the trial had started. We await the full publication in order to assess this further. </p> </section> <section id="CD012555-sec-0087"> <h4 class="title">Other potential sources of bias</h4> <section id="CD012555-sec-0088"> <h5 class="title">Use of a validated scale</h5> <p>We assessed whether any scaled data was recorded using an appropriate validated scale. Validated scales reported in the trials that we assessed to be at low risk of bias included: </p> <p> <ul id="CD012555-list-0018"> <li> <p>visual analogue scale (VAS);</p> </li> <li> <p>Functional Living Index‐Emesis (FLIE);</p> </li> <li> <p>European Organisation for Research and Treatment of Cancer Quality‐of‐Life questionnaire (EORTC QLQ‐C30); </p> </li> <li> <p>MD Anderson Symptom Inventory (MDASI);</p> </li> <li> <p>Functional Assessment of Cancer Therapy ‐ General (FACT‐G), version 3;</p> </li> <li> <p>tool for assessing control of nausea and vomiting (The Multinational Association for Supportive Care in Cancer (MASCC)) scale; </p> </li> <li> <p>Hospital Anxiety and Depression Scale (HADS);</p> </li> <li> <p>World Health Organization Quality of Life Instruments (WHO‐QOL‐BREF); and</p> </li> <li> <p>the Rhodes Index.</p> </li> </ul> </p> <p>We were unable to find data relating to the validation of the WHO anticancer drug toxicity, WHO digestive tract reaction classification standard of anticancer drugs, grading criteria and Common Terminology Criteria for Adverse Events (CTCAE), version 3.0, which we therefore assessed to be at high risk of bias. We assessed <a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a> to be at unclear risk of bias; <a href="./references#CD012555-bbs2-0012" title="WangX , WangL , WangH , ZhangH . Effectiveness of olanzapine combined with ondansetron in the prevention of chemotherapy‐induced nausea and vomiting of non‐small cell lung cancer. Cell Biochemistry and Biophysics2015;72:471‐3. ">Wang 2015</a> and <a href="./references#CD012555-bbs2-0014" title="ZhaoJ , LiX , JinghuaG , LiY , LiJ , ShiY , et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy ‐ induced nausea and vomiting. Modern Oncology. Modern Oncology, 2014; Vol. 22, issue 8:1941‐3. ">Zhao 2014</a> at high risk of bias; and 11 other studies at low risk of bias, based on the scales they reported using (<a href="./references#CD012555-bbs2-0001" title="ClemonsM , BouganimN , SmithS , MazzarelloS , VandermeerL , SegalR , et al. Risk model‐guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early‐stage breast cancer: a randomized clinical trial. JAMA Oncology2016;2(2):225‐31. DranitsarisG , MazzarelloS , SmithS , VandermeerL , BouganimN , ClemonsM . Measuring the impact of guideline‐based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Supportive Care in Cancer2016;24(4):1563‐9. ">Clemons 2016</a>; <a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a>; <a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>; <a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a>; <a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a>; <a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>; <a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a>; <a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>; <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>; <a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a>; <a href="./references#CD012555-bbs2-0013" title="ZhangD . Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting (AOPDPCINV). clinicaltrials.gov/ct2/show/NCT02484911 (accessed 28 September 2017). ">Zhang 2017</a>). </p> </section> <section id="CD012555-sec-0089"> <h5 class="title">Size of study</h5> <p>We also assessed the risk of bias according to the number of participants per arm. As is convention in Cochrane Pain, Palliative and Supportive Care (PaPaS) reviews, we assessed studies to be at low risk of bias if they had 200 or more participants in each treatment arm. We assessed studies to be at unclear risk of bias if they randomised 50 to 199 participants to each treatment arm, and we assessed trials with fewer than 50 participants in each treatment arm to be at high risk of bias. </p> <p>Eight studies had a small sample size and therefore were at high risk of bias (<a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a>; <a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>; <a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a>; <a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>; <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>; <a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a>; <a href="./references#CD012555-bbs2-0012" title="WangX , WangL , WangH , ZhangH . Effectiveness of olanzapine combined with ondansetron in the prevention of chemotherapy‐induced nausea and vomiting of non‐small cell lung cancer. Cell Biochemistry and Biophysics2015;72:471‐3. ">Wang 2015</a>; <a href="./references#CD012555-bbs2-0014" title="ZhaoJ , LiX , JinghuaG , LiY , LiJ , ShiY , et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy ‐ induced nausea and vomiting. Modern Oncology. Modern Oncology, 2014; Vol. 22, issue 8:1941‐3. ">Zhao 2014</a>). Five studies were of moderate size and were therefore at unclear risk of bias (<a href="./references#CD012555-bbs2-0001" title="ClemonsM , BouganimN , SmithS , MazzarelloS , VandermeerL , SegalR , et al. Risk model‐guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early‐stage breast cancer: a randomized clinical trial. JAMA Oncology2016;2(2):225‐31. DranitsarisG , MazzarelloS , SmithS , VandermeerL , BouganimN , ClemonsM . Measuring the impact of guideline‐based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Supportive Care in Cancer2016;24(4):1563‐9. ">Clemons 2016</a>; <a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a>; <a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a>; <a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a>; <a href="./references#CD012555-bbs2-0013" title="ZhangD . Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting (AOPDPCINV). clinicaltrials.gov/ct2/show/NCT02484911 (accessed 28 September 2017). ">Zhang 2017</a>). Only one trial, which recruited 401 participants in total across the two arms, was at low risk of bias (<a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>). </p> </section> </section> </section> <section id="CD012555-sec-0090"> <h3 class="title" id="CD012555-sec-0090">Effects of interventions</h3> <p>See: <a href="./full#CD012555-tbl-0001"><b>Summary of findings for the main comparison</b> Olanzapine compared to placebo/no treatment for the prevention and treatment of cancer‐related nausea and vomiting in adults</a>; <a href="./full#CD012555-tbl-0002"><b>Summary of findings 2</b> Olanzapine compared to NK1 antagonist for the prevention and treatment of cancer‐related nausea and vomiting in adults</a> </p> <p>Please see <a href="./full#CD012555-tbl-0001">summary of findings Table for the main comparison</a> for the main comparison <b>olanzapine versus placebo or no treatment.</b> </p> <p>Please see <a href="./full#CD012555-tbl-0002">summary of findings Table 2</a> for <b>olanzapine versus NK1 antagonists.</b> </p> <section id="CD012555-sec-0091"> <h4 class="title">Olanzapine versus placebo or no treatment</h4> <p>Nine studies (N = 1000 participants) compared olanzapine with placebo or no treatment (<a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a>; <a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>; <a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a>; <a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>; <a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>; <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>; <a href="./references#CD012555-bbs2-0012" title="WangX , WangL , WangH , ZhangH . Effectiveness of olanzapine combined with ondansetron in the prevention of chemotherapy‐induced nausea and vomiting of non‐small cell lung cancer. Cell Biochemistry and Biophysics2015;72:471‐3. ">Wang 2015</a>; <a href="./references#CD012555-bbs2-0013" title="ZhangD . Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting (AOPDPCINV). clinicaltrials.gov/ct2/show/NCT02484911 (accessed 28 September 2017). ">Zhang 2017</a>; <a href="./references#CD012555-bbs2-0014" title="ZhaoJ , LiX , JinghuaG , LiY , LiJ , ShiY , et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy ‐ induced nausea and vomiting. Modern Oncology. Modern Oncology, 2014; Vol. 22, issue 8:1941‐3. ">Zhao 2014</a>). </p> <p>Seven studies used olanzapine for the length of the chemotherapy cycle (typically five days), and two used it for a longer duration (eight weeks). Of the longer‐duration studies, <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a> used it for participants receiving chemotherapy whilst <a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a> used it in participants not undergoing chemotherapy or radiotherapy. Instead <a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a> gave megestrol as a treatment for anorexia and cachexia as the standard treatment regimen, with the addition of olanzapine in the intervention arm. </p> <p>We investigated the results for this comparison using subgroup analyses with respect to the dose of olanzapine. The results are presented at the end of the 'Effects of interventions' section. </p> <section id="CD012555-sec-0092"> <h5 class="title">Absence of nausea or vomiting over the time period studied</h5> <p>There is moderate‐quality evidence that oral olanzapine increases the likelihood of being free from nausea or vomiting over the whole time period of the study when compared to placebo or no treatment (RR 1.98, 95% CI 1.59 to 2.47; participants = 561; studies = 3; I² = 0%), or (OR 5.48, 95% CI 1.35 to 22.20; I² = 85%). The anticipated absolute effect was 24.6% more (95% CI 14.8% more to 36.9% more), participants being free from nausea or vomiting. We calculated the number needed to treat for an additional beneficial outcome (NNTB), in order for one additional participant to be free from nausea and vomiting during the course of their treatment over standard therapy to be 5 (95% CI 3.3 ‐ 6.6), using an online calculator tool (<a href="./references#CD012555-bbs2-0071" title="GraphPad SoftwareInc . GraphPad. Version accessed 26 October 2017. GraphPad Software Inc, 2017. ">GraphPad</a>). </p> <p>We downgraded the quality of this evidence to moderate due to inconsistency. The risk of nausea and vomiting in the control group varied from 19% to 40%. This variation was probably due to the characteristics of the trials being different (such as type of cancer, chemotherapy treatment given, dose of olanzapine etc). We observed statistical heterogeneity when we assessed this using odds ratios (I² = 85%), and therefore we used a random‐effects model in this analysis. We identified a high risk of bias for one or two key domains for these studies. See <a href="./references#CD012555-fig-0004" title="">Analysis 1.1</a>. </p> <p>One of these studies, <a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>, reported absence of nausea overall and absence of vomiting overall as two separate outcomes. We chose to include the 'absence of nausea overall' data in the data contributing to our primary outcome of 'absence of nausea or vomiting over the time period studied'. This was because CINV is thought to be centrally mediated, rather than due to a mechanical cause leading to partial or complete obstruction of the gut. Nausea, therefore, most frequently precedes vomiting in participants with CINV. We acknowledge that this may slightly underestimate the incidence of nausea or vomiting in this study, should any participants have experienced vomiting unheralded by nausea, but recognise that this would be an infrequent occurrence. Additionally, when we added the data from <a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a> to the data from <a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a> and <a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a>, the size of the effect reduced leading us to report a more conservative assessment of the efficacy of olanzapine in preventing overall nausea and vomiting rather than inflating it. This is because <a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a> and <a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a> reported relatively small numbers of participants when compared to <a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>. </p> </section> <section id="CD012555-sec-0093"> <h5 class="title">Serious adverse events (extra pyramidal adverse events, prolonged QTc interval, neutropenia and agranulocytosis), as measured by the proportion of participants experiencing at least one of these events) </h5> <p>We are uncertain whether olanzapine increases the likelihood of experiencing a serious adverse event when compared to placebo or no treatment (RR 2.46, 95% CI 0.48 to 12.55; participants = 889; studies = 7 (<a href="./references#CD012555-fig-0005" title="">Analysis 1.2</a>), or OR 2.50, 95% CI 0.48 to 13.04), with an anticipated absolute difference of 0.7% more (CI 0.2% fewer to 5.2% more; low‐quality evidence). Of these seven studies, only one reported any serious adverse events (<a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>). Five of these events were in the olanzapine arm. Two of these serious adverse events were haematological, although the exact nature of these was not stated. Three serious adverse events were not defined. Olanzapine is known to increase the risk of agranulocytosis, although the type of haematological abnormality found when monitoring the participants was not elucidated in the paper (<a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>). </p> <p>We downgraded the quality of this evidence to low due to imprecision and inconsistency. There was only a small number of events (5 in olanzapine, 2 in control arm), in one trial only and no events in either arm of six other trials, leading to wide confidence intervals. Additionally, we identified a high risk of bias for one domain for <a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a> and <a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>. We identified a high risk of bias for two domains for <a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a>, <a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>, and <a href="./references#CD012555-bbs2-0013" title="ZhangD . Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting (AOPDPCINV). clinicaltrials.gov/ct2/show/NCT02484911 (accessed 28 September 2017). ">Zhang 2017</a>, and we identified a high risk of bias in three domains for <a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a> and <a href="./references#CD012555-bbs2-0014" title="ZhaoJ , LiX , JinghuaG , LiY , LiJ , ShiY , et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy ‐ induced nausea and vomiting. Modern Oncology. Modern Oncology, 2014; Vol. 22, issue 8:1941‐3. ">Zhao 2014</a>. The proportion of information from trials at high risk of bias is sufficient to affect the interpretation of results. </p> </section> <section id="CD012555-sec-0094"> <h5 class="title">Participant's perception of treatment</h5> <section id="CD012555-sec-0095"> <h6 class="title">Participant satisfaction measured by any scale, including Likert</h6> <p>No studies reported participant satisfaction as an outcome measure.</p> </section> <section id="CD012555-sec-0096"> <h6 class="title">Participant preference</h6> <p>One placebo‐controlled RCT (<a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>), asked participants if they wished to use the drug they had been allocated to in the next chemotherapy cycle. In the olanzapine group, 83% (20/24), stated that they would like to use the drug compared to 58% (14/24), in the group receiving placebo (RR 1.43, 95% CI 0.97 to 2.09; participants = 48; studies = 1; low‐quality evidence). See <a href="./references#CD012555-fig-0006" title="">Analysis 1.3</a>. </p> <p>We downgraded the quality of the evidence to moderate‐quality due to imprecision. There was a very small sample size, 24 participants per arm, resulting in very large confidence intervals. We identified a high risk of bias in one key domain for this study. </p> </section> <section id="CD012555-sec-0097"> <h6 class="title">Quality of life</h6> <p>Four studies assessed quality of life using different instruments. We felt it was not appropriate to attempt meta‐analysis of these results as the domains measured by the scales were too heterogeneous. Three studies suggested that quality of life improved, although <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a> reported "no significant difference". </p> <p><a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a> (N = 48), reports that the "[olanzapine) group experienced a better QOL than the control group, as reported on the Functional Living Index‐Emesis questionnaire (P &lt; 0.0004)" and that "all patients in the [olanzapine) group indicated that CINV did not affect their daily activities (FLI‐E score &lt; 36mm), whereas 36% of the patients in the control group had their daily life activities affected by CINV". </p> <p><a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a> (N = 100), assessed global health status using the EEORTC QLQ C30 scale (Global Health Status range 2 to 14, higher scores equal better quality of life). The global health status in the control group deteriorated from 10.08 ± 0.43 before treatment to 8.70 ± 0.44; P &lt; 0.0001 after treatment, whereas the global health status improved in the olanzapine group (before 9.48 ± 0.48 and after treatment 9.60 ± 0.47; P = 0.537). </p> <p><a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a> (N = 80), reported that 58% (23 of 39), of participants in the megestrol plus olanzapine arm had an "improved" quality of life at four and eight weeks compared to 13.5% (5/37), who received megestrol alone, on the FACT‐G (version 3) scale. However, the criteria for a participant to be considered to have an 'improved' quality of life was not defined. </p> <p><a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a> (N = 30), reported that "no significant difference was observed between the case and control groups about the patients QOL in ... total QOL score (P &gt; 0.05)" when olanzapine plus standard therapy was compared to standard therapy alone using the WHO‑QOL‑BREF scale. </p> </section> <section id="CD012555-sec-0098"> <h6 class="title">Number of participants with Patient Global Impression of Change (PGIC), of much improved or very much improved (or equivalent wording) </h6> <p>No studies reported this outcome.</p> </section> </section> <section id="CD012555-sec-0099"> <h5 class="title">Other adverse events</h5> <p>We found low‐quality evidence that olanzapine may increase the risk of other adverse events when compared to placebo or no treatment (RR 1.71, 95% CI 0.99 to 2.96; participants = 332; studies = 4; I² = 0%). However, there is some uncertainty about this result. See <a href="./references#CD012555-fig-0007" title="">Analysis 1.4</a>. </p> <p>We downgraded the quality of the evidence to low due to imprecision and inconsistency. There were wide confidence intervals and there was large variation in risks of adverse events between studies, with one study reporting an event rate of 23% in the placebo arm and 35% in the olanzapine arm. We identified a high risk of bias for one key domain for <a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>, two key domains for <a href="./references#CD012555-bbs2-0013" title="ZhangD . Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting (AOPDPCINV). clinicaltrials.gov/ct2/show/NCT02484911 (accessed 28 September 2017). ">Zhang 2017</a>, and three key domains for the remaining studies. </p> <p><a href="./references#CD012555-bbs2-0013" title="ZhangD . Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting (AOPDPCINV). clinicaltrials.gov/ct2/show/NCT02484911 (accessed 28 September 2017). ">Zhang 2017</a> reported the highest rates of adverse events (21/60 in the olanzapine arm and 14/60 in the control arm). In the olanzapine arm these included abdominal distension (N = 6), dry mouth (N = 1), dizziness (N = 2), headache (N = 1), and drowsiness (N = 11). The reason for the high instance of adverse events in the intervention and control arms is not clear. <a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a> reported that one participant experienced drowsiness with olanzapine. <a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a> reported two participants who experienced mild sedation with olanzapine. <a href="./references#CD012555-bbs2-0012" title="WangX , WangL , WangH , ZhangH . Effectiveness of olanzapine combined with ondansetron in the prevention of chemotherapy‐induced nausea and vomiting of non‐small cell lung cancer. Cell Biochemistry and Biophysics2015;72:471‐3. ">Wang 2015</a> reported that one participant experienced "mild drowsiness" with olanzapine. </p> </section> <section id="CD012555-sec-0100"> <h5 class="title">Somnolence or fatigue</h5> <p>We found moderate‐quality evidence that the risk of participants experiencing somnolence or fatigue probably increases with olanzapine (RR 2.33, 95% CI 1.30 to 4.18; participants = 464; studies = 5; I² = 17%), when compared to placebo or no treatment. See <a href="./references#CD012555-fig-0008" title="">Analysis 1.5</a>. </p> <p>We downgraded the quality of the evidence to moderate due to inconsistency. There was unexplained heterogeneity in the risk of somnolence between studies making it difficult to be confident that the true effect lies close to the estimate of the effect. </p> <p>However, the reported incidence of somnolence in the olanzapine group varied greatly between studies from 1 out of 42 (2.4%), to 13 out of 40 (32.5%). The study with highest incidence of somnolence and fatigue (<a href="./references#CD012555-bbs2-0014" title="ZhaoJ , LiX , JinghuaG , LiY , LiJ , ShiY , et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy ‐ induced nausea and vomiting. Modern Oncology. Modern Oncology, 2014; Vol. 22, issue 8:1941‐3. ">Zhao 2014</a>), also administered a sedating antihistamine in its standard treatment regimen, which is known to interact with antipsychotic medication, exacerbating somnolence (<a href="./references#CD012555-bbs2-0082" title="EMC . Nytol One‐A‐Night. www.medicines.org.uk/emc/medicine/19778 (accessed 1 November 2017). ">Medicines.org</a>). </p> <p>When we excluded this study from the analysis, the risk of somnolence increased (RR 5.29, 95% CI 1.73 to 16.18; participants = 384; studies = 4; I² = 0%). </p> </section> <section id="CD012555-sec-0101"> <h5 class="title">Withdrawals due to all causes</h5> <p>We did not find evidence of a difference in the likelihood of withdrawal from studies between the olanzapine and no treatment/placebo groups although the overall withdrawal rate in both arms was low (RR 0.99, 95% CI 0.57 to 1.73; participants = 943; studies = 8; I² = 0%). See <a href="./references#CD012555-fig-0009" title="">Analysis 1.6</a>. </p> <section id="CD012555-sec-0102"> <h6 class="title">Withdrawals due to lack of efficacy</h6> <p>Six RCTs (422 participants), reported that there were no withdrawals due to lack of efficacy in either arm. See <a href="./references#CD012555-fig-0010" title="">Analysis 1.7</a>. </p> </section> <section id="CD012555-sec-0103"> <h6 class="title">Withdrawals due to adverse events</h6> <p>Of the six RCTs with data for withdrawals, only one RCT reported one withdrawal due to an adverse event in the olanzapine arm. No withdrawals due to adverse events were reported in the placebo/no treatment arms in any study (RR 3.00, 95% CI 0.13 to 70.16; participants = 422; studies = 6). We are uncertain if olanzapine increases the risk of withdrawal due to an adverse event. See <a href="./references#CD012555-fig-0011" title="">Analysis 1.8</a>. </p> </section> <section id="CD012555-sec-0104"> <h6 class="title">Withdrawals due to death</h6> <p>Seven RCTs (542 participants), reported that there were no deaths during the study period. </p> </section> </section> <section id="CD012555-sec-0105"> <h5 class="title">50% reduction in the severity of nausea or vomiting from baseline, as measured by a validated scale </h5> <p>No RCTs reported the number of participants with a 50% or greater reduction in the severity of nausea or vomiting from baseline, using a validated scale. </p> </section> <section id="CD012555-sec-0106"> <h5 class="title">Incidence of breakthrough nausea and vomiting and use of rescue antiemetics</h5> <p>Olanzapine may reduce the need for breakthrough antiemetics (RR 0.38, 95% CI 0.10 to 1.47; participants = 501; studies = 2; I² = 54%). Due to the high heterogeneity observed, we used a random‐effects model for this analysis. See <a href="./references#CD012555-fig-0012" title="">Analysis 1.9</a>. </p> </section> <section id="CD012555-sec-0107"> <h5 class="title">No nausea or vomiting at different time points</h5> <section id="CD012555-sec-0108"> <h6 class="title">No overall nausea or overall vomiting</h6> <p>Olanzapine reduced nausea over the whole trial period compared to placebo or no treatment but the results are from only one study (RR 1.67, 95% CI 1.18 to 2.35; participants = 401; studies = 1). See <a href="./references#CD012555-fig-0013" title="">Analysis 1.10</a>. </p> <p>Olanzapine increased the likelihood of being free from vomiting over the whole trial period when we consider it alone compared to placebo or no treatment (RR 1.30, 95% CI 1.12 to 1.51; participants = 220; studies = 2; I² = 0%). See <a href="./references#CD012555-fig-0014" title="">Analysis 1.11</a>. </p> </section> <section id="CD012555-sec-0109"> <h6 class="title">No anticipatory (prior to chemotherapy), nausea or vomiting</h6> <p>No trials reported anticipatory nausea or vomiting as an outcome.</p> </section> <section id="CD012555-sec-0110"> <h6 class="title">No acute (within 24 hours of administration of chemotherapy), nausea or vomiting</h6> <p>We are uncertain if the likelihood of being free from acute nausea increases with olanzapine compared to no treatment/placebo (RR 1.37, 95% CI 0.95 to 1.98; participants = 585; studies = 3; I² = 89%). See <a href="./references#CD012555-fig-0015" title="">Analysis 1.12</a>. </p> <p>We are uncertain if freedom from acute vomiting increases with olanzapine administration compared to placebo or no treatment when analysed using a random‐effects model due to the high heterogeneity (RR 1.11, 95% CI 0.97 to 1.28; participants = 702; studies = 5; I² = 80%). See <a href="./references#CD012555-fig-0016" title="">Analysis 1.13</a>. </p> <p>We are uncertain if freedom from acute nausea and vomiting increases with olanzapine administration compared to placebo or no treatment when analysed using a random‐effects model due to the high heterogeneity (RR 1.21, 95% CI 0.86 to 1.69; participants = 164; studies = 2; I² = 58%). See <a href="./references#CD012555-fig-0017" title="">Analysis 1.14</a>. </p> </section> <section id="CD012555-sec-0111"> <h6 class="title">No delayed (two to five days after administration of chemotherapy), nausea or vomiting</h6> <p>Olanzapine increased the likelihood of being free from delayed nausea in comparison to placebo or no treatment (RR 1.71, 95% CI 1.40 to 2.09; participants = 585; studies = 3; I² = 0%). See <a href="./references#CD012555-fig-0018" title="">Analysis 1.15</a>. </p> <p>Olanzapine increased the likelihood of being free from delayed vomiting in comparison to placebo or no treatment (RR 1.28, 95% CI 1.14 to 1.42; participants = 702; studies = 5; I² = 2%). See <a href="./references#CD012555-fig-0019" title="">Analysis 1.16</a>. </p> <p>Olanzapine almost doubles the likelihood of being free from delayed nausea and vomiting compared to placebo or no treatment (RR 1.98, 95% CI 1.61 to 2.44; participants = 264; studies = 3; I² = 25%). See <a href="./references#CD012555-fig-0020" title="">Analysis 1.17</a>. </p> </section> </section> </section> <section id="CD012555-sec-0112"> <h4 class="title">Olanzapine versus NK1 antagonists</h4> <p>Only one study (<a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a>), with 20 participants compared olanzapine with an NK1 antagonist (aprepitant), therefore we were unable to draw conclusions with certainty for this comparison. </p> <section id="CD012555-sec-0113"> <h5 class="title">Absence of nausea or vomiting over the time period studied</h5> <p><a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0114"> <h5 class="title">Serious adverse events (extra pyramidal adverse events, prolonged QTc interval, neutropenia and agranulocytosis), as measured by the proportion of participants experiencing at least one of these events </h5> <p>The study reported serious adverse events in participants receiving olanzapine. We are uncertain whether this may favour the NK1 antagonist arm (RR 0.33, 95% CI 0.02 to 7.32 very low‐quality evidence). See <a href="./references#CD012555-fig-0021" title="">Analysis 2.1</a>. </p> <p>We downgraded the quality of evidence to very low due to imprecision and study limitations. There was only one study with a small sample size (n = 20), and very few events (one event in NK1 arm), leading to very imprecise results. The study states "for the first 2 cycles of chemotherapy", however, the length of each cycle was not defined. </p> </section> <section id="CD012555-sec-0115"> <h5 class="title">Participant's perception of treatment</h5> <p><a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a> did not report participant satisfaction, participant preference, quality of life, or number of participants with Patient Global Impression of Change (PGIC), of much improved or very much improved. </p> </section> <section id="CD012555-sec-0116"> <h5 class="title">Other adverse events</h5> <p><a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0117"> <h5 class="title">Somnolence or fatigue</h5> <p>We are uncertain whether olanzapine increases somnolence and fatigue when compared to an NK1 antagonist (RR 1.33, 95% CI 0.40 to 4.49; participants = 20; studies = 1; very low‐quality evidence). See <a href="./references#CD012555-fig-0022" title="">Analysis 2.2</a>. </p> <p>We downgraded the evidence to very low quality due to imprecision and study limitations. There was only one study with a small sample size (n = 20), leading to very imprecise results. The study states "for the first 2 cycles of chemotherapy", however, the length of each cycle was not defined. </p> </section> <section id="CD012555-sec-0118"> <h5 class="title">Withdrawals due to all causes</h5> <p>One participant in the olanzapine arm of <a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a> lost their daily diary and therefore had to be withdrawn (RR 3.00, 95% CI 0.14 to 65.90; participants = 20; studies = 1). See <a href="./references#CD012555-fig-0023" title="">Analysis 2.3</a>. </p> <p>There were no reported withdrawals due to lack of efficacy, adverse events or death.</p> </section> <section id="CD012555-sec-0119"> <h5 class="title">50% reduction in the severity of nausea or vomiting from baseline, as measured by a validated scale </h5> <p><a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0120"> <h5 class="title">Incidence of breakthrough nausea and vomiting and use of rescue antiemetics</h5> <p><a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0121"> <h5 class="title">No nausea or vomiting at different time points</h5> <p>We are uncertain if olanzapine is less effective than NK1 antagonists in preventing overall nausea (RR 0.67, 95% CI 0.14 to 3.17; participants = 20), due to data from a single study with a small sample size. See <a href="./references#CD012555-fig-0027" title="">Analysis 2.7</a>. </p> <p>We are uncertain if olanzapine is less effective than NK1 antagonists in preventing acute nausea (RR 0.60, 95% CI 0.19 to 1.86; participants = 20; studies = 1) (<a href="./references#CD012555-fig-0028" title="">Analysis 2.8</a>), or in preventing delayed nausea (RR 1.33, 95% CI 0.40 to 4.49; participants = 20; studies = 1) (<a href="./references#CD012555-fig-0029" title="">Analysis 2.9</a>), as there is insufficient evidence. </p> <p>The study did not report the outcomes no vomiting, no anticipatory (prior to chemotherapy) nausea or vomiting, or no delayed (two to five days after administration of chemotherapy) nausea or vomiting. </p> </section> </section> <section id="CD012555-sec-0122"> <h4 class="title">Olanzapine versus prokinetic</h4> <p>Only one study compared olanzapine with prokinetic (metoclopramide), as treatment for breakthrough nausea and vomiting (<a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a>; 280 participants), therefore we were unable to draw conclusions with certainty for this comparison. All participants in both study groups also received background treatment including a 5‐HT3 antagonist, NK1 antagonist and dexamethasone. Of the 280 participants, 112 had breakthrough CINV and received the treatment. </p> <section id="CD012555-sec-0123"> <h5 class="title">Absence of nausea or vomiting over the time period studied</h5> <p><a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0124"> <h5 class="title">Serious adverse events (extra pyramidal adverse events, prolonged QTc interval, neutropenia and agranulocytosis), as measured by the proportion of participants experiencing at least one of these events </h5> <p><a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a> reported that no participants in either the olanzapine or the metoclopramide arm experienced any serious adverse event, including extra pyramidal features. See <a href="./references#CD012555-fig-0030" title="">Analysis 3.1</a>. </p> </section> <section id="CD012555-sec-0125"> <h5 class="title">Participant's perception of treatment</h5> <p><a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a> did not report participant satisfaction, participant preference, quality of life, or number of participants with Patient Global Impression of Change (PGIC), of much improved or very much improved. </p> </section> <section id="CD012555-sec-0126"> <h5 class="title">Other adverse events</h5> <p><a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0127"> <h5 class="title">Somnolence or fatigue</h5> <p><a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0128"> <h5 class="title">Withdrawals due to all causes</h5> <p>It is uncertain whether olanzapine leads to a difference in withdrawal rates in the olanzapine arm over metoclopramide (RR 0.93, 95% CI 0.14 to 6.38; participants = 112; studies = 1). As only two participants withdrew from each arm the events rate is too low to assess with certainty. See <a href="./references#CD012555-fig-0031" title="">Analysis 3.2</a>. </p> <section id="CD012555-sec-0129"> <h6 class="title">Withdrawals due to lack of efficacy</h6> <p>One participant withdrew from the olanzapine arm and two from the metoclopramide arm due to lack of efficacy. We are uncertain whether this may favour the olanzapine arm (RR 0.47, 95% CI 0.04 to 4.99; participants = 112; studies = 1). See <a href="./references#CD012555-fig-0032" title="">Analysis 3.3</a>. </p> </section> <section id="CD012555-sec-0130"> <h6 class="title">Withdrawals due to adverse events</h6> <p>No participants withdrew due to adverse events in either arm. See <a href="./references#CD012555-fig-0033" title="">Analysis 3.4</a>. </p> </section> <section id="CD012555-sec-0131"> <h6 class="title">Withdrawals due to death</h6> <p>There were no withdrawals due to death were reported in either arm. See <a href="./references#CD012555-fig-0034" title="">Analysis 3.5</a>. </p> </section> </section> <section id="CD012555-sec-0132"> <h5 class="title">50% reduction in the severity of nausea or vomiting from baseline, as measured by a validated scale </h5> <p><a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0133"> <h5 class="title">Incidence of breakthrough nausea and vomiting and use of rescue antiemetics</h5> <p><a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0134"> <h5 class="title">No nausea or vomiting at different time points</h5> <p><a href="./references#CD012555-bbs2-0008" title="NavariR , NagyC , GrayS . Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2012;20:S47. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Journal of Clinical Oncology2012;30(15 suppl 1):‐. NavariR , NagyC , GrayS . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer2013; Vol. 21, issue 6:1655‐63. ">Navari 2013b</a> did not report no anticipatory (prior to chemotherapy) nausea or vomiting, no acute (within 24 hours of administration of chemotherapy) nausea or vomiting, or no delayed (two to five days after administration of chemotherapy) nausea or vomiting. </p> <section id="CD012555-sec-0135"> <h6 class="title">No overall nausea or overall vomiting</h6> <p>Olanzapine may increase the likelihood of being free from nausea over the whole period of a study when compared with metoclopramide (RR 2.95, 95% CI 1.73 to 5.02; participants = 112; studies = 1; <a href="./references#CD012555-fig-0035" title="">Analysis 3.6</a>), and of being free from vomiting (RR 3.03, 95% CI 1.78 to 5.14; participants = 112; studies = 1). We assessed this study as being at low or unclear risk of bias for all key domains. See <a href="./references#CD012555-fig-0036" title="">Analysis 3.7</a>. </p> </section> </section> </section> <section id="CD012555-sec-0136"> <h4 class="title">Olanzapine versus 5‐HT3 Antagonists</h4> <p><a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a> (N = 62), was the only included RCT that compared olanzapine to 5‐HT3 antagonists, therefore we were unable to draw conclusions with certainty for this comparison. This was a three‐arm, parallel‐group study that compared olanzapine to ondansetron and palonosetron. To avoid the risk of double counting the olanzapine data we decided to combine the two 5‐HT3 arm results rather than reporting the data as olanzapine versus palonosetron and olanzapine versus ondansetron. </p> <section id="CD012555-sec-0137"> <h5 class="title">Absence of nausea or vomiting over the time period studied</h5> <p><a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0138"> <h5 class="title">Serious adverse events (extra pyramidal adverse events, prolonged QTc interval, neutropenia and agranulocytosis), as measured by the proportion of participants experiencing at least one of these events </h5> <p><a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a> reported no serious adverse events in either arm. See <a href="./references#CD012555-fig-0037" title="">Analysis 4.1</a>. </p> </section> <section id="CD012555-sec-0139"> <h5 class="title">Participant's perception of treatment</h5> <p><a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a> did not report participant satisfaction, participant preference, quality of life, or number of participants with Patient Global Impression of Change (PGIC), of much improved or very much improved. </p> </section> <section id="CD012555-sec-0140"> <h5 class="title">Other adverse events</h5> <p><a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0141"> <h5 class="title">Somnolence or fatigue</h5> <p><a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0142"> <h5 class="title">Withdrawals due to all causes</h5> <p><a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a> reported two withdrawals in the olanzapine arm (22 participants), and one in the combined 5‐HT3 arm (44 participants), (RR 3.64, 95% CI 0.35 to 37.88; participants = 62; studies = 1). With so few events reported it is unclear whether there is a difference between the treatment groups. See <a href="./references#CD012555-fig-0040" title="">Analysis 4.4</a>. </p> <section id="CD012555-sec-0143"> <h6 class="title">Withdrawals due to lack of <i>e</i>fficacy </h6> <p>The two withdrawals in the olanzapine arm were due to lack of efficacy compared with one in the 5‐HT3 antagonists arm (RR 3.64, 95% CI 0.35 to 37.88; participants = 62; studies = 1). With so few events reported it is unclear whether there is a difference between the treatment groups. See <a href="./references#CD012555-fig-0041" title="">Analysis 4.5</a>. </p> <p><a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a> reported no withdrawals due to adverse events or death in either arm. </p> </section> </section> <section id="CD012555-sec-0144"> <h5 class="title">50% reduction in the severity of nausea or vomiting from baseline, as measured by a validated scale </h5> <p>It is uncertain whether the use of olanzapine leads to more participants experiencing a 50% reduction in the severity of nausea or vomiting in the acute phase compared to 5‐H3 antagonists (RR 1.36, 95% CI 0.80 to 2.34; participants = 62; studies = 1; <a href="./references#CD012555-fig-0038" title="">Analysis 4.2</a>). Olanzapine may have led to more participants with a 50% reduction in severity of nausea or vomiting in the delayed phase when assessed at 48 hours (RR 1.82, 95% CI 1.11 to 2.97; participants = 62; studies = 1; <a href="./references#CD012555-fig-0039" title="">Analysis 4.3</a>), compared to palonosetron and ondansetron. </p> </section> <section id="CD012555-sec-0145"> <h5 class="title">Incidence of breakthrough nausea and vomiting and use of rescue antiemetics</h5> <p><a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0146"> <h5 class="title">No nausea or vomiting at different time points</h5> <p><a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a> did not report overall, anticipatory (prior to chemotherapy), acute (within 24 hours of administration of chemotherapy), or delayed (two to five days after administration of chemotherapy) nausea or vomiting. </p> </section> </section> <section id="CD012555-sec-0147"> <h4 class="title">Olanzapine versus dexamethasone</h4> <p>Only one unblinded study (two reports, <a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a>), with 229 participants, compared oral olanzapine 10 mg daily for five days to 10 mg of intravenous dexamethasone each day, on day 2 to day 5, therefore we were unable to draw conclusions with certainty for this comparison. </p> <section id="CD012555-sec-0148"> <h5 class="title">Absence of nausea or vomiting over the time period studied</h5> <p><a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0149"> <h5 class="title">Serious adverse events (extra pyramidal adverse events, prolonged QTc interval, neutropenia and agranulocytosis), as measured by the proportion of participants experiencing at least one of these events </h5> <p><a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a> reported no serious adverse events in either arm. See <a href="./references#CD012555-fig-0044" title="">Analysis 5.1</a>. </p> </section> <section id="CD012555-sec-0150"> <h5 class="title">Participant's perception of treatment</h5> <p><a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a> did not report participant satisfaction, participant preference, or Patient Global Impression of Change (PGIC). </p> <section id="CD012555-sec-0151"> <h6 class="title">Quality of life</h6> <p><a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a> used the EORTC QLQ C30 version 3.0 scale to measure quality of life. They reported the Global Health Status domain (range: 0 to 100, higher scores equal better quality of life), and found that the change in Global Health Status score was greater for participants in the olanzapine group (improved by 3.25 points), than the dexamethasone group (decreased by 1.92 points). The study authors compared the results of the two groups using a T test and reported the P value as 0.005, although they did not comment on the clinical significance of this change. </p> </section> </section> <section id="CD012555-sec-0152"> <h5 class="title">Other adverse events</h5> <p><a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0153"> <h5 class="title">Somnolence or fatigue</h5> <p><a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a> report that 88 out of the 121 participants in the olanzapine arm experienced somnolence or fatigue but did not report the incidence of somnolence or fatigue in the comparison arm. It was therefore not possible to analyse these data. </p> </section> <section id="CD012555-sec-0154"> <h5 class="title">Withdrawals due to all causes</h5> <p>The study did not report withdrawals due to lack of efficacy, adverse events or death in either arm (<a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a>). See <a href="./references#CD012555-fig-0045" title="">Analysis 5.2</a>. </p> </section> <section id="CD012555-sec-0155"> <h5 class="title">50% reduction in the severity of nausea or vomiting from baseline, as measured by a validated scale </h5> <p><a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0156"> <h5 class="title">Incidence of breakthrough nausea and vomiting and use of rescue antiemetics</h5> <p><a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0157"> <h5 class="title">No nausea or vomiting at different time points</h5> <section id="CD012555-sec-0158"> <h6 class="title">No overall nausea or overall vomiting</h6> <p>Olanzapine may increase the likelihood of being free from nausea (RR 1.73, 95% CI 1.37 to 2.18; participants = 229; studies = 1; <a href="./references#CD012555-fig-0046" title="">Analysis 5.3</a>), and may slightly improve being free from vomiting (RR 1.27, 95% CI 1.10 to 1.48; participants = 229; studies = 1; <a href="./references#CD012555-fig-0047" title="">Analysis 5.4</a>), over the whole period of the study when compared to dexamethasone. </p> </section> <section id="CD012555-sec-0159"> <h6 class="title">No anticipatory (prior to chemotherapy), nausea or vomiting</h6> <p><a href="./references#CD012555-bbs2-0002" title="LiuJ , TanL , ZhangH , LiH , LiuX , YanZ , et al. QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist. European Journal of Cancer Care2015;24(3):436‐43. TanL , LiuJ , LiuX , ChenJ , YanZ , YangH , et al. Clinical research of olanzapine for prevention of chemotherapy‐induced nausea and vomiting. Journal of Experimental and Clinical Cancer Research2009; Vol. 28:131. ">Liu/Tan 2015</a> did not report this outcome. </p> </section> <section id="CD012555-sec-0160"> <h6 class="title">No acute (within 24 hours of administration of chemotherapy), nausea or vomiting</h6> <p>Olanzapine may lead to little or no difference in rates of acute nausea (RR 1.07, 95% CI 0.99 to 1.14; participants = 229; studies = 1; <a href="./references#CD012555-fig-0048" title="">Analysis 5.5</a>), or acute vomiting (RR 1.01, 95% CI 0.94 to 1.08; participants = 229; studies = 1; <a href="./references#CD012555-fig-0049" title="">Analysis 5.6</a>), when compared to dexamethasone. </p> </section> <section id="CD012555-sec-0161"> <h6 class="title">No delayed (two to five days after administration of chemotherapy), nausea or vomiting</h6> <p>Olanzapine may slightly improve the likelihood of being free from delayed nausea (RR 1.66, 95% CI 1.33 to 2.08; participants = 229; studies = 1; <a href="./references#CD012555-fig-0050" title="">Analysis 5.7</a>), and delayed vomiting (RR 1.25, 95% CI 1.07 to 1.45; participants = 229; studies = 1; <a href="./references#CD012555-fig-0051" title="">Analysis 5.8</a>), when compared to dexamethasone. </p> </section> </section> </section> <section id="CD012555-sec-0162"> <h4 class="title">Subgroup analyses</h4> <p>We were only able to complete subgroup analysis for the comparison of olanzapine versus placebo or no treatment, as this was the only comparison with sufficient data. Methods for the subgroup are presented in the methods section: <a href="#CD012555-sec-0060">Subgroup analysis and investigation of heterogeneity</a>. </p> <section id="CD012555-sec-0163"> <h5 class="title">Effect of dose on efficacy and adverse events</h5> <p>We assessed the effect of dose (2.5 mg versus 5 mg versus 10 mg twice daily), on efficacy and adverse events. This was to establish whether there could be a dose response effect of olanzapine in the context of nausea and vomiting, in order to identify the lowest effective dose and the dose associated with the fewest adverse events. </p> <section id="CD012555-sec-0164"> <h6 class="title">Doses analysed</h6> <p>There were sufficient data to undertake subgroup analysis to assess 5 mg and 10 mg daily doses. Some studies gave these as daily doses, and others as divided doses (i.e. 2.5 mg twice a day or 5 mg twice a day). Although one study (<a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>), used 2.5 mg daily the data were not presented in a way that we could extract only the effect of the 2.5 mg dose. </p> </section> <section id="CD012555-sec-0165"> <h6 class="title">Efficacy</h6> <section id="CD012555-sec-0166"> <p><b>No nausea or vomiting over the trial period</b></p> <p>The subgroup analysis results found that, compared to placebo/no treatment the 5 mg and 10 mg dose may have similar efficacies in preventing nausea and vomiting over the whole trial period. The test for subgroup differences did not indicate that there were differences between the groups (P = 0.86; I² = 0%). <a href="./references#CD012555-fig-0052" title="">Analysis 6.1</a>. </p> <p> <ul id="CD012555-list-0019"> <li> <p>5 mg olanzapine: RR 2.00, 95% CI 1.19 to 3.36; participants = 60; studies = 1</p> </li> <li> <p>10 mg olanzapine: RR 1.98, 95% CI 1.40 to 2.80; participants = 501; studies = 2; I<sup>2</sup> = 50% </p> </li> </ul> </p> </section> </section> <section id="CD012555-sec-0167"> <h6 class="title">Adverse events</h6> <section id="CD012555-sec-0168"> <p><b>Serious adverse events</b></p> <p>5 mg olanzapine: none of the five studies included (N = 388) reported any serious adverse events in either the olanzapine or placebo/no treatment arm. </p> <p>10 mg olanzapine: two studies (N = 501) reported serious adverse events. Only one study found any adverse events and reported five serious adverse events in the olanzapine arm and two in the comparison arm (RR 2.46, 95% CI 0.48 to 12.55; participants = 501; studies = 2; <a href="./references#CD012555-fig-0053" title="">Analysis 6.2</a>). The nature of all seven serious adverse events was not described, however, the paper stated that two of the serious adverse events in the olanzapine arm were "haematologic". Olanzapine is known to increase the risk of agranulocytosis, although the type of haematological abnormality found when monitoring the participants was not elucidated in the paper (<a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a>). </p> <p>Whilst this might represent an increased risk of serious adverse events with the 10 mg daily dose of olanzapine, this evidence is of low quality and when considering it is a subgroup analysis is not advisable to take this as a causal link<i>.</i> </p> </section> <section id="CD012555-sec-0169"> <p><b>Other adverse events</b></p> <p>We are uncertain whether other adverse events are increased more with a 5 mg olanzapine dose (RR 4.00, 95% CI 0.46 to 34.85; participants = 128; studies = 2; I² = 0%), compared with a 10 mg olanzapine dose (RR 1.55, 95% CI 0.88 to 2.73; participants = 204; studies = 2; I² = 0%; <a href="./references#CD012555-fig-0054" title="">Analysis 6.3</a>). The test for subgroup differences did not indicate there were significant differences between the groups (P = 0.41, I² = 0%). </p> </section> <section id="CD012555-sec-0170"> <p><b>Somnolence or fatigue</b></p> <p>The use of 10 mg olanzapine may be associated with an increased risk of somnolence or fatigue (RR 5.33, 95% CI 1.60 to 17.81; participants = 304; studies = 3; I² = 0%), when compared to the 5 mg dose (RR 1.48, 95% CI 0.75 to 2.91; participants = 160; studies = 2; I² = 0%). However, the test for subgroup differences indicates that there is no significant difference between the two groups (P = 0.07; I² = 69.8%; <a href="./references#CD012555-fig-0055" title="">Analysis 6.4</a>). </p> </section> </section> <section id="CD012555-sec-0171"> <h6 class="title">Serious adverse events when administered for longer than five days</h6> <p>It should be noted that, apart from two RCTs (<a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>; <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>), the data identified in this review only describe the short‐term administration of olanzapine for nausea and vomiting, usually up to a maximum of five days' duration. <a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a> (N = 80) administered 5 mg olanzapine daily for eight weeks and reported no serious adverse events. <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a> (N = 30) used olanzapine doses ranging from 2.5 mg to 10 mg daily, for eight weeks, according to individual participant tolerance. The study did not report any adverse events, serious or otherwise. </p> </section> </section> <section id="CD012555-sec-0172"> <h5 class="title">Summary</h5> <p>From the pre‐specified but observational subgroup analysis, there is an indication that the 5 mg dose might achieve as good an antiemetic effect as the 10 mg dose with less somnolence and fatigue. It is uncertain whether there is an increased risk of serious or other adverse events with 10 mg compared to 5 mg of olanzapine. </p> </section> <section id="CD012555-sec-0173"> <h5 class="title">Other planned subgroups</h5> <p>There was insufficient evidence to undertake the planned subgroup analysis to assess the impact of the different clinical settings (chemotherapy, radiotherapy, chemoradiotherapy or no active cancer treatment), on the efficacy of olanzapine. Equally, there was insufficient evidence to undertake the planned subgroup analysis to assess the impact of MEC or HEC, on its efficacy. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012555-sec-0174" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012555-sec-0174">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012555-sec-0263">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012555-sec-0174"></div> <section id="CD012555-sec-0175"> <h3 class="title" id="CD012555-sec-0175">Summary of main results</h3> <p>We included 14 RCTs (1917 participants), from high‐, middle‐ and low‐income countries, representing over 24 different cancers. Nine studies compared olanzapine with placebo/no treatment for the prevention of CINV (<a href="./full#CD012555-tbl-0001">summary of findings Table for the main comparison</a>). All participants also received standard antiemetic treatment. Four RCTs each compared olanzapine with one of the following active comparisons: NK1 antagonists (participants = 20), 5‐HT3 antagonists (participants = 62), prokinetics (participants = 112), and dexamethasone (participants = 229). The comparison against NK1 antagonists is presented in <a href="./full#CD012555-tbl-0002">summary of findings Table 2</a>. We included a further RCT in our qualitative synthesis but this study did not contribute data to the quantitative analysis (<a href="./references#CD012555-bbs2-0001" title="ClemonsM , BouganimN , SmithS , MazzarelloS , VandermeerL , SegalR , et al. Risk model‐guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early‐stage breast cancer: a randomized clinical trial. JAMA Oncology2016;2(2):225‐31. DranitsarisG , MazzarelloS , SmithS , VandermeerL , BouganimN , ClemonsM . Measuring the impact of guideline‐based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Supportive Care in Cancer2016;24(4):1563‐9. ">Clemons 2016</a>). </p> <section id="CD012555-sec-0176"> <h4 class="title">Efficacy</h4> <section id="CD012555-sec-0177"> <h5 class="title">Absence of nausea or vomiting over the whole time period studies</h5> <p>Three out of nine studies contributed data to our primary outcome of 'Absence of nausea or vomiting over the time period studied'. There is moderate‐quality evidence that olanzapine probably almost doubles the likelihood of being free from nausea and vomiting over the trial period when compared to placebo or no treatment. </p> <p>The primary efficacy outcome of no nausea or vomiting over the trial period was not reported in any of the trials comparing olanzapine against an active treatment. </p> </section> <section id="CD012555-sec-0178"> <h5 class="title">Efficacy for no nausea or no vomiting over different time periods</h5> <section id="CD012555-sec-0179"> <h6 class="title">Efficacy for the overall period of the study</h6> <p>When compared against no treatment or placebo olanzapine probably increases the likelihood of not having nausea or not having vomiting over the whole time period studied. When olanzapine was compared against prokinetics and dexamethasone, there may have been a slight reduction in nausea and a slight reduction in vomiting. No other comparisons reported this outcome. </p> </section> <section id="CD012555-sec-0180"> <h6 class="title">Efficacy for the acute phase of the study</h6> <p>Compared to no treatment or placebo it is uncertain whether olanzapine impacts greatly on acute nausea or acute vomiting. When compared against active comparators, there was little or no difference between acute nausea versus NK1 antagonists and dexamethasone. No other comparisons reported this outcome. </p> </section> <section id="CD012555-sec-0181"> <h6 class="title">Efficacy for the delayed phase of the study</h6> <p>When compared to no treatment or placebo, olanzapine probably increases the likelihood of freedom from delayed nausea and delayed vomiting. There was little or no difference in delayed nausea when olanzapine was compared against NK1 antagonists but there may have been a slight reduction in both nausea and vomiting in the delayed phase with olanzapine compared against dexamethasone. No other comparisons reported this outcome. </p> <p>The trial comparing olanzapine with 5‐HT3 antagonists reported that, although there was little or no difference in the percentage of participants with a 50% improvement in nausea at 24 hours, they may have a slight improvement with olanzapine at 48 hours. </p> <p>Whilst olanzapine almost doubles the likelihood of being free from nausea and vomiting overall and in the delayed phase, it does not appear to impact greatly, if at all, acute nausea and vomiting when compared to placebo/no treatment, NK1 antagonists or dexamethasone. The studies that compared olanzapine to prokinetics or 5‐HT3 antagonists did not report incidence of acute nausea and vomiting. The reason for its delayed onset of antiemetic action is not clear from our analysis. It is possible that this may be related to when olanzapine achieves steady state as its "half‐life ranges from 21 to 54 hours (5th to 95th percentile; mean of 30 hr)" (<a href="./references#CD012555-bbs2-0068" title="USFood , Drug Administration(FDA) . ZYPREXA® olanzapine tablets ZYPREXA® ZYDIS® olanzapine orally disintegrating tablets ZYPREXA® intramuscular olanzapine for Injection. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4399b1‐05%20(Zyprexa%20(olanzapine)%20Labeling).pdf accessed 23 October 2017. ">FDA</a>). </p> </section> </section> <section id="CD012555-sec-0182"> <h5 class="title">Adverse events</h5> <section id="CD012555-sec-0183"> <h6 class="title">Serious adverse events with oral olanzapine</h6> <p>It is uncertain whether olanzapine increases the risk of serious adverse events compared with no treatment or placebo, as only one trial out of seven reported any serious adverse events. Post‐marketing adverse events surveillance may be more reflective of the true incidence of these rare events. </p> </section> <section id="CD012555-sec-0184"> <h6 class="title">Serious adverse events with long‐term oral olanzapine</h6> <p>Only two RCTs administered olanzapine for nausea and vomiting, for more than five days (<a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>; <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>). <a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a> administered 5 mg daily for eight weeks and reported no serious adverse events. <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a> used doses ranging from 2.5 mg to 10 mg daily for eight weeks, according to individual participant tolerance, but provided no report of adverse event data, serious or otherwise. We are therefore very uncertain as to the risks of serious adverse events when olanzapine is administered for longer than five days. Whilst the only frequently identified adverse event across all the included trials was somnolence, and serious adverse effects were infrequently identified, RCTs are not the best way of identifying adverse events, particularly those that occur infrequently. In view of the paucity of data relating to long‐term administration of olanzapine, clinicians should be aware of and monitor for adverse events, including extra pyramidal features, prolonged QTc interval, neutropenia and agranulocytosis, and diabetes mellitus if olanzapine is administered for longer than five days (<a href="./references#CD012555-bbs2-0056" title="Anonymous . Zyprexa 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg coated tablets. Zyprexa Velotab 5 mg, 10 mg, 15 mg, and 20 mg orodispersible tablets. www.medicines.org.uk/emc/medicine/614 (accessed 29 September 2017). ">Anonymous 2017</a>). </p> </section> </section> <section id="CD012555-sec-0185"> <h5 class="title">Somnolence and fatigue</h5> <p>There is moderate‐quality evidence that olanzapine increases the risk of somnolence and fatigue, although this may be partially attenuated when 5 mg of olanzapine daily is administered compared to 10 mg daily. </p> </section> <section id="CD012555-sec-0186"> <h5 class="title">Quality of life</h5> <p>There is a suggestion that olanzapine may slightly improve overall quality of life, or prevent the reduction in quality of life seen in the control groups when chemotherapy is administered, although it was not possible to analyse these data as studies used a wide range of scores to assess them and the reporting was poor. </p> </section> </section> </section> <section id="CD012555-sec-0187"> <h3 class="title" id="CD012555-sec-0187">Overall completeness and applicability of evidence</h3> <section id="CD012555-sec-0188"> <h4 class="title">Evidence gaps</h4> <p>Additional published data and studies are required to assess the impact of 2.5 mg, 5 mg and 10 mg doses on the efficacy and safety of olanzapine. </p> <p>There was only one trial that studied participants who were not receiving active anticancer treatment with chemotherapy, radiotherapy or chemoradiotherapy (<a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>). One trial included participants receiving chemoradiotherapy (<a href="./references#CD012555-bbs2-0006" title="NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Blood2015;126(23):1910. NakagakiM , BarrasM , CurleyC , ButlerJ , KennedyG . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy‐induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer2017;25(2):607‐13. ">Nakagaki 2017</a>), and there was none where participants only received radiotherapy. This limits the applicability of the results of this review in participants receiving radiotherapy alone predominantly and with less certainty to those receiving no active treatment. Further research is required in these populations. </p> <p>There was only one study that compared olanzapine head to head against an NK1 antagonist and this study was underpowered with only 10 participants per arm (<a href="./references#CD012555-bbs2-0011" title="ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy‐induced nausea and vomiting [abstract no. 9633]. Journal of Clinical Oncology2009;27((15S Part I)):516. ShumwayN , TerrazzinoS , JonesC . A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management2015;8(3):233‐41. ">Shumway 2015</a>), therefore we believe that further research is needed to assess whether olanzapine is superior, non‐inferior or inferior to NK1 antagonists. </p> <p>No RCT followed participants receiving olanzapine for more than eight weeks. Longer term, larger studies are needed to improve our understanding of the risk of serious adverse events (particularly extrapyramidal side effects, hyperglycaemia, agranulocytosis and QTc prolongation), when participants require olanzapine over longer time periods. </p> <p>Finally, despite searching for RCTs that administered olanzapine by any route, we found only studies that used the oral route. Further studies are needed to evaluate the administration of olanzapine via non‐oral routes, as this lack of evidence currently limits its clinical use as an antiemetic. </p> </section> <section id="CD012555-sec-0189"> <h4 class="title">Palliation of other important clinical symptoms</h4> <section id="CD012555-sec-0190"> <h5 class="title">Anxiety and depression</h5> <p><a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a> assessed anxiety and depression on the validated HADS, over the participants' course of chemotherapy. They reported that anxiety and depression increased in the control group with the administration of chemotherapy. In the olanzapine group they noted an improvement in both anxiety and depression. </p> </section> <section id="CD012555-sec-0191"> <h5 class="title">Anorexia and cachexia</h5> <p>Three of the included RCTs reported an improvement in anorexia and cachexia in the olanzapine compared to the control group (<a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>; <a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a>; <a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016</a>). </p> <p>Further systematic reviews are therefore needed to establish the role of olanzapine in the palliation of cachexia, anxiety, depression and delirium. </p> </section> </section> <section id="CD012555-sec-0192"> <h4 class="title">Serious adverse events and common drug interactions when olanzapine is injected</h4> <p>The review authors noted that, whilst we could not identify any RCTs that reported using an injectable form of olanzapine, these have been reported in case series. These reports note that respiratory depression occurs when olanzapine is administered via the intravenous route in doses of 1.25 mg, 2.5 mg and 5 mg. Severe respiratory depression leading to hypoxia requiring airway stimulation, repositioning or intubation has been reported (<a href="./references#CD012555-bbs2-0081" title="MartelM , KleinL , RivardR , ColevJ . A large retrospective cohort of patients receiving intravenous olanzapine in the emergency department. Society for Academic Emergency Medicine2016;23:29‐33. ">Martel 2016</a>). In light of these serious safety concerns and in the absence of any RCTs in which the intravenous route or any other injectable route has been used, we caution against extrapolation of the oral data to the intravenous route, as there is currently insufficient data to support the use of intravenous olanzapine. </p> <p>Additionally, it is important to note that if olanzapine is injected intramuscularly, there is also known to be a risk of cardiovascular and respiratory depression. It is advised that blood pressure, heart rate and respiratory rate are monitored for a minimum of four hours following intramuscular administration and that at least one hour has elapsed following intramuscular administration before parenteral benzodiazepines are administered (<a href="./references#CD012555-bbs2-0057" title="British National Formulary. www.evidence.nhs.uk/formulary/bnf/current/4‐central‐nervous‐system/42‐drugs‐used‐in‐psychoses‐and‐related‐disorders/421‐antipsychotic‐drugs/second‐generation‐antipsychotic‐drugs/olanzapine (accessed 28 September 2017). ">BNF</a>). This is of particular relevance to Palliative Medicine Specialists, as is the caution in patients with ileus (<a href="./references#CD012555-bbs2-0057" title="British National Formulary. www.evidence.nhs.uk/formulary/bnf/current/4‐central‐nervous‐system/42‐drugs‐used‐in‐psychoses‐and‐related‐disorders/421‐antipsychotic‐drugs/second‐generation‐antipsychotic‐drugs/olanzapine (accessed 28 September 2017). ">BNF</a>). </p> </section> </section> <section id="CD012555-sec-0193"> <h3 class="title" id="CD012555-sec-0193">Quality of the evidence</h3> <p>There is moderate‐quality evidence that olanzapine probably improves nausea and vomiting when compared to placebo or no control, but probably leads to somnolence and fatigue. However, the quality of evidence for all other outcomes was low or very low. We therefore cannot interpret these results of these outcomes with certainty and further research is needed to address these. </p> <p>Whilst there is moderate‐quality evidence to support olanzapine in CINV when added to standard antiemetic therapy, further research is needed to establish olanzapine's role in chemoradiotherapy, radiotherapy and in participants not receiving active anticancer treatment. </p> <p>Downgrading of evidence was primarily for the imprecision of the results due to the small sample sizes and low event rates (adverse events). There were also large variations between some of the trials in the base rates of some outcomes. This may have been due to different doses of olanzapine, different population characteristics and cancer treatments, or differences in the standard adjuvant antiemetic regimens between trials. The individual trials were generally judged to be at an 'unclear' or 'low' risk of bias. Only six of the studies presented clear information on randomisation, and only three had clear data on allocation concealment. This is perhaps surprising given the age of the studies. </p> </section> <section id="CD012555-sec-0194"> <h3 class="title" id="CD012555-sec-0194">Potential biases in the review process</h3> <section id="CD012555-sec-0195"> <h4 class="title">Publication bias</h4> <p>We did not detect any serious publication bias and there were insufficient studies in each comparison to produce funnel plots for any outcome. </p> <p>We could only adequately assess full‐text RCTs, abstracts where additional information was provided by the study author, or unpublished trials where the full results were made available to us. We therefore excluded four RCTs that had only been published as abstracts, despite requesting additional information from the study authors. We identified two terminated unpublished RCTs and one completed unpublished RCT <a href="./references#CD012555-bbs2-0036" title="ChiCTR‐TTRCC‐14004093 . Olanzapine versus aprepitant for the prevention of high dose cisplatin‐induced nausea and vomiting: a randomized phase III trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR‐TTRCC‐14004093 (accessed 28 September 2017). ">CTRCC‐14004093</a>, for which we were unable to obtain results. </p> <p>One RCT was unobtainable (<a href="./references#CD012555-bbs2-0042" title="Wang , Wang . Effectiveness of olanzapine in prevention of chemotherapy induced nausea and vomiting. Clin J Clin (full journal title not available)2012;6:7406‐7. ">Wang 2012</a>). <a href="./references#CD012555-bbs2-0003" title="LuY L , LiuW , DuY J , FengL , WangY D , WangL . Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Chinese Journal of Cancer Prevention and Treatment2013;20(7):544‐54. ">Lu 2013</a> and <a href="./references#CD012555-bbs2-0014" title="ZhaoJ , LiX , JinghuaG , LiY , LiJ , ShiY , et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy ‐ induced nausea and vomiting. Modern Oncology. Modern Oncology, 2014; Vol. 22, issue 8:1941‐3. ">Zhao 2014</a> were translated from Chinese and data extracted by one translator. Additionally, full texts in German, Dutch and other Chinese language papers were translated and reviewed at the full‐text screening stage before exclusion. Given the number of foreign language studies identified, a search of the foreign language databases may have identified more studies. </p> <p>Additionally, given the high number of studies that are ongoing or yet to be published as full‐text articles, it will be important to update this review when these become available. </p> </section> <section id="CD012555-sec-0196"> <h4 class="title">Potential biases within the data analysis</h4> <p>As discussed above, we elected to include the data from <a href="./references#CD012555-bbs2-0009" title="AhlbornM . Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy [Olanzapin: erweiterung der praventionsmoglichkeiten von ubelkeit und erbrechen nach hoch emetogener]. Chemotherapie Onkologe2016;22(12):992‐3. MammatasL , KoningsI . Olanzapine prevents nausea and vomiting from chemotherapy [Olanzapine voorkomt misselijkheid en braken bij chemotherapie]. Nederlands Tijdschrift voor Geneeskunde2016;160(41):43. NavariR , QinR , RuddyJ , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting. New England Journal of Medicine. NEJM, 2016; Vol. 375:134‐42. NavariR , QinR , RuddyK , LiuH , PowellS , BajajM , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2015;33((29 suppl. 1)):176. ">Navari 2016a</a> for 'overall absence of nausea' in our analysis of 'overall nausea and vomiting' in an attempt to reduce the risk of overestimating the relative risk of being free from nausea and vomiting over the whole trial period that is present when only data from studies with small sample size is considered. This resulted in a reduction in the size of anticipated absolute effect and the size of relative risk reported. </p> <p>It is important to remain vigilant for these, as RCTs are not the most effective way of monitoring adverse events, particularly serious but rare adverse events, such as extra pyramidal adverse events, prolonged QTc interval, neutropenia and agranulocytosis, and diabetes mellitus, which are likely to be underreported in RCT data due to the small numbers of participants and short trial duration. </p> <p>Instead of reporting overall absence of nausea and vomiting, most studies reported 'complete response' as their primary outcome. This was most frequently defined as no vomiting or use of breakthrough antiemetic medications over the course of the trial. We acknowledge that this outcome is likely to be more easily measured as it removes any concern over the possible subjectivity of nausea assessment and self‐reporting, as any breakthrough medication would lead to a documented administration. However, the review authors were concerned that some participants might have felt nauseous but not received breakthrough medication for any number of reasons, whilst still being documented as having completely responded to the intervention. We were concerned that using this surrogate outcome might lead to an over estimation of the efficacy of olanzapine, when in fact, participants had experienced nausea but had not been treated with breakthrough medication. We felt that being entirely free from nausea or vomiting would be of greater importance to patients than whether their nausea reached a threshold severe enough to require breakthrough medication and whether they were able to receive the medication. We considered that freedom from nausea and vomiting was a 'hard' outcome, meaning that we were less likely to overestimate the efficacy of olanzapine in our analysis. </p> </section> </section> <section id="CD012555-sec-0197"> <h3 class="title" id="CD012555-sec-0197">Agreements and disagreements with other studies or reviews</h3> <section id="CD012555-sec-0198"> <h4 class="title">Compared to Cochrane Reviews of the antiemetic efficacy of antipsychotics</h4> <p>Two other antipsychotics are frequently used as antiemetics.</p> <p>Haloperidol is a dopamine receptor antagonist. It is administered via the oral, subcutaneous, intravenous or intramuscular route and may be administered via the intranasal route. <a href="./references#CD012555-bbs2-0085" title="Murray‐BrownF , DormanS . Haloperidol for the treatment of nausea and vomiting in palliative care patients. Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD006271.pub3] ">Murray‐Brown 2015</a> found only one RCT of 22 participants, who were given haloperidol as a gel on the wrist, which is "reported not to be absorbed by this route" and concluding that there was insufficient RCT evidence to determine its effectiveness in their Cochrane systematic review. </p> <p>Levomepromazine is another antipsychotic that is currently used as an antiemetic. As with olanzapine, it is known to act on a range of neurotransmitter receptors including dopaminergic, cholinergic, serotonin and histamine. Unfortunately, <a href="./references#CD012555-bbs2-0065" title="CoxL , DarvillE , DormanS . Levomepromazine for nausea and vomiting in palliative care. Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009420.pub3] ">Cox 2015</a> found no eligible RCTs in their Cochrane systematic review. </p> <p>This is, therefore, the first Cochrane systematic review to find RCT‐level evidence to support the theory that an antipsychotic medication improves nausea and vomiting in participants with a cancer diagnosis. </p> </section> <section id="CD012555-sec-0199"> <h4 class="title">Compared to other systematic reviews and meta‐analyses</h4> <p>The findings of this Cochrane systematic review of olanzapine for the prevention and treatment of nausea and vomiting in adults are in keeping with all nine independent systematic reviews and meta‐analyses on the topic. </p> <p> <ul id="CD012555-list-0020"> <li> <p><a href="./references#CD012555-bbs2-0096" title="WangS , YangZ , ZhangL . Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy. Asian Pacific Journal of Cancer Prevention2014;15(22):9587‐92. ">Wang 2014</a> found that olanzapine increased the odds of being free from nausea and vomiting in both the overall (OR 1.95, CI 1.17 to 3.23; P = 0.01), and delayed phases (OR 2.65, CI 1.36 to 5.15, P = 0.004). </p> </li> <li> <p><a href="./references#CD012555-bbs2-0080" title="KumarR , SinghN , ThekkekaraR , SinghS , HarringtonS , ShahM . Efficacy of olanzapine for prevention of chemotherapy‐induced nausea and vomiting: A systematic review and meta‐analysis. Journal of Clinical Oncology. Conference2017;35(15 Supplement 1):‐. ">Kumar 2017</a> reported that "olanzapine was statistically superior for five primary endpoints except for no nausea in acute period. In the non‐steroids cohort, olanzapine was superior for no emesis in all three periods but statistically significant only for delayed period." </p> </li> <li> <p><a href="./references#CD012555-bbs2-0076" title="HockingC , KichenadasseG . Olanzapine for chemotherapy‐induced nausea and vomiting: a systematic review. Supportive Care in Cancer2014;22(4):1143‐51. ">Hocking 2014</a> found that "regimens including olanzapine were associated with significant improvements in CINV prevention with both HEC and MEC." </p> </li> <li> <p>In a narrative systematic review <a href="./references#CD012555-bbs2-0095" title="van derVorstM , NeefjesE , KoningsI , VerheulH . Prophylactic treatment for delayed chemotherapy‐induced nausea and vomiting after non‐AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials. Supportive Care in Cancer2015;23(8):2499‐506. ">van der Vorst 2015</a> reported that "olanzapine...show[ed) highly effective complete response (CR), rates." </p> </li> <li> <p>Equally, <a href="./references#CD012555-bbs2-0098" title="YoodeeJ , PermsuwanU , NimworapanM . Efficacy and safety of olanzapine for the prevention of chemotherapy‐induced nausea and vomiting: A systematic review and meta‐analysis. Critical Reviews in Oncology/Hematology2017;112:‐. ">Yoodee 2017</a> concluded that "olanzapine is effective and safe at reducing during the delayed and overall phase of the CINV prevention". </p> </li> <li> <p>Recently, <a href="./references#CD012555-bbs2-0097" title="YangT , LiuQ , LuM , MaL , ZhouY , CuiY . Efficacy of olanzapine for the prophylaxis of chemotherapy‐induced nausea and vomiting: a meta‐analysis. British Journal of Clinical Pharmacology2017;83(7):1369‐79. ">Yang 2017</a> also concluded that "olanzapine is an excellent alternative for the prophylaxis of CINV. Olanzapine 5 mg per day should be recommended as the initial dose because of equivalent efficacy to a 10 mg dose but a lower potential risk of side effects. Further studies are needed to explore the optimal combination of medicines." </p> </li> <li> <p><a href="./references#CD012555-bbs2-0061" title="ChiuL , ChowR , PopovicM , NavariR , ShumwayN , ChiuN , et al. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy‐induced nausea and vomiting (CINV): a systematic review and meta‐analysis. Supportive Care in Cancer2016;24(5):2381‐92. ">Chiu 2016a</a> again found that "olanzapine is more efficacious than other standard antiemetics for the rescue of CINV and its inclusion improves control in the prevention setting. Given the possible reduction in side effects, the use of a 5‐mg dose of olanzapine should be considered. Future RCTs should compare the 5‐mg versus the 10‐mg dosages further and report on the efficacy and percentage of patients developing side effects." </p> </li> <li> <p><a href="./references#CD012555-bbs2-0062" title="ChowR , ChiuL , NavariR , PassikS , ChiuN , PopovicM , et al. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy‐induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Supportive Care in Cancer2016;24(2):1001‐8. ">Chow 2016</a> analysed the data from phase one and phase two clinical trials of olanzapine as an antiemetic. They concluded that "olanzapine is efficacious and safe when used as a prophylaxis for CINV." </p> </li> <li> <p><a href="./references#CD012555-bbs2-0060" title="ChelkebaL , GideyK , MamoA , YohannesB , MatsoT , MelakuT . Olanzapine for chemotherapy‐induced nausea and vomiting: systematic review and meta‐analysis. Pharmacy Practice2017;15(1):877. ">Chelkeba 2017</a> summarised the results of their meta‐analysis by concluding that "the bottom line is that olanzapine containing regimen is statistically superior to non‐olanzapine regimen in preventing CINV in all endpoints and phases." </p> </li> </ul> </p> </section> <section id="CD012555-sec-0200"> <h4 class="title">Compared to cost‐effectiveness studies</h4> <p><a href="./references#CD012555-bbs2-0059" title="ChanthawongS , LimY H , SubongkotS , ChanA , AndalusiaR , BustamamR S , et al. Cost‐effectiveness analysis of olanzapine‐containing antiemetic therapy for managing highly emetogenic chemotherapy in south east Asia: a multinational study. Supportive Care in Cancer2017;25(2 Supplement 1):S64‐5. ">Chanthawong 2017</a> performed a cost‐effectiveness analysis across four countries in South East Asia. They used "a decision tree model, clinical and economic outcomes" evaluate management of CINV following HEC. The study found that "the addition of olanzapine is cost‐effective and viable to prevent CINV" in Thailand, Malaysia, Indonesia, and Singapore when olanzapine was added to standard doublet (dexamethasone and ondansetron), and triplet (dexamethasone and palonosetron and aprepitant), antiemetic therapy. </p> <p>In the UK in 2017 the cost of a five‐day course of 5 mg orodispersible olanzapine to prevent CINV during a standard cycle of chemotherapy is GBP 7.30. This can be compared to the cost of a three‐day course of aprepitant oral capsules at GBP 100.64 or a course of a single intravenous injection ampoule of fosaprepitant at GBP 47.42, with the additional nursing cost of intravenous administration (<a href="./references#CD012555-bbs2-0057" title="British National Formulary. www.evidence.nhs.uk/formulary/bnf/current/4‐central‐nervous‐system/42‐drugs‐used‐in‐psychoses‐and‐related‐disorders/421‐antipsychotic‐drugs/second‐generation‐antipsychotic‐drugs/olanzapine (accessed 28 September 2017). ">BNF</a>). However, it is yet to be established whether olanzapine is superior, non‐inferior or inferior to NK1 antagonists. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012555-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD012555-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/full#CD012555-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD012555-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/full#CD012555-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD012555-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/full#CD012555-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 1 No nausea or vomiting over trial period." data-id="CD012555-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 1 No nausea or vomiting over trial period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 2 Serious adverse events." data-id="CD012555-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 2 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 3 Participant preference ‐ wish to use drug in next treatment." data-id="CD012555-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 3 Participant preference ‐ wish to use drug in next treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 4 Other adverse events." data-id="CD012555-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 4 Other adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 5 Somnolence/fatigue." data-id="CD012555-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 5 Somnolence/fatigue.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 6 Withdrawals due to all causes." data-id="CD012555-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 6 Withdrawals due to all causes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 7 Withdrawals due to lack of efficacy." data-id="CD012555-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 7 Withdrawals due to lack of efficacy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 8 Withdrawals due to adverse events." data-id="CD012555-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 8 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 9 Breakthrough nausea/vomiting requiring antiemetics over trial period." data-id="CD012555-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 9 Breakthrough nausea/vomiting requiring antiemetics over trial period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 10 No nausea over trial period." data-id="CD012555-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 10 No nausea over trial period.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 11 No vomiting over trial period." data-id="CD012555-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 11 No vomiting over trial period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 12 No acute nausea (within 24 h of chemotherapy)." data-id="CD012555-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 12 No acute nausea (within 24 h of chemotherapy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 13 No acute vomiting (within 24 h of chemotherapy)." data-id="CD012555-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 13 No acute vomiting (within 24 h of chemotherapy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 14 No acute nausea or vomiting (within 24 h of chemotherapy)." data-id="CD012555-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 14 No acute nausea or vomiting (within 24 h of chemotherapy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 15 No delayed nausea (1‐5 days after chemotherapy)." data-id="CD012555-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 15 No delayed nausea (1‐5 days after chemotherapy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 16 No delayed vomiting (1‐5 days after chemotherapy)." data-id="CD012555-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 16 No delayed vomiting (1‐5 days after chemotherapy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Olanzapine vs placebo/no treatment, Outcome 17 No delayed nausea or vomiting (1‐5 days after chemotherapy)." data-id="CD012555-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Olanzapine vs placebo/no treatment, Outcome 17 No delayed nausea or vomiting (1‐5 days after chemotherapy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Olanzapine vs NK1 antagonist, Outcome 1 Serious adverse events." data-id="CD012555-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Olanzapine vs NK1 antagonist, Outcome 1 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Olanzapine vs NK1 antagonist, Outcome 2 Somnolence/fatigue." data-id="CD012555-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Olanzapine vs NK1 antagonist, Outcome 2 Somnolence/fatigue.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Olanzapine vs NK1 antagonist, Outcome 3 Withdrawals due to all causes." data-id="CD012555-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Olanzapine vs NK1 antagonist, Outcome 3 Withdrawals due to all causes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Olanzapine vs NK1 antagonist, Outcome 4 Withdrawals due to lack of efficacy." data-id="CD012555-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Olanzapine vs NK1 antagonist, Outcome 4 Withdrawals due to lack of efficacy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Olanzapine vs NK1 antagonist, Outcome 5 Withdrawals due to adverse events." data-id="CD012555-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Olanzapine vs NK1 antagonist, Outcome 5 Withdrawals due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Olanzapine vs NK1 antagonist, Outcome 6 Withdrawals due to death." data-id="CD012555-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Olanzapine vs NK1 antagonist, Outcome 6 Withdrawals due to death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Olanzapine vs NK1 antagonist, Outcome 7 No nausea over trial period." data-id="CD012555-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Olanzapine vs NK1 antagonist, Outcome 7 No nausea over trial period.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Olanzapine vs NK1 antagonist, Outcome 8 No acute nausea (within 24 h of chemotherapy)." data-id="CD012555-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Olanzapine vs NK1 antagonist, Outcome 8 No acute nausea (within 24 h of chemotherapy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Olanzapine vs NK1 antagonist, Outcome 9 No delayed nausea (1‐5 days after chemotherapy)." data-id="CD012555-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Olanzapine vs NK1 antagonist, Outcome 9 No delayed nausea (1‐5 days after chemotherapy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Olanzapine vs prokinetic, Outcome 1 Serious adverse events." data-id="CD012555-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Olanzapine vs prokinetic, Outcome 1 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Olanzapine vs prokinetic, Outcome 2 Withdrawals due to all causes." data-id="CD012555-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Olanzapine vs prokinetic, Outcome 2 Withdrawals due to all causes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Olanzapine vs prokinetic, Outcome 3 Withdrawals due to lack of efficacy." data-id="CD012555-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Olanzapine vs prokinetic, Outcome 3 Withdrawals due to lack of efficacy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Olanzapine vs prokinetic, Outcome 4 Withdrawals due to adverse events." data-id="CD012555-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Olanzapine vs prokinetic, Outcome 4 Withdrawals due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Olanzapine vs prokinetic, Outcome 5 Withdrawals due to death." data-id="CD012555-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Olanzapine vs prokinetic, Outcome 5 Withdrawals due to death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Olanzapine vs prokinetic, Outcome 6 No nausea over trial period." data-id="CD012555-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Olanzapine vs prokinetic, Outcome 6 No nausea over trial period.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Olanzapine vs prokinetic, Outcome 7 No vomiting over trial period." data-id="CD012555-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Olanzapine vs prokinetic, Outcome 7 No vomiting over trial period.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Olanzapine vs 5‐HT3 antagonist, Outcome 1 Serious adverse events." data-id="CD012555-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Olanzapine vs 5‐HT3 antagonist, Outcome 1 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Olanzapine vs 5‐HT3 antagonist, Outcome 2 50% improvement in nausea at 24 h on a validated scale." data-id="CD012555-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Olanzapine vs 5‐HT3 antagonist, Outcome 2 50% improvement in nausea at 24 h on a validated scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Olanzapine vs 5‐HT3 antagonist, Outcome 3 50% improvement in nausea at 48 h on a validated scale." data-id="CD012555-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Olanzapine vs 5‐HT3 antagonist, Outcome 3 50% improvement in nausea at 48 h on a validated scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Olanzapine vs 5‐HT3 antagonist, Outcome 4 Withdrawals due to all causes." data-id="CD012555-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Olanzapine vs 5‐HT3 antagonist, Outcome 4 Withdrawals due to all causes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Olanzapine vs 5‐HT3 antagonist, Outcome 5 Withdrawals due to lack of efficacy." data-id="CD012555-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Olanzapine vs 5‐HT3 antagonist, Outcome 5 Withdrawals due to lack of efficacy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Olanzapine vs 5‐HT3 antagonist, Outcome 6 Withdrawals due to adverse events." data-id="CD012555-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Olanzapine vs 5‐HT3 antagonist, Outcome 6 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Olanzapine vs 5‐HT3 antagonist, Outcome 7 Withdrawals due to death." data-id="CD012555-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Olanzapine vs 5‐HT3 antagonist, Outcome 7 Withdrawals due to death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Olanzapine vs dexamethasone, Outcome 1 Serious adverse events." data-id="CD012555-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Olanzapine vs dexamethasone, Outcome 1 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Olanzapine vs dexamethasone, Outcome 2 Withdrawals due to all causes." data-id="CD012555-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Olanzapine vs dexamethasone, Outcome 2 Withdrawals due to all causes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Olanzapine vs dexamethasone, Outcome 3 No nausea over trial period." data-id="CD012555-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Olanzapine vs dexamethasone, Outcome 3 No nausea over trial period.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Olanzapine vs dexamethasone, Outcome 4 No vomiting over trial period." data-id="CD012555-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Olanzapine vs dexamethasone, Outcome 4 No vomiting over trial period.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Olanzapine vs dexamethasone, Outcome 5 No acute nausea (within 24 h of chemotherapy)." data-id="CD012555-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Olanzapine vs dexamethasone, Outcome 5 No acute nausea (within 24 h of chemotherapy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Olanzapine vs dexamethasone, Outcome 6 No acute vomiting (within 24 h of chemotherapy)." data-id="CD012555-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Olanzapine vs dexamethasone, Outcome 6 No acute vomiting (within 24 h of chemotherapy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Olanzapine vs dexamethasone, Outcome 7 No delayed nausea (1‐5 days after chemotherapy)." data-id="CD012555-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Olanzapine vs dexamethasone, Outcome 7 No delayed nausea (1‐5 days after chemotherapy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Olanzapine vs dexamethasone, Outcome 8 No delayed vomiting (1‐5 days after chemotherapy)." data-id="CD012555-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Olanzapine vs dexamethasone, Outcome 8 No delayed vomiting (1‐5 days after chemotherapy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Subgroup (dose): olanzapine vs placebo/no treatment, Outcome 1 No nausea or vomiting over trial period." data-id="CD012555-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Subgroup (dose): olanzapine vs placebo/no treatment, Outcome 1 No nausea or vomiting over trial period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Subgroup (dose): olanzapine vs placebo/no treatment, Outcome 2 Serious adverse events." data-id="CD012555-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Subgroup (dose): olanzapine vs placebo/no treatment, Outcome 2 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Subgroup (dose): olanzapine vs placebo/no treatment, Outcome 3 Other adverse events." data-id="CD012555-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Subgroup (dose): olanzapine vs placebo/no treatment, Outcome 3 Other adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012555-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/urn:x-wiley:14651858:media:CD012555:CD012555-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_t/tCD012555-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Subgroup (dose): olanzapine vs placebo/no treatment, Outcome 4 Somnolence/fatigue." data-id="CD012555-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Subgroup (dose): olanzapine vs placebo/no treatment, Outcome 4 Somnolence/fatigue.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/media/CDSR/CD012555/image_n/nCD012555-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012555-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Olanzapine compared to placebo/no treatment for the prevention and treatment of cancer‐related nausea and vomiting in adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Olanzapine compared to placebo/no treatment for the prevention and treatment of cancer‐related nausea and vomiting in adults</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> adults with cancer </p> <p><b>Setting:</b> hospital or medical institutions; either inpatient or not stated if inpatient or outpatient<br/> <b>Intervention:</b> olanzapine<br/> <b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Results</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Without olanzapine</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>With olanzapine</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Difference</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No nausea or vomiting over trial period</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.98 (1.59 to 2.47)</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population: 561 participants (3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Olanzapine probably improves freedom from nausea or vomiting over the trial period when compared to placebo or no intervention if used in conjunction with standard therapy </p> <p>(OR 5.48 (95% CI 1.35 to 22.20) I² = 85%).</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.7%<br/> (39.9 to 62.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.6% more<br/> (14.8 more to 36.9 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 2.46<br/> (0.48 to 12.55) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population: 889 participants (7 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain if olanzapine increases the risk of serious adverse events when compared to placebo or no intervention if used in conjunction with standard therapy. Six RCTs reported no serious adverse events in either arm </p> <p>(OR 2.50, 95% CI 0.48 to 13.04; I² = 0%).</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1%<br/> (0.2 to 5.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7% more<br/> (0.2 fewer to 5.2 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Participant preference ‐ wish to use drug in next treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.43<br/> (0.97 to 2.09) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population: 48 participants (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Moderate<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain if participants preferred olanzapine when compared to placebo or no intervention if used in conjunction with standard therapy </p> <p>(OR 3.57, 95% CI 0.93 to 13.72).</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.4%<br/> (56.6 to 100.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.1% more<br/> (1.8 fewer to 63.6 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Study population: 258 participants (4 RCTs)</p> <p><a href="./references#CD012555-bbs2-0004" title="MizukamiN , YamauchiM , KoikeK , WatanabeA , IchiharaK , MasumoriN , et al. Olanzapine for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double‐blind, placebo‐controlled study. Journal of Pain and Symptom Management2014;47(3):542‐50. ">Mizukami 2014</a>: "[olanzapine] group experienced a better QOL than the control group, as reported on the Functional Living Index‐Emesis questionnaire (P &lt; 0.0004)". </p> <p><a href="./references#CD012555-bbs2-0005" title="MukhopadhyayS , KwatraG , AliceK , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):145‐54. MukhopadhyayS , KwatraG , AliceP , BadyalD . Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2016;25:1‐10. MukhopadhyayS , KwatraG , BadyalD , KingsleyP . Olanzapine, concurrent chemo‐radiation patients and chemotherapy induced nausea and vomiting: the surprise continues. Supportive Care in Cancer2014;22(1 suppl. 1):S99. MukhopadhyayS , KwatraG , JeyarajP , BadyalD . Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study. Supportive Care in Cancer2015;23(1 suppl. 1):S126‐7. MukhopadhyayS , KwatraG , KingsleyP , BadyalD , MukhopadhyayB . Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients. Clinical Therapeutics2015;1:e108. MukhopadhyayS , KwatraG , PamelaA , BadyalD . Erratum to: Role of olanzapine in chemotherapy‐induced nausea and vomiting on platinum‐based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer2017;25(1):155‐6. ">Mukhopadhyay 2016</a>: global health status improved in the olanzapine group using the EORTC QLQ C30. Control group's global health status deteriorated from 10.08 ± 0.43 before treatment to 8.70 ± 0.44 P &lt; 0.0001 after chemotherapy. This decline was not seen in the olanzapine group (before 9.48 ± 0.48 and after treatment 9.60 ± 0.47; P = 0.537). </p> <p><a href="./references#CD012555-bbs2-0007" title="NavariR . Treatment of cancer related anorexia with megestrol acetate and olanzapine. Psycho‐Oncology2009;18:S47‐8. NavariR , BrennerM . Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care in Cancer2009;17(7):971. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate. Journal of Clinical Oncology2008;26(15 suppl):9576. NavariR , BrennerM . Treatment of cancer‐related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer2010; Vol. 18, issue 8:951‐6. ">Navari 2010b</a> 23/39 participants in the megestrol plus olanzapine arm had an improved QOL at 4 and 8 weeks compared to 5/37 who received megestrol alone on the "Functional Assessment of Cancer Therapy‐General (version 3)". </p> <p><a href="./references#CD012555-bbs2-0010" title="NikbakhshN , SadeghiM , RamzaniE , MoudiS , BijaniA , YousefiR , et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. Journal of Research in Medical Sciences2016;21:88. ">Nikbakhsh 2016:</a> "no significant difference was observed between the case and control groups about the patients QOL in ... total QOL score (P &gt; 0.05)" using the WHO‑QOL‑BREF </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is unclear whether participants who used olanzapine had an improved quality of life compared to placebo or no intervention, if used with standard therapy due to inter‐study heterogeneity in scales used. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Patient Global Impression of Change</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome was not measured or not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Other adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.71<br/> (0.99 to 2.96) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population: 332 participants (4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Olanzapine may lead to more adverse events when compared to placebo or no treatment if used in conjunction with standard therapy </p> <p>(OR 2.05, 95% CI 0.99 to 4.22; I² = 0%).</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.4%<br/> (8.3 to 25.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0% more<br/> (0.1 fewer to 16.5 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Somnolence/fatigue</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 2.33<br/> (1.30 to 4.18) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population: 464 participants (5 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Olanzapine probably leads to increased risk of somnolence or fatigue when compared to placebo or no intervention if used in conjunction with standard therapy </p> <p>(OR 2.84, 95% CI 1.39 to 5.78; I² = 0%).</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.4%<br/> (7.0 to 24.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2% more<br/> (1.9 more to 18.8 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>EORTC QLQ‐C30:</b> European Organisation for Research and Treatment of Cancer quality of life questionnaire; <b>QOL:</b> quality of life; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio; <b>WHO‐QOL‐BREF:</b> World Health Organization Quality of Life‐BREF </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded to moderate quality due to inconsistency (‐1). The risk of nausea and vomiting in the control group varied from 19% to 40%. This variation was probably due to the characteristics of the trials being different (such as type of cancer, chemotherapy treatment given, dose of olanzapine etc). We observed statistical heterogeneity when using odds ratios (I² = 85%). <br/> <sup>2</sup>Downgraded to low quality due to imprecision (‐1) and inconsistency (‐1). There was only a small number of events (5 in olanzapine, 2 in control arm) in one trial only. No events in either arm of six other trials, leading to wide confidence intervals.<br/> <sup>3</sup>Downgraded to moderate quality due to imprecision (‐1). There was a very small sample size, 24 participants per arm, resulting in very large confidence intervals.<br/> <sup>4</sup>Downgraded to low quality due to imprecision (‐1) and inconsistency (‐1). There were wide confidence intervals. There was large variation in risks of adverse events between studies with one study reporting an event rate of 23% in the placebo arm and 35% in the olanzapine arm.<br/> <sup>5</sup>Downgraded to moderate quality due to inconsistency (‐1). There was unexplained heterogeneity in the risk of somnolence between studies making it difficult to be confident that the true effect lies close to the estimate of the effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Olanzapine compared to placebo/no treatment for the prevention and treatment of cancer‐related nausea and vomiting in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/full#CD012555-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012555-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Olanzapine compared to NK1 antagonist for the prevention and treatment of cancer‐related nausea and vomiting in adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Olanzapine compared to NK1 antagonist for the prevention and treatment of cancer‐related nausea and vomiting in adults</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with cancer </p> <p><b>Setting:</b> military medical centre; not stated if inpatient or outpatient<br/> <b>Intervention:</b> olanzapine<br/> <b>Comparison:</b> NK1 antagonist </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Results</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With NK1 antagonist</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>With olanzapine</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Difference</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No nausea or vomiting over trial period</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome was not measured.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.02 to 7.32) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population: 20 participants (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are uncertain if there is a difference in the incidence of serious adverse events with olanzapine compared with NK1 antagonists. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome was not measured or not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome was not measured or not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient Global Impression of Change</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome was not measured or not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome was not measured or not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Somnolence/fatigue</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.33<br/> (0.40 to 4.49) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population: 20 participants (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are uncertain whether there is a difference in incidence of somnolence or fatigue with olanzapine compared with NK1 antagonists (OR 1.56, 95% CI 0.24 to 9.91). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.0%<br/> (12.0 to 100.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10% more<br/> (18 fewer to 104.7 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded to very low quality due to imprecision (‐1) and very serious study limitations (‐2). There was only one study with a small sample size (n = 20) and very few events (1 event in NK1 arm) leading to very imprecise results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Olanzapine compared to NK1 antagonist for the prevention and treatment of cancer‐related nausea and vomiting in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/full#CD012555-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012555-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Olanzapine vs placebo/no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 No nausea or vomiting over trial period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.59, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [0.48, 12.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participant preference ‐ wish to use drug in next treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.97, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Other adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.99, 2.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Somnolence/fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [1.30, 4.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawals due to all causes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>943</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.57, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Withdrawals due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 70.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Breakthrough nausea/vomiting requiring antiemetics over trial period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.10, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 No nausea over trial period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.18, 2.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 No vomiting over trial period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.12, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 No acute nausea (within 24 h of chemotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.95, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 No acute vomiting (within 24 h of chemotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.97, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 No acute nausea or vomiting (within 24 h of chemotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.86, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 No delayed nausea (1‐5 days after chemotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.40, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 No delayed vomiting (1‐5 days after chemotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.14, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 No delayed nausea or vomiting (1‐5 days after chemotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.61, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Olanzapine vs placebo/no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012555-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Olanzapine vs NK1 antagonist</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Somnolence/fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.40, 4.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawals due to all causes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.14, 65.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Withdrawals due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawals due to death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 No nausea over trial period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.14, 3.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 No acute nausea (within 24 h of chemotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.6 [0.19, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 No delayed nausea (1‐5 days after chemotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.40, 4.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Olanzapine vs NK1 antagonist</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012555-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Olanzapine vs prokinetic</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawals due to all causes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.14, 6.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawals due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.04, 4.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawals due to death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 No nausea over trial period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [1.73, 5.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 No vomiting over trial period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [1.78, 5.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Olanzapine vs prokinetic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012555-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Olanzapine vs 5‐HT3 antagonist</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 50% improvement in nausea at 24 h on a validated scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.80, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 50% improvement in nausea at 48 h on a validated scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.11, 2.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Withdrawals due to all causes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.64 [0.35, 37.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawals due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.64 [0.35, 37.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Withdrawals due to death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Olanzapine vs 5‐HT3 antagonist</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012555-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Olanzapine vs dexamethasone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawals due to all causes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 No nausea over trial period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.37, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 No vomiting over trial period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.10, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 No acute nausea (within 24 h of chemotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.99, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 No acute vomiting (within 24 h of chemotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.94, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 No delayed nausea (1‐5 days after chemotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.33, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 No delayed vomiting (1‐5 days after chemotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.07, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Olanzapine vs dexamethasone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012555-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Subgroup (dose): olanzapine vs placebo/no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 No nausea or vomiting over trial period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.59, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [1.19, 3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.40, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [0.48, 12.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [0.48, 12.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Other adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.99, 2.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [0.46, 34.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.88, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Somnolence/fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [1.30, 4.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.75, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.33 [1.60, 17.81]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Subgroup (dose): olanzapine vs placebo/no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012555.pub2/references#CD012555-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012555.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012555-note-0008">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012555-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012555-note-0006">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD012555-note-0005">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012555-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012555-note-0007">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD012555-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012555-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012555-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012555\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012555\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012555\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012555\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012555\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012555\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012555\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012555\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012555\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012555\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012555\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012555\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012555\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012555\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012555\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012555\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012555\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012555\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012555.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012555.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012555.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012555.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012555.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724441092"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012555.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724441096"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012555.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e62e3cd8ff3fd',t:'MTc0MDcyNDQ0MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 